Smilow Cancer Hospital Head and Neck Cancers Program
55 Park Street
Ste Phase I Clinical Trial Infusion Center
New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511
Barbara Burtness, MD
Internal Medicine, Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Biography
Barbara Burtness, MD, is a Yale Medicine medical oncologist who sees patients at Yale Cancer Center. She has made it her life’s mission to help people diagnosed with head and neck cancer, which can be a devastating disease even after it is cured—it can impact a person’s appearance, as well as the ability to speak, swallow, and eat.
“Patients often encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration, and feeding tube dependence,” says Dr. Burtness. “Younger patients may have to deal with these side effects for decades after cancer treatment.”
A careful treatment approach can help prevent these problems. She and her team evaluate the tumor location and decide which primary treatment (surgery or radiation therapy) will best cure the cancer and cause the fewest possible negative outcomes.
A professor of medicine at Yale School of Medicine, Dr. Burtness’ research lab is actively studying new cures for head and neck cancers. “We want to help improve these patients’ quality of life,” she says.
Titles
- Anthony N. Brady Professor of Medicine (Medical Oncology)
- Chief Translational Research Officer, Yale Cancer Center
- Chief, Head and Neck Cancers/Sarcoma
- Co-Leader, Developmental Therapeutics, Yale Cancer Center
- Associate Cancer Center Director for Translational Research, Yale Cancer Center
Education & Training
- FellowshipMemorial Sloan Kettering Cancer Center (1993)
- ResidencyYale-New Haven Hospital (1989)
- InternshipYale-New Haven Hospital (1987)
- MDSUNY at Stonybrook (1986)
- ABBryn Mawr College (1982)
Languages Spoken
- English
- Deutsch (German)
Additional Information
Honors & Recognitions
- Leadership in Diversity, Equity and Inclusion: Yale Cancer Center (2023)
- Yale Cancer Center Clinical Science Prize: Yale Cancer Center (2020)
- Wharton Lecturer: Princess Margaret Cancer Center (2019)
- Robert L. Krigel Award, Excellence in Teaching and Clinical Oncology: Fox Chase Cancer Center (2012)
- Top Doctor: U.S. News and World Report
- Best Doctors in America: Best Doctors
Board Certifications
- AB of Internal Medicine, Internal Medicine (1989)
Professional Service
- ECOG-ACRIN (2021 - Present): Chair, Task Force on Advancement of Women
- ECOG-ACRIN (2006 - Present): Chair of the ECOG-ACRIN Head and Neck Therapeutics Committee
Publications
- Dzienis M, Cundom J, Fuentes C, Spreafico A, Nordlinger M, Pastor A, Alesi E, Neki A, Fung A, Lima I, Oppelt P, da Cunha G, Burtness B, Franke F, Tseng J, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. Journal Of Clinical Oncology 2024, 42: 2989-2999. PMID: 39038265, PMCID: PMC11361359, DOI: 10.1200/jco.23.02625.
- Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse H, Su T, Cruz‐Gomez S, Lee S, Menges F, Parent L, Ratjen L, Burtness B, Fortner J, Zimmerman J. Multiplexable and Scalable Aqueous Synthesis Platform for Oleate‐Based, Bilayer‐Coated Gold Nanoparticles (Small 25/2024). Small 2024, 20 DOI: 10.1002/smll.202470191.
- Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'malley B, Ozer E, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2024, 42: 6009-6009. DOI: 10.1200/jco.2024.42.16_suppl.6009.
- Siu L, McQuarrie K, Bidadi B, Liu C, Black C, Wang A, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Harrington K, Machiels J. A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden. Journal Of Clinical Oncology 2024, 42: 11116-11116. DOI: 10.1200/jco.2024.42.16_suppl.11116.
- Long G, Haddad R, Robert C, Mortier L, Schadendorf D, Uppaluri R, Svane I, Saiag P, Lim A, Soria Rivas A, Scolyer R, Chaney M, Abildgaard C, Ahmad Q, Ringeisen F, McDowell D, Burtness B. A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors. Journal Of Clinical Oncology 2024, 42: tps2701-tps2701. DOI: 10.1200/jco.2024.42.16_suppl.tps2701.
- Colevas A, Chung C, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Worden F, Johnson F, Saba N, Burtness B, Julian R, Bauman J, Jotte R, Seiwert T, Dunn L, Chaney M, Margossian S, Levisetti M, Pai S. A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Journal Of Clinical Oncology 2024, 42: 6004-6004. DOI: 10.1200/jco.2024.42.16_suppl.6004.
- Bhatia A, Hayashi H, Kogawa T, Nishina T, Fountzilas C, Castillo D, McKean M, Colombo N, Smithy J, Fayette J, Chandra S, Powles T, Kudchadkar R, Sternberg D, Sullivan K, Yueh S, Clinthorne G, Burtness B. HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors. Journal Of Clinical Oncology 2024, 42: tps3164-tps3164. DOI: 10.1200/jco.2024.42.16_suppl.tps3164.
- Evans E, Fisher T, Mallow C, Foster A, Leonard J, Chaney M, Mekhail T, Seetharamu N, Steuer C, Saba N, Adkins D, Beck J, Algazi A, Burtness B, Baumgart M, Giampoli E, Hager S, Chay C, Spira A, Zauderer M. Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer. Journal Of Clinical Oncology 2024, 42: 2603-2603. DOI: 10.1200/jco.2024.42.16_suppl.2603.
- Shah H, Cohen O, Bourdillon A, Burtness B, Boffa D, Young M, Judson B, Mehra S. Identifying Opportunities to Deliver High‐Quality Cancer Care Across a Health System: A Clinical Responsibility. Otolaryngology 2024, 171: 445-456. PMID: 38606669, DOI: 10.1002/ohn.755.
- Colevas A, Chung C, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Margossian S, Pai S. A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e87. DOI: 10.1016/j.ijrobp.2024.01.192.
- Machiels J, TAO Y, Burtness B, Tahara M, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Black C, Norquist J, Gumuscu B, Bidadi B, Siu L. Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC). International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e39-e40. DOI: 10.1016/j.ijrobp.2024.01.091.
- Harrington K, Kim H, Salas S, Oliva M, Metcalf R, Bernsdorf M, Kim J, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, O'Hara K, Pathiraja K, Gumuscu B, Bidadi B, Burtness B. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e42. DOI: 10.1016/j.ijrobp.2024.01.095.
- Yarbrough W, Schrank T, Burtness B, Issaeva N. De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses 2024, 16: 536. PMID: 38675879, PMCID: PMC11053602, DOI: 10.3390/v16040536.
- Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple R, Shabbir Ahmed F, Schultz B, Flieder D, Connolly D, Psyrri A, Burtness B, Rimm D. An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers. Oral Oncology 2024, 152: 106750. PMID: 38547779, PMCID: PMC11060915, DOI: 10.1016/j.oraloncology.2024.106750.
- Hasan A, Demidova E, Czyzewicz P, Shah S, Devarajan K, Galloway T, Einarson M, Burtness B, Golemis E, Meyer J, Arora S. Abstract 5143: Molecular investigation of a polymorphic variant in JMJD1C that associates with chemoradiotherapy outcomes in locally advanced rectal and head and neck cancer. Cancer Research 2024, 84: 5143-5143. DOI: 10.1158/1538-7445.am2024-5143.
- Haider S, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann B, Judson B, Prasad M, Burtness B, Aboian M, Canis M, Reichel C, Baumeister P, Payabvash S. Impact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266637. PMID: 38514087, DOI: 10.2967/jnumed.123.266637.
- Contrera K, Patel M, Burtness B, Mehra R, Ferris R. The role of surgery and deescalation for HPV‐related oropharyngeal cancer. Cancer 2024 PMID: 38497569, DOI: 10.1002/cncr.35287.
- Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse H, Su T, Cruz‐Gomez S, Lee S, Menges F, Parent L, Ratjen L, Burtness B, Fortner J, Zimmerman J. Multiplexable and Scalable Aqueous Synthesis Platform for Oleate‐Based, Bilayer‐Coated Gold Nanoparticles. Small 2024, 20: e2309919. PMID: 38377304, DOI: 10.1002/smll.202309919.
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsBrahmer J, Long G, Hamid O, Garon E, Herbst R, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri T, Cohen E, Diaz L, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani P, Jafari N, Bird S, Snyder E, Gause C, Bracco O, Pietanza M, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. European Journal Of Cancer 2024, 199: 113530. PMID: 38295556, PMCID: PMC11227881, DOI: 10.1016/j.ejca.2024.113530.
- Argiris A, Flamand Y, Savvides P, Johnson J, Vathiotis I, Levine M, Li S, Forastiere A, Burtness B. A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305. European Journal Of Cancer 2023, 199: 113509. PMID: 38215573, PMCID: PMC11376484, DOI: 10.1016/j.ejca.2023.113509.
- Hasan A, Demidova E, Czyzewicz P, Shah S, Devarajan K, Galloway T, Einarson M, Burtness B, Golemis E, Meyer J, Arora S. Abstract PR013: Association of a polymorphic variant in JMJD1C with response to chemoradiotherapy in rectal cancer and head and neck cancer: Implications for a diverse population. Cancer Epidemiology Biomarkers & Prevention 2023, 32: pr013-pr013. DOI: 10.1158/1538-7755.disp23-pr013.
- Greil R, Burtness B, Laban S, Braña I, Nin R, Fuereder T, Bratland Å, Licitra L, Rordorf T, Psyrri A, Popovtzer A, Hughes B, Tahara M, Lin J, Gumuscu B, Lerman N, Harrington K. 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study. Immuno-Oncology Technology 2023, 20: 100578. DOI: 10.1016/j.iotech.2023.100578.
- Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.
- Harrington K, Cohen E, Soulières D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Swaby R, Lin J, Ge J, Lerman N, Tourneau C. Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncology 2023, 147: 106587. PMID: 37925894, DOI: 10.1016/j.oraloncology.2023.106587.
- Chung C, Adkins D, Dimitrios Colevas A, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Chaney M, Agensky L, Goel A, Quayle S, Margossian S, Levisetti M, Pai S. 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients. 2023, a764-a764. DOI: 10.1136/jitc-2023-sitc2023.0674.
- Fisher T, Evans E, Mallow C, Foster A, Leonard J, Chaney M, Mekhail T, Seetharamu N, Steuer C, Saba N, Adkins D, Thaddeus Beck J, Algazi A, Burtness B, Baumgart M, Hager S, Chay C, Spira A, Zauderer M. 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84). 2023, a767-a767. DOI: 10.1136/jitc-2023-sitc2023.0676.
- Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Redman R, Stokes W, Rudra S, Mell L, Sacco A, Spencer S, Nabell L, Yao M, Cury F, Mitchell D, Jones C, Firat S, Contessa J, Galloway T, Currey A, Harris J, Curran W, Le Q. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma. JAMA Oncology 2023, 9: 1565-1573. PMID: 37768670, PMCID: PMC10540060, DOI: 10.1001/jamaoncol.2023.3809.
- Tahara M, Machiels J, Tao Y, Burtness B, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Swaby R, Zhang Y, Bidadi B, Siu L. PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412. Annals Of Oncology 2023, 34: s1380. DOI: 10.1016/j.annonc.2023.09.109.
- Harrington K, Kim H, Salas S, Oliva M, Metcalf R, Bernsdorf M, Kim J, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, O'Hara K, Pathiraja K, Gumuscu B, Bidadi B, Burtness B. Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009. Clinical Cancer Research 2023, 29: po-003-po-003. DOI: 10.1158/1557-3265.aacrahns23-po-003.
- Hasan A, Demidova E, Shah S, Czyzewicz P, Devarajan K, Galloway T, Burtness B, Golemis E, Meyer J, Arora S. Abstract PO-032: Association of a polymorphic variant in JMJD1C with tumor recurrence after adjuvant chemoradiation therapy in head and neck squamous cell carcinoma. Clinical Cancer Research 2023, 29: po-032-po-032. DOI: 10.1158/1557-3265.aacrahns23-po-032.
- Schrank T, Kothari A, Weir W, Stepp W, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward M, Wu D, Burtness B, Anderson K, Baldwin A, Yarbrough W, Issaeva N. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2216532120. PMID: 37523561, PMCID: PMC10410762, DOI: 10.1073/pnas.2216532120.
- Snyder R, Burtness B, Cho M, Del Rivero J, Doroshow D, Hitchcock K, Kalyan A, Kim C, Lukovic J, Parikh A, Sanford N, Singh B, Shen C, Shroff R, Vijayvergia N, Goodman K, Kunz P. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership. Journal Of The National Cancer Institute 2023, 115: 1132-1138. PMID: 37364007, PMCID: PMC11009492, DOI: 10.1093/jnci/djad121.
- Stockton S, Catalano P, Cohen S, Burtness B, Mitchell E, Dotan E, Lubner S, Kumar P, Mulcahy M, Fisher G, Crandall T, Benson A. Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The Oncologist 2023, 28: 827-e822. PMID: 37104870, PMCID: PMC10485278, DOI: 10.1093/oncolo/oyad096.
- Kann B, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly H, Juliano A, Payabvash S, Guenette J, Uppaluri R, Margalit D, Schoenfeld J, Tishler R, Haddad R, Aerts H, Garcia J, Flamand Y, Subramaniam R, Burtness B, Ferris R. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. The Lancet Digital Health 2023, 5: e360-e369. PMID: 37087370, PMCID: PMC10245380, DOI: 10.1016/s2589-7500(23)00046-8.
- Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm D. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Research Communications 2023, 3: 558-563. PMID: 37057033, PMCID: PMC10088911, DOI: 10.1158/2767-9764.crc-22-0299.
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung C. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2023, 41: 3851-3862. PMID: 36977289, DOI: 10.1200/jco.22.01994.
- Burtness B. First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened? Journal Of Clinical Oncology 2023, 41: 2134-2137. PMID: 36877893, DOI: 10.1200/jco.22.02349.
- Belzer A, Pach J, Mortlock R, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal J. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD International 2023, 11: 174-175. PMID: 37252181, PMCID: PMC10213716, DOI: 10.1016/j.jdin.2023.02.007.
- Verma A, Burtness B. Top advances of the year: Head and neck cancer. Cancer 2023, 129: 1308-1312. PMID: 36692372, DOI: 10.1002/cncr.34654.
- Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J. Author Correction: Head and neck squamous cell carcinoma. Nature Reviews Disease Primers 2023, 9: 4. PMID: 36658129, DOI: 10.1038/s41572-023-00418-5.
- Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.
- Burtness B, Lin J, Souliéres D. Methodologic Concerns in Secondary Analysis of KEYNOTE-048. JAMA Oncology 2022, 8: 1853-1854. PMID: 36264563, DOI: 10.1001/jamaoncol.2022.5068.
- Qian D, Ulrich B, Peng G, Zhao H, Conneely K, Miller A, Bruner D, Eldridge R, Wommack E, Higgins K, Shin D, Saba N, Smith A, Burtness B, Park H, Stokes W, Beitler J, Xiao C. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood. International Journal Of Radiation Oncology • Biology • Physics 2022, 115: 1217-1228. PMID: 36410685, DOI: 10.1016/j.ijrobp.2022.11.009.
- Gavrielatou N, Warrell J, Aung T, Vathiotis L, Economopoulou P, Burtness B, Psyrri A, Rimm D. 133 Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma. 2022, a146-a146. DOI: 10.1136/jitc-2022-sitc2022.0133.
- Hutcheson K, Peterson C, Barbon C, Quon H, Mehra R, Ringash J, Lewin J, Flamand Y, Duvvuri U, Ozer E, Thomas G, Kupferman M, Koch W, Bell R, Saba N, Panwar A, Annino D, Wagner L, Ferris R, Burtness B. Reduced Aspiration Rates for 50 Gy Postoperative Radiation in HPV-Associated Oropharynx Cancer in E3311: A Trial of the ECOG-ACRIN Cancer Research Group. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s27-s28. DOI: 10.1016/j.ijrobp.2022.07.380.
- Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal Of Clinical Oncology 2022, 41: 790-802. PMID: 36219809, PMCID: PMC9902012, DOI: 10.1200/jco.21.02508.
- Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Journal Of The National Cancer Institute 2022, 114: 1619-1627. PMID: 36053203, PMCID: PMC9745425, DOI: 10.1093/jnci/djac163.
- Soulieres D, Harrington K, Le Tourneau C, Silva J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Lin J, Lerman N, Gumuscu B, Cohen E. 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Annals Of Oncology 2022, 33: s843. DOI: 10.1016/j.annonc.2022.07.782.
- Tahara M, Greil R, Rischin D, Harrington K, Burtness B, De Castro G, Psyrri A, Brana I, Neupane P, Bratland Å, Fuereder T, Hughes B, Nin R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Gumuscu B, Lerman N, Soulieres D. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Annals Of Oncology 2022, 33: s844. DOI: 10.1016/j.annonc.2022.07.783.
- Machiels J, Tao Y, Burtness B, Tahara M, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Swaby R, Zhang Y, Gumuscu B, Bidadi B, Siu L. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2022, 33: s1399. DOI: 10.1016/j.annonc.2022.08.029.
- Burtness B. Integrating Targeted Therapies in the Management of Head and Neck Cancers. The Cancer Journal 2022, 28: 329-330. PMID: 36165719, DOI: 10.1097/ppo.0000000000000624.
- Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404). Journal Of Clinical Oncology 2022, 40: 4240-4249. PMID: 35867947, PMCID: PMC9916043, DOI: 10.1200/jco.22.00229.
- Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society Of Clinical Oncology Educational Book 2022, 42: 1-14. PMID: 35486888, DOI: 10.1200/edbk_350442.
- Fisher T, Evans E, Mallow C, Foster A, Boise M, Smith E, Leonard J, Chaney M, Beck J, Hager S, Saba N, Steuer C, Adkins D, Burtness B, Zauderer M. Abstract CT111: Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84). Cancer Research 2022, 82: ct111-ct111. DOI: 10.1158/1538-7445.am2022-ct111.
- Chung C, Colevas A, Adkins D, Gibson M, Rodriguez C, Sukari A, Bauman J, Wirth L, Johnson F, Saba N, Burtness B, Dunn L, Seiwert T, Worden F, Muzaffar J, Margossian S, Moniz R, Quayle S, Levisetti M, Pai S. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Journal Of Clinical Oncology 2022, 40: 6045-6045. DOI: 10.1200/jco.2022.40.16_suppl.6045.
- Argiris A, Flamand Y, Savvides P, Johnson J, Li S, Forastiere A, Burtness B. A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. Journal Of Clinical Oncology 2022, 40: 6026-6026. DOI: 10.1200/jco.2022.40.16_suppl.6026.
- Fisher T, Evans E, Mallow C, Foster A, Boise M, Smith E, Leonard J, Chaney M, Beck J, Hager S, Mekhail T, Seetharamu N, Baumgart M, Saba N, Steuer C, Adkins D, Burtness B, Zauderer M. Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). Journal Of Clinical Oncology 2022, 40: e18033-e18033. DOI: 10.1200/jco.2022.40.16_suppl.e18033.
- Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.
- Mehra R, Flamand Y, Quon H, Garcia J, Weinstein G, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Gross N, Bell R, Saba N, Lango M, Bayon R, Burtness B, Ferris R. Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2022, 40: 6077-6077. DOI: 10.1200/jco.2022.40.16_suppl.6077.
- Haider S, Sharaf K, Zeevi T, Mahajan A, Forghani R, Judson B, Kann B, Burtness B, Reichel C, Baumeister P, Payabvash S. PET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients. Laryngo-Rhino-Otologie 2022, 101: s184-s184. DOI: 10.1055/s-0042-1746471.
- Haider S, Sharaf K, Zeevi T, Mahajan A, Forghani R, Judson B, Kann B, Burtness B, Reichel C, Baumeister P, Payabvash S. PET/CT-Radiomics zuzüglich zum UICC-Staging könnten die Prognostik des Progressionsfreien Überlebens (PFS) und Gesamtüberlebens (OS) beim Oropharyngealen Plattenepithelkarzinom (OPSCC) verbessern. Laryngo-Rhino-Otologie 2022, 101: s13-s13. DOI: 10.1055/s-0042-1747116.
- Fisher T, Evans E, Mallow C, Foster A, Boise M, Smith E, Leonard J, Chaney M, Beck J, Hager S, Saba N, Steuer C, Adkins D, Burtness B, Zauderer M. Phase 1/2 Study of Pepinemab in Combination with Pembrolizumab as First-Line Treatment of Advanced, Recurrent or Metastatic Head and Neck Cancer (KEYNOTE B84). International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e36. DOI: 10.1016/j.ijrobp.2021.12.084.
- Schoenfeld J, Cohen E, Nutting C, Licitra L, Burtness B, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Bourhis J. Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e20-e21. DOI: 10.1016/j.ijrobp.2021.12.046.
- Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e43-e44. DOI: 10.1016/j.ijrobp.2021.12.101.
- Yarbrough W, Schrank T, Blumberg J, Patel S, Hackman T, Lumley C, Burtness B, Issaeva N. Predictive Molecular Biomarkers for HPV-Associated Head and Neck Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e17-e18. DOI: 10.1016/j.ijrobp.2021.12.178.
- Chung C, Colevas A, Gibson M, Adkins D, Sukari A, Wirth L, Burtness B, Bauman J, Rodriguez C, Worden F, Saba N, Glisson B, Dunn L, Seiwert T, Agensky L, Levisetti M, Lynam R, Margossian S, Moniz R, Quayle S, Pienta K, Pai S. 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Journal For ImmunoTherapy Of Cancer 2021, 9: a468-a468. DOI: 10.1136/jitc-2021-sitc2021.438.
- Qian D, Ulrich B, Peng G, Zhao H, Conneely K, Miller A, Bruner D, Eldridge R, Wommack E, Higgins K, Shin D, Saba N, Smith A, Burtness B, Park H, Stokes W, Beitler J, Xiao C. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-Treatment DNA Methylation in Peripheral Blood. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s143-s144. DOI: 10.1016/j.ijrobp.2021.07.323.
- Harrington K, Siu L, Burtness B, Cohen E, Licitra L, Rischin D, Zhu Y, Okpara C, Pinheiro C, Swaby R, Machiels J, Tahara M. P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study. Oral Oncology 2021, 118: 7-8. DOI: 10.1016/s1368-8375(21)00375-4.
- Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology 2021, 118: 10-11. DOI: 10.1016/s1368-8375(21)00381-x.
- Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable? Journal Of Clinical Oncology 2021, 39: 2732-2733. PMID: 34043410, DOI: 10.1200/jco.21.00594.
- Xiao C, Beitler JJ, Peng G, Levine ME, Conneely KN, Zhao H, Felger JC, Wommack EC, Chico CE, Jeon S, Higgins KA, Shin DM, Saba NF, Burtness BA, Bruner DW, Miller AH. Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study. Cancer 2021, 127: 3361-3371. PMID: 34027995, DOI: 10.1002/cncr.33641.
- Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia J, Ringash J, Lewin J, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Kupferman M, Bell R, Saba N, Lango M, Wagner L, Burtness B. Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). Journal Of Clinical Oncology 2021, 39: 6010-6010. DOI: 10.1200/jco.2021.39.15_suppl.6010.
- Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Mell L, Spencer S, Stokes W, Yao M, Mitchell D, Harris J, Curran W, Le Q. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal Of Clinical Oncology 2021, 39: 6014-6014. DOI: 10.1200/jco.2021.39.15_suppl.6014.
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Saboda K, Obara S, Chung C. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6015-6015. DOI: 10.1200/jco.2021.39.15_suppl.6015.
- Forman R, Bhatia A, Burtness B. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. Journal Of Clinical Oncology 2021, 39: 6042-6042. DOI: 10.1200/jco.2021.39.15_suppl.6042.
- Bourhis J, Burtness B, Licitra L, Nutting C, Schoenfeld J, Sarkouh R, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen E. TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer. Journal Of Clinical Oncology 2021, 39: tps6091-tps6091. DOI: 10.1200/jco.2021.39.15_suppl.tps6091.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Entwicklung bildbasierter Radiomics-Biomarker für den Humanen Papillomavirus (HPV)-Status beim oropharyngealen Plattenepithelkarzinom (OPSCC) mittels Machine-Learning-Algorithmen. Laryngo-Rhino-Otologie 2021, 100: s65. DOI: 10.1055/s-0041-1727786.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Devising novel imaging biomarkers for Human Papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC): applying radiomics and machine learning algorithms. Laryngo-Rhino-Otologie 2021, 100: s99. DOI: 10.1055/s-0041-1727889.
- Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.
- Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.
- Petit C, Lacas B, Pignon J, Le Q, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar M, Lee J, Ghi M, Sanguineti G, Temam S, Cheugoua-Zanetsie M, O'Sullivan B, Posner M, Vokes E, Hernandez J, Szutkowski Z, Lartigau E, Budach V, Suwiński R, Poulsen M, Kumar S, Laskar S, Mazeron J, Jeremic B, Simes J, Zhong L, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P, Groups M, Adelstein D, Agarwal J, Alfonsi M, Argiris A, Aupérin A, Bacigalupo A, Bar-Ad V, Bartelink H, Beadle B, Belkacemi Y, Bensadoun R, Bernier J, Blanchard P, Bourhis J, Bratland Å, Brizel D, Budach V, Budach W, Burtness B, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Cheugoua-Zanetsie M, Cho K, Choussy O, Hernandez J, Denham J, Dobrowsky W, Dominello M, Driessen C, Fallai C, Forastiere A, Fortpied C, Fountzilas G, Garaud P, Garden A, Gery B, Ghadjar P, Ghi M, Laskar S, Graff-Cailleaud P, Grau C, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hay J, Hayoz S, Horiot J, Hitt R, Jeremic B, Johansen J, Jones C, Julieron M, Kristensen C, Kumar S, Lacas B, Langendijk J, Lapeyre M, Lartigau E, Licitra L, Le Q, Lee J, Lee P, Lewin F, Li Y, Lopes A, Lotayef M, Maciejewski B, Mazeron J, Mehta S, Michalski W, Moon J, Moon S, Moyal E, Nankivell M, Nilsson P, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Parmar M, Petit C, Pignon J, Pointreau Y, Posner M, Poulsen M, Quon H, Racadot S, Rosenthal D, Rovea P, Redda M, Sanguineti G, Shenouda G, Simes J, Sharma A, Simon C, Sire C, Skladowski K, Spencer S, Staar S, Strojan P, Stromberger C, Suwinski R, Szutkowski Z, Takácsi-Nagy Z, Tao Y, Temam S, Thomson D, Tobias J, Torres-Saavedra P, Torri V, Tripcony L, Trotti A, Tseroni V, van Herpen C, van Tinteren H, Vermorken J, Viegas C, Vokes E, Waldron J, Wernecke K, Widder J, Wolf G, Wong S, Wu J, Yamazaki H, Zaktonik B, Zackrisson B, Zhong L. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. The Lancet Oncology 2021, 22: 727-736. PMID: 33862002, DOI: 10.1016/s1470-2045(21)00076-0.
- Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Redda M, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP, Group M, Adelstein D, Alfonsi M, Belkacemi Y, Bar-Ad V, Bernier J, Bratland Å, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Choi K, Choussy O, Collette L, Cruz J, Dani C, Dauzier E, Forastiere A, Garaud P, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hayoz S, Horiot J, Jeremic B, Karrison T, Langendijk J, Lapeyre M, Lartigau E, Leong T, Le Q, Lee P, Lewin F, Lin A, Lopes A, Mehta S, Moon J, Moyal E, Occéan B, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Petit C, Quon H, Sanguineti G, Satar T, Simes J, Simon C, Sire C, Staar S, Stromberger C, Strojan P, Temam S, Thomson D, Timochenko A, Torri V, Tseroni V, Vermorken J, Vokes E, Waldron J, Wernecke K, Widder J, Zackrisson B. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy And Oncology 2021, 156: 281-293. PMID: 33515668, PMCID: PMC8386522, DOI: 10.1016/j.radonc.2021.01.013.
- Burtness B, Contessa J. Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer. Journal Of The National Cancer Institute 2021, 113: 652-653. PMID: 33429429, PMCID: PMC8168139, DOI: 10.1093/jnci/djaa187.
- Cmelak A, Dietrich MS, Li S, Ridner S, Forastiere A, Burtness BA, Cella D, Murphy BA. ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer. Cancers Of The Head & Neck 2020, 5: 12. PMID: 33353553, PMCID: PMC7756946, DOI: 10.1186/s41199-020-00059-1.
- Zandberg D, Ferris R, Laux D, Mehra R, Nabell L, Kaczmar J, Gibson M, Kim Y, Neupane P, Bauman J, Julian R, Adkins D, Cohen E, Burtness B, Bermingham C, Dupage A, Desbien A, Loi A, Nuyten D, Saba N. 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. Annals Of Oncology 2020, 31: s1446-s1447. DOI: 10.1016/j.annonc.2020.10.559.
- Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers 2020, 6: 92. PMID: 33243986, PMCID: PMC7944998, DOI: 10.1038/s41572-020-00224-3.
- Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Swaby R. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology 2020, 34: 532-541. PMID: 33239737, DOI: 10.1038/s41379-020-00710-9.
- Khan SA, Burke M, Zhu F, Yang DH, Dubyk C, Mehra R, Lango MJ, Ridge JA, Sher DJ, Burtness B. Survivin expression and impact on head and neck cancer outcomes. Oral Oncology 2020, 112: 105049. PMID: 33221541, PMCID: PMC10916757, DOI: 10.1016/j.oraloncology.2020.105049.
- Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Journal For ImmunoTherapy Of Cancer 2020, 8: a376-a376. DOI: 10.1136/jitc-2020-sitc2020.0351.
- Pai S, Adkins D, Wirth L, Chung C, Gibson M, Sukari A, Worden F, Colevas D, Saba N, Burtness B, Rodriguez C, Bauman J, Glisson B, Dunn L, Suri A, Haydock M, Quayle S, Cemerski S, Leader M, Brown J, Pienta K, Simcox M. 354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer. 2020, a216.1-a216. DOI: 10.1136/jitc-2020-sitc2020.0354.
- Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.
- Haider SP, Sharaf K, Zeevi T, Baumeister P, Reichel C, Forghani R, Kann BH, Petukhova A, Judson BL, Prasad ML, Liu C, Burtness B, Mahajan A, Payabvash S. Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics. Translational Oncology 2020, 14: 100906. PMID: 33075658, PMCID: PMC7568193, DOI: 10.1016/j.tranon.2020.100906.
- Burtness B, Ge J. Reply to “Keynote 48: Is it really for everyone?”. Oral Oncology 2020, 112: 104983. PMID: 33032941, DOI: 10.1016/j.oraloncology.2020.104983.
- Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le Q, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtness BA, Ghi MG, Sanguineti G, O’Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon J, Mell LK, Intergroup F. Predictive classifier for intensive treatment of head and neck cancer. Cancer 2020, 126: 5263-5273. PMID: 33017867, DOI: 10.1002/cncr.33212.
- Siu L, Burtness B, Cohen E, Harrington K, Licitra L, Rischin D, Zhu Y, Okpara C, Pinheiro C, Swaby R, Machiels J, Tahara M. LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2020, 31: s683-s684. DOI: 10.1016/j.annonc.2020.08.1088.
- Greil R, Rischin D, Harrington K, Soulières D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Swaby R, Gumuscu B, Burtness B. Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2020, 31: s660-s661. DOI: 10.1016/j.annonc.2020.08.1030.
- Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. Cancer Research 2020, 80: lb-258-lb-258. DOI: 10.1158/1538-7445.am2020-lb-258.
- Burtness B, Zhang Y, Harrington KJ, Rischin D. Further clinical interpretation and implications of KEYNOTE-048 findings – Authors' reply. The Lancet 2020, 396: 379-380. PMID: 32771104, DOI: 10.1016/s0140-6736(20)30900-4.
- Ferris RL, Flamand Y, Holsinger FC, Weinstein GS, Quon H, Mehra R, Garcia JJ, Hinni ML, Gross ND, Sturgis EM, Duvvuri U, Méndez E, Ridge JA, Magnuson JS, Higgins KA, Patel MR, Smith RB, Karakla DW, Kupferman ME, Malone JP, Judson BL, Richmon J, Boyle JO, Bayon R, O'Malley BW, Ozer E, Thomas GR, Koch WM, Bell RB, Saba NF, Li S, Sigurdson ER, Burtness B. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncology 2020, 110: 104797. PMID: 32679405, PMCID: PMC7771718, DOI: 10.1016/j.oraloncology.2020.104797.
- Haider SP, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kann BH, Judson BL, Prasad ML, Burtness B, Mahajan A, Payabvash S. Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma. Cancers 2020, 12: 1778. PMID: 32635216, PMCID: PMC7407414, DOI: 10.3390/cancers12071778.
- Husain ZA, Burtness BA. High Dose Cisplatin: Still the One? International Journal Of Radiation Oncology • Biology • Physics 2020, 107: 615-616. PMID: 32589986, DOI: 10.1016/j.ijrobp.2019.09.026.
- Ridge J, Ringash J, Yao M, Blakaj D, Razaq M, Colevas A, Beitler J, Jones C, Dunlap N, Seaward S, Spencer S, Galloway T, Dignam J, Le Q, Gillison M, Sturgis E, Phan J, Trotti A, Harris J, Eisbruch A, Harari P, Adelstein D, Koyfman S, Burtness B. Abstract IA20: Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial*. Clinical Cancer Research 2020, 26: ia20-ia20. DOI: 10.1158/1557-3265.aacrahns19-ia20.
- Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, Alves GV, Lima I, Pointreau Y, Hughes B, Aksoy S, Hetnal M, Ge JY, Brown H, Cheng J, Bidadi B, Siu LL. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncology 2020, 16: 1235-1243. PMID: 32490686, DOI: 10.2217/fon-2020-0184.
- Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia J, Chung C, Gillison M, Duvvuri U, O'malley B, Ozer E, Thomas G, Koch W, Kupferman M, Bell R, Saba N, Lango M, Mendez E, Burtness B. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). Journal Of Clinical Oncology 2020, 38: 6500-6500. DOI: 10.1200/jco.2020.38.15_suppl.6500.
- Harrington K, Rischin D, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Gumuscu B, Swaby R, Burtness B. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6505-6505. DOI: 10.1200/jco.2020.38.15_suppl.6505.
- Rischin D, Harrington K, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Burtness B. Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. Journal Of Clinical Oncology 2020, 38: 6530-6530. DOI: 10.1200/jco.2020.38.15_suppl.6530.
- Burtness B, Deneka A, Baca Y, Serebriiskii I, Parker M, Nicolas E, Lee J, Wise-Draper T, Sukari A, Somer B, Golemis E. Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6552-6552. DOI: 10.1200/jco.2020.38.15_suppl.6552.
- Siu L, Burtness B, Cohen E, Harrington K, Licitra L, Rischin D, Zhu Y, Lee C, Pinheiro C, Swaby R, Machiels J, Tahara M. Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6589-tps6589. DOI: 10.1200/jco.2020.38.15_suppl.tps6589.
- Bauman J, Roe D, Saba N, Bauman J, Kaczmar J, Burtness B, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Bhatia A, Giri A, Caulin C, Stabile L, Centuori S, Chung C. Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6594-tps6594. DOI: 10.1200/jco.2020.38.15_suppl.tps6594.
- Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal Of The National Cancer Institute 2020, 113: 171-181. PMID: 32407532, PMCID: PMC7850527, DOI: 10.1093/jnci/djaa063.
- Haider SP, Mahajan A, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kucukkaya AS, Kann BH, Judson BL, Prasad ML, Burtness B, Payabvash S. PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2978-2991. PMID: 32399621, DOI: 10.1007/s00259-020-04839-2.
- Haider SP, Burtness B, Yarbrough WG, Payabvash S. Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. Cancers Of The Head & Neck 2020, 5: 6. PMID: 32391171, PMCID: PMC7197186, DOI: 10.1186/s41199-020-00053-7.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Devising novel imaging biomarkers for Human Papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC): applying radiomics and machine learning algorithms. Laryngo-Rhino-Otologie 2020, 99: s163. DOI: 10.1055/s-0040-1711024.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Entwicklung bildbasierter Radiomics-Biomarker für den Humanen Papillomavirus (HPV)-Status beim oropharyngealen Plattenepithelkarzinom (OPSCC) mittels Machine-Learning-Algorithmen. Laryngo-Rhino-Otologie 2020, 99: s116. DOI: 10.1055/s-0040-1711657.
- Jacobs D, Park H, Young M, Olino K, Rahmati R, Mehra S, Burtness B, Judson B. Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1191-1192. DOI: 10.1016/j.ijrobp.2019.11.099.
- Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancerSaeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.
- Deneka AY, Einarson MB, Bennett J, Nikonova AS, Elmekawy M, Zhou Y, Lee JW, Burtness BA, Golemis EA. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers 2020, 12: 306. PMID: 32012873, PMCID: PMC7072436, DOI: 10.3390/cancers12020306.
- Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.
- Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. Journal Of Clinical Oncology 2019, 38: 472-479. PMID: 31815582, PMCID: PMC7007287, DOI: 10.1200/jco.19.00925.
- Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S. Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal Of Clinical Oncology 2019, 38: 1304-1311. PMID: 31815574, DOI: 10.1200/jco.19.02031.
- Baro M, Lopez Sambrooks C, Burtness BA, Lemmon MA, Contessa JN. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics 2019, 18: 2124-2134. PMID: 31387891, PMCID: PMC6825559, DOI: 10.1158/1535-7163.mct-19-0163.
- Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak W, Hong RL, Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D, Investigators K, Lerzo G, Tatangelo M, Varela M, Zarba J, Boyer M, Gan H, Gao B, Hughes B, Mallesara G, Rischin D, Taylor A, Burian M, Fuereder T, Greil R, Barrios C, de Castro D, Castro G, Franke F, Girotto G, Lima I, Nicolau U, Pinto G, Santos L, Victorino A, Chua N, Couture F, Gregg R, Hansen A, Hilton J, McCarthy J, Soulieres D, Ascui R, Gonzalez P, Villanueva L, Torregroza M, Zambrano A, Holeckova P, Kral Z, Melichar B, Prausova J, Vosmik M, Andersen M, Gyldenkerne N, Jurgens H, Putnik K, Reinikainen P, Gruenwald V, Laban S, Aravantinos G, Boukovinas I, Georgoulias V, Psyrri A, Kwong D, Al-Farhat Y, Csoszi T, Erfan J, Horvai G, Landherr L, Remenar E, Ruzsa A, Szota J, Billan S, Gluck I, Gutfeld O, Popovtzer A, Benasso M, Bui S, Ferrari V, Licitra L, Nole F, Fujii T, Fujimoto Y, Hanai N, Hara H, Matsumoto K, Mitsugi K, Monden N, Nakayama M, Okami K, Oridate N, Shiga K, Shimizu Y, Sugasawa M, Tahara M, Takahashi M, Takahashi S, Tanaka K, Ueda T, Yamaguchi H, Yamazaki T, Yasumatsu R, Yokota T, Yoshizaki T, Kudaba I, Stara Z, Ishak W, Cheah S, Ponce J, Mendoza R, Hernandez C, Soto F, Buter J, Hoeben A, Oosting S, Suijkerbuijk K, Bratland A, Brydoey M, Alvarez R, Mas L, Caguioa P, Querol J, Regala E, Tamayo M, Villegas E, Kawecki A, Karpenko A, Klochikhin A, Smolin A, Zarubenkov O, Goh B, Cohen G, du Toit J, Jordaan C, Landers G, Ruff P, Szpak W, Tabane N, Brana I, Docampo L, Lavernia J, Mesia R, Abel E, Muratidu V, Nielsen N, Cristina V, Rordorf T, Rothschild S, Hong R, Wang H, Yang M, Yeh S, Yen C, Ngamphaiboon N, Soparattanapaisarn N, Sriuranpong V, Aksoy S, Cicin I, Ekenel M, Harputluoglu H, Ozyilkan O, Harrington K, Agarwala S, Ali H, Alter R, Anderson D, Bruce J, Burtness B, Campbell N, Conde M, Deeken J, Edenfield W, Feldman L, Gaughan E, Goueli B, Halmos B, Hegde U, Hunis B, Jotte R, Karnad A, Khan S, Laudi N, Laux D, Martincic D, McCune S, McGaughey D, Misiukiewicz K, Mulford D, Nadler E, Neupane P, Nunnink J, Ohr J, O'Malley M, Patson B, Paul D, Popa E, Powell S, Redman R, Rella V, Lima C, Sivapiragasam A, Su Y, Sukari A, Wong S, Yilmaz E, Yorio J. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 2019, 394: 1915-1928. PMID: 31679945, DOI: 10.1016/s0140-6736(19)32591-7.
- Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncology 2019, 99: 104460. PMID: 31683169, PMCID: PMC7749717, DOI: 10.1016/j.oraloncology.2019.104460.
- Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.
- Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2019, 37: 3266-3274. PMID: 31618129, PMCID: PMC6980834, DOI: 10.1200/jco.19.00555.
- Cohen E, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Bal T, Juco J, Aurora-Garg D, Huang L, Swaby R, Emancipator K. 1115PD Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040. Annals Of Oncology 2019, 30: v452-v453. DOI: 10.1093/annonc/mdz252.007.
- Husain Z, Lee N, Eskander A, Park H, mehra S, Burtness B. 1149P Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Annals Of Oncology 2019, 30: v466. DOI: 10.1093/annonc/mdz252.041.
- Yu J, Tsay C, Sasaki C, Son Y, Decker R, Mehra S, Burtness B. 1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Annals Of Oncology 2019, 30: v457. DOI: 10.1093/annonc/mdz252.019.
- Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant TherapyLOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.
- Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant TherapyLoganadane G, Kann B, Park H, Johnson S, Mehra S, Judson B, Bhatia A, Belkacemi Y, Yarbrough W, Burtness B, Husain Z. Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e375-e376. DOI: 10.1016/j.ijrobp.2019.06.1628.
- Kann B, Hicks D, Payabvash S, Mahajan A, Gupta V, Burtness B, Husain Z, Aneja S. External Validation and Radiologist Comparison of a Deep Learning Model (DLM) to Identify Extranodal Extension (ENE) in Head and Neck Squamous Cell Carcinoma (HNSCC) with Pretreatment Computed Tomography (CT) Imaging. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s71. DOI: 10.1016/j.ijrobp.2019.06.525.
- Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology 2019, 5: 1170-1180. PMID: 31194247, PMCID: PMC6567846, DOI: 10.1001/jamaoncol.2019.1146.
- Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Journal For ImmunoTherapy Of Cancer 2019, 7: 184. PMID: 31307547, PMCID: PMC6632213, DOI: 10.1186/s40425-019-0662-5.
- Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology 2019, 16: 669-683. PMID: 31189965, DOI: 10.1038/s41571-019-0227-z.
- Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2019, 25: 3430-3442. PMID: 30755439, PMCID: PMC6548643, DOI: 10.1158/1078-0432.ccr-18-0440.
- Rischin D, Harrington K, Greil R, Soulieres D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland A, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Jin F, Gumuscu B, Burtness B. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal Of Clinical Oncology 2019, 37: 6000-6000. DOI: 10.1200/jco.2019.37.15_suppl.6000.
- Ho A, Foster N, Zoroufy A, Worden F, Price K, Adkins D, Bowles D, Kang H, Burtness B, Sherman E, Morton R, Katabi N, Munster P, Schwartz G. Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. Journal Of Clinical Oncology 2019, 37: 6020-6020. DOI: 10.1200/jco.2019.37.15_suppl.6020.
- Harrington K, Cohen E, Soulieres D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Lin J, Cheng J, Swaby R, Le Tourneau C. Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state. Journal Of Clinical Oncology 2019, 37: 6026-6026. DOI: 10.1200/jco.2019.37.15_suppl.6026.
- Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.
- Lee NCJ, Eskander A, Park HS, Mehra S, Burtness BA, Husain Z. Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Cancer 2019, 125: 2975-2983. PMID: 31090934, DOI: 10.1002/cncr.32161.
- Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncology 2019, 94: 32-40. PMID: 31178210, DOI: 10.1016/j.oraloncology.2019.05.009.
- Xiang JJ, Uy NF, Minja FJ, Verter EE, Burtness BA. Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report. The Laryngoscope 2019, 130: 907-910. PMID: 31058321, DOI: 10.1002/lary.28042.
- Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal Of Clinical Oncology 2019, 37: jco.19.00441. PMID: 31021656, DOI: 10.1200/jco.19.00441.
- Miccio J, Kelly J, Kann B, An Y, Park H, Verma V, Mehra S, Judson B, Burtness B, Husain Z. OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e1. DOI: 10.1016/s0360-3016(19)30402-x.
- Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncology 2019, 91: 69-78. PMID: 30926065, PMCID: PMC6855599, DOI: 10.1016/j.oraloncology.2019.02.026.
- Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head & Neck 2019, 41: 1928-1934. PMID: 30758123, PMCID: PMC6542589, DOI: 10.1002/hed.25634.
- Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019, 125: 2018-2026. PMID: 30748002, PMCID: PMC6541535, DOI: 10.1002/cncr.32001.
- Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene 2019, 38: 3475-3487. PMID: 30647454, PMCID: PMC6499643, DOI: 10.1038/s41388-018-0657-6.
- Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ, investigators K, Acosta-Rivera M, Adkins D, Aghmesheh M, Ahn M, Airoldi M, Aleknavicius E, Al-Farhat Y, Algazi A, Almokadem S, Alyasova A, Bauman J, Benasso M, Berrocal A, Bray V, Burtness B, Caponigro F, Castro A, Cescon T, Chan K, Chaudhry A, Chauffert B, Cohen E, Csoszi T, De Boer J, Delord J, Dietz A, Dinis J, Dupuis C, Digue L, Erfan J, Alvarez Y, Evans M, Fidler M, Forster M, Friesland S, Ganti A, Geoffrois L, Grant C, Gruenwald V, Harrington K, Hoffmann T, Horvai G, Inciura A, Jang R, Jankowska P, Jimeno A, Joseph M, Ramiro A, Karaszewska B, Kawecki A, Keilholz U, Keller U, Kim S, Kocsis J, Kotecki N, Kozloff M, Lambea J, Landherr L, Lantsukhay Y, Lazarev S, Lee L, Le Tourneau C, Licitra L, Lifirenko I, Mach N, Martincic D, Matorin O, McGrath M, Machiels J, Mehra R, Misiukiewicz K, Morris J, Mufazalov F, Niu J, Srinivasan D, Segura P, Rauch D, Ribeiro M, Rodriguez C, Rolland F, Russo A, Ruzsa A, Sanches F, Shin S, Shtiveland M, Soulieres D, Soria A, Specenier P, Szekanecz E, Szota J, van Herpen C, Velez-Cortes H, Walsh W, Wilop S, Winterhalder R, Wojtukiewicz M, Wong D, Zandberg D. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet 2018, 393: 156-167. PMID: 30509740, DOI: 10.1016/s0140-6736(18)31999-8.
- Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet 2018, 393: 40-50. PMID: 30449625, PMCID: PMC6541928, DOI: 10.1016/s0140-6736(18)32779-x.
- Kann B, Aneja S, Loganadane G, Kelly J, Smith S, Decker R, Yarbrough W, Malhotra A, Burtness B, Husain Z. Successful Identification of Head and Neck Cancer (HNC) Nodal Metastasis (NM) and Extranodal Extension (ENE) Using Deep Learning Neural Networks. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s60. DOI: 10.1016/j.ijrobp.2018.06.169.
- Le Tourneau C, Cohen E, Harrington K, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Soulières D. 1047PD Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. Annals Of Oncology 2018, 29: viii373-viii374. DOI: 10.1093/annonc/mdy287.003.
- Zakeri K, Rotolo F, Lacas B, Vitzthum L, Le Q, Gregoire V, Overgaard J, Tobias J, Zackrisson B, Parmar M, Burtness B, Ghi M, Sanguineti G, O'Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Pignon J, Mell L. 1052PD Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). Annals Of Oncology 2018, 29: viii375-viii376. DOI: 10.1093/annonc/mdy287.008.
- Machiels J, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, Delord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 1121TiP KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2018, 29: viii398. DOI: 10.1093/annonc/mdy287.078.
- Burtness B, Harrington K, Greil R, Soulières D, Tahara M, De Castro G, Psyrri A, Rotllan N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Roy A, Cheng J, Jin F, Rischin D. LBA8_PR KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals Of Oncology 2018, 29: viii729. DOI: 10.1093/annonc/mdy424.045.
- Kann BH, Aneja S, Loganadane GV, Kelly JR, Smith SM, Decker RH, Yu JB, Park HS, Yarbrough WG, Malhotra A, Burtness BA, Husain ZA. Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. Scientific Reports 2018, 8: 14036. PMID: 30232350, PMCID: PMC6145900, DOI: 10.1038/s41598-018-32441-y.
- Cheraghlou S, Torabi SJ, Husain ZA, Otremba MD, Osborn HA, Mehra S, Yarbrough WG, Burtness BA, Judson BL. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. The Laryngoscope 2018, 129: 684-691. PMID: 30151832, DOI: 10.1002/lary.27475.
- Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.
- Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2018, 1-5. DOI: 10.1007/978-3-319-78762-6_1.
- Kiseleva A, Beck T, Serebriiskii I, Liu H, Burtness B, Golemis E. Targeting the ErbB Family in Head and Neck Cancer. Current Cancer Research 2018, 7-61. DOI: 10.1007/978-3-319-78762-6_2.
- Parameswaran J, Burtness B. P53 in Head and Neck Squamous Cell Carcinoma. Current Cancer Research 2018, 249-274. DOI: 10.1007/978-3-319-78762-6_9.
- Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations. Otolaryngology 2018, 159: 987-997. PMID: 30060700, DOI: 10.1177/0194599818779052.
- Deneka A, Einarson M, Lee J, Nikonova A, Burtness B, Golemis E. Abstract 5814: Synthetic lethal therapy to overcome resistance to AURKA inhibition in HPV-negative head and neck cancer. Cancer Research 2018, 78: 5814-5814. DOI: 10.1158/1538-7445.am2018-5814.
- Soulieres D, Cohen E, Tourneau C, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Harrington K. Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. Cancer Research 2018, 78: ct115-ct115. DOI: 10.1158/1538-7445.am2018-ct115.
- Cohen R, Fayette J, Posner M, Lefebvre G, Bauman J, Salas S, Even C, Seiwert T, Colevas D, Jimeno A, Saada E, Burtness B, André P, Paturel C, Bonnafous C, Soulié A, Tirouvanziam-Martin A, Zerbib R, Boyer-Chammard A. Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy. Cancer Research 2018, 78: ct158-ct158. DOI: 10.1158/1538-7445.am2018-ct158.
- Siu L, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, DeLord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Machiels J. Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. Cancer Research 2018, 78: ct163-ct163. DOI: 10.1158/1538-7445.am2018-ct163.
- Seiwert T, Haddad R, Bauml J, Weiss J, Pfister D, Gupta S, Mehra R, Gluck I, Kang H, Worden F, Eder J, Tahara M, Burtness B, Liu S, Webber A, Huang L, Mogg R, Cristescu R, Cheng J, Chow L. Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). Cancer Research 2018, 78: lb-339-lb-339. DOI: 10.1158/1538-7445.am2018-lb-339.
- Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal Of Cancer 2018, 119: 153-159. PMID: 29955135, PMCID: PMC6048158, DOI: 10.1038/s41416-018-0131-9.
- Kluwe C, Cmelak A, Burtness B. Oropharyngeal Cancer: HPV-Positive Disease. 2018 DOI: 10.1891/9780826137784.0013.
- Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncology 2018, 82: 122-130. PMID: 29909886, DOI: 10.1016/j.oraloncology.2018.02.010.
- Cohen E, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Ellison M, Cheng J, Chirovsky D, Swaby R, Harrington K. Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040. Journal Of Clinical Oncology 2018, 36: 6013-6013. DOI: 10.1200/jco.2018.36.15_suppl.6013.
- Machiels J, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, Delord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. Journal Of Clinical Oncology 2018, 36: tps6094-tps6094. DOI: 10.1200/jco.2018.36.15_suppl.tps6094.
- Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.
- Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 479-490. PMID: 29752322, DOI: 10.6004/jnccn.2018.0026.
- Bhatia AK, Burtness BA, Decker RH. Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2018, 36: jco.2018.77.798. PMID: 29547345, DOI: 10.1200/jco.2018.77.7987.
- Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncology 2018, 79: 64-70. PMID: 29598952, DOI: 10.1016/j.oraloncology.2018.02.017.
- Machiels J, Yen C, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 96TiP Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: xi28. DOI: 10.1093/annonc/mdx711.077.
- Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.
- Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.
- Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Response. Journal Of The National Cancer Institute 2017, 110: 433-434. PMID: 29121329, DOI: 10.1093/jnci/djx230.
- Yen C, Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 373TiP KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: x110. DOI: 10.1093/annonc/mdx665.036.
- Burtness B. The tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets? Cancer 2017, 124: 14-17. PMID: 29053184, DOI: 10.1002/cncr.31059.
- Kelly J, An Y, Park H, Yarbrough W, Burtness B, Husain Z. Evaluation of Pathology-Based Staging for HPV-Associated Squamous Cell Carcinoma of the Oropharynx in a Large National Sample. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e347. DOI: 10.1016/j.ijrobp.2017.06.1430.
- Kelly J, An Y, Park H, Yarbrough W, Burtness B, Husain Z. Survival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s43-s44. DOI: 10.1016/j.ijrobp.2017.06.114.
- Cohen E, Harrington K, Le Tourneau C, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Wang Y, Tuozzo A, Swaby R, Soulieres D. LBA45_PR Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Annals Of Oncology 2017, 28: v628. DOI: 10.1093/annonc/mdx440.040.
- Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Grégoire V, Shekar T, Brown H, Cheng J, Siu L. 1105TiP Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial. Annals Of Oncology 2017, 28: v392. DOI: 10.1093/annonc/mdx374.056.
- Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.
- Eze N, Lo YC, Burtness B. Biomarker driven treatment of head and neck squamous cell cancer. Cancers Of The Head & Neck 2017, 2: 6. PMID: 31093353, PMCID: PMC6460531, DOI: 10.1186/s41199-017-0025-1.
- Bhatia AK, Lee J, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez‐Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.
- Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer. American Journal Of Clinical Oncology 2017, 40: 393-398. PMID: 26986978, PMCID: PMC5026539, DOI: 10.1097/coc.0000000000000171.
- Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z. Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study. JAMA Oncology 2017, 3: 1107-1111. PMID: 28056116, PMCID: PMC5824218, DOI: 10.1001/jamaoncol.2016.5769.
- Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals Of Oncology 2017, 28: 2526-2532. PMID: 28961833, PMCID: PMC5834024, DOI: 10.1093/annonc/mdx344.
- Parameswaran J, Burtness B. Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 969-973. PMID: 28721906, DOI: 10.1016/j.ijrobp.2017.03.003.
- Mufson J, Handorf E, Weidhaas J, Lango M, Burtness B, Golemis E, Ridge J, Mehra R. Abstract 4732: Analysis of KRAS variant in a cohort of resected HPV negative HNSCC. Cancer Research 2017, 77: 4732-4732. DOI: 10.1158/1538-7445.am2017-4732.
- Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Ent Instructions for Authors. Ear, Nose & Throat Journal 2017, 96: 271-272. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.
- Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.
- Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 761-770. PMID: 28596256, DOI: 10.6004/jnccn.2017.0101.
- Lee N, Kelly J, Park H, Yarbrough W, Burtness B, Husain Z. (S040) The Risk of Level IB Nodal Involvement in Oropharynx Cancer: Guidance for Submandibular Gland Sparing Irradiation. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e12. DOI: 10.1016/j.ijrobp.2017.02.076.
- Bledsoe T, Park H, Stahl J, Yarbrough W, Burtness B, Decker R, Husain Z. (S027) Hypofractionated Radiotherapy Is associated With Improved Overall Survival Among Patients With Early-Stage Glottic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e8-e9. DOI: 10.1016/j.ijrobp.2017.02.063.
- Iqbal S, McDonough S, Lenz H, Ilson D, Burtness B, Nangia C, Barzi A, Schneider C, Liu J, Dotan E, Guthrie K, Hochster H. A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. Journal Of Clinical Oncology 2017, 35: 4009-4009. DOI: 10.1200/jco.2017.35.15_suppl.4009.
- Argiris A, Li S, Savvides P, Ohr J, Gilbert J, Levine M, Haigentz M, Saba N, Chakravarti A, Ikpeazu C, Schneider C, Pinto H, Forastiere A, Burtness B. Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. Journal Of Clinical Oncology 2017, 35: 6000-6000. DOI: 10.1200/jco.2017.35.15_suppl.6000.
- Burtness B, Haddad R, Dinis J, Trigo Perez J, Yokota T, Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia C, Chaves-Conde M, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen E. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal Of Clinical Oncology 2017, 35: 6001-6001. DOI: 10.1200/jco.2017.35.15_suppl.6001.
- Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I, Eder J, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Huang L, Ayers M, Mogg R, Cristescu R, Cheng J, Mehra R. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2017, 35: 6009-6009. DOI: 10.1200/jco.2017.35.15_suppl.6009.
- Wirth L, Burtness B, Mehra R, Bauman J, Lee J, Smith N, Lefranc-Torres A, Westra W, Bishop J, Faquin W, Lin D, Pai S. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. Journal Of Clinical Oncology 2017, 35: 6053-6053. DOI: 10.1200/jco.2017.35.15_suppl.6053.
- Cmelak A, Flamand Y, Li S, Marur S, Murphy B, Cella D, Forastiere A, Burtness B. Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies. Journal Of Clinical Oncology 2017, 35: 6074-6074. DOI: 10.1200/jco.2017.35.15_suppl.6074.
- Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Shekar T, Brown H, Cheng J, Siu L. KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Journal Of Clinical Oncology 2017, 35: tps6090-tps6090. DOI: 10.1200/jco.2017.35.15_suppl.tps6090.
- Tawfik B, Gerber D, Burtness B, Hughes R, Myers L, Sumer B, Truelson J, Strom T, Kurian P, Saleem S, Pearson J, Zhu H, Khan S. Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). Journal Of Clinical Oncology 2017, 35: tps6098-tps6098. DOI: 10.1200/jco.2017.35.15_suppl.tps6098.
- Parameswaran J, Lee J, Sandoval-Schaefer T, Koo J, Burtness B. Combination of WEE1 and AURKA inhibition in HPV negative head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2017, 35: e14105-e14105. DOI: 10.1200/jco.2017.35.15_suppl.e14105.
- Eze N, Chung C, Neumeister V, Sandoval-Schaefer T, Lee J, Burtness B. PTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C). Journal Of Clinical Oncology 2017, 35: e17520-e17520. DOI: 10.1200/jco.2017.35.15_suppl.e17520.
- Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109: djx042. PMID: 28521361, DOI: 10.1093/jnci/djx042.
- Marur S, Cmelak AJ, Burtness B. Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials. Journal Of Clinical Oncology 2017, 35: jco.2017.72.291. PMID: 28430529, DOI: 10.1200/jco.2017.72.2918.
- Marur S, Li S, Cmelak A, Burtness B. Reply to A. Garden et al. Journal Of Clinical Oncology 2017, 35: jco.2017.72.827. PMID: 28430530, DOI: 10.1200/jco.2017.72.8279.
- An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma. Cancer 2017, 123: 2762-2772. PMID: 28323338, DOI: 10.1002/cncr.30598.
- Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.
- Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 358-365. PMID: 27737449, DOI: 10.1001/jamaoncol.2016.4581.
- Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. Practical Radiation Oncology 2017, 7: e317-e321. PMID: 28356201, DOI: 10.1016/j.prro.2017.02.004.
- Psyrri A, Rampias T, Burtness B. Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 125. PMID: 27607105, DOI: 10.1001/jamaoncol.2016.3409.
- Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2016, 35: 490-497. PMID: 28029303, PMCID: PMC5455313, DOI: 10.1200/jco.2016.68.3300.
- Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le Q, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2016, 123: 1259-1271. PMID: 27906454, PMCID: PMC5705038, DOI: 10.1002/cncr.30449.
- Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncology 2016, 62: 147-148. PMID: 27776933, DOI: 10.1016/j.oraloncology.2016.10.007.
- Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.
- Blanchard P, Landais C, Petit C, Zhang Q, Grégoire V, Tobias J, Burtness B, Ghi M, Janot F, Overgaard J, Wolf G, Lewin F, Hitt R, Corvo R, Budach V, Trotti A, Fortpied C, Hackshaw A, Bourhis J, Pignon J. 950O Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group. Annals Of Oncology 2016, 27: vi328. DOI: 10.1093/annonc/mdw376.02.
- Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Molecular Cancer Therapeutics 2016, 15: 2486-2497. PMID: 27507850, PMCID: PMC5522587, DOI: 10.1158/1535-7163.mct-16-0243.
- Kelly J, Park H, An Y, Decker R, Contessa J, Yarbrough W, Burtness B, Judson B, Husain Z. Comparison of Upfront Surgery Versus Chemoradiation for cT1-2 N1-2b Oropharynx Squamous Cell Carcinoma Based on Human Papillomavirus Status. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e327. DOI: 10.1016/j.ijrobp.2016.06.1451.
- Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal Of Clinical Oncology 2016, 34: 3838-3845. PMID: 27646946, PMCID: PMC6804896, DOI: 10.1200/jco.2016.68.1478.
- Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL. Proposing prognostic thresholds for lymph node yield in clinically lymph node‐negative and lymph node‐positive cancers of the oral cavity. Cancer 2016, 122: 3624-3631. PMID: 27479645, DOI: 10.1002/cncr.30227.
- Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal Of Clinical Oncology 2016, 34: 2736-2742. PMID: 27382098, PMCID: PMC5019745, DOI: 10.1200/jco.2015.65.5092.
- Subramanian HE, Park HS, Barbieri A, Mahajan A, Judson BL, Mehra S, Yarbrough WG, Burtness BA, Husain ZA. Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study. Cancers Of The Head & Neck 2016, 1: 7. PMID: 31093337, PMCID: PMC6460847, DOI: 10.1186/s41199-016-0008-7.
- Burtness B. Introducing cancers of the head and neck, a new open access journal. Cancers Of The Head & Neck 2016, 1: 3. PMID: 31093333, PMCID: PMC6457142, DOI: 10.1186/s41199-016-0001-1.
- L K, B B, A F, RF H, E H, MK G. Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer. Journal Of Cancer Science And Clinical Oncology 2016, 3 DOI: 10.15744/2394-6520.3.105.
- Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. The Lancet Oncology 2016, 17: 956-965. PMID: 27247226, DOI: 10.1016/s1470-2045(16)30066-3.
- Bhatia A, Lee J, Pinto H, Jacobs C, Limburg P, Arusell R, Dunphy E, Khandekar J, Reiner S, Baez-Diaz L, Celano P, Li S, Li Y, Burtness B, Pandya K. Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590). Journal Of Clinical Oncology 2016, 34: 1507-1507. DOI: 10.1200/jco.2016.34.15_suppl.1507.
- Chow L, Mehra R, Haddad R, Mahipal A, Weiss J, Berger R, Eder J, Burtness B, Tahara M, Keam B, Le D, Muro K, Geva R, Chung H, Lin C, Ayers M, Aurora-Garg D, Lunceford J, Cheng J, Seiwert T. Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal Of Clinical Oncology 2016, 34: 6010-6010. DOI: 10.1200/jco.2016.34.15_suppl.6010.
- Mehra R, Seiwert T, Mahipal A, Weiss J, Berger R, Eder J, Burtness B, Tahara M, Keam B, Le D, Muro K, Geva R, Chung H, Lin C, Meister A, Hille D, Cheng J, Chow L, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. Journal Of Clinical Oncology 2016, 34: 6012-6012. DOI: 10.1200/jco.2016.34.15_suppl.6012.
- Khan S, Ci B, Gerber D, McFadden D, Beg M, Xie Y, Kurian P, Cabanillas M, Busaidy N, Sherman S, Heilmann A, Ross J, Bailey M, Burtness B, Ali S. Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). Journal Of Clinical Oncology 2016, 34: 6014-6014. DOI: 10.1200/jco.2016.34.15_suppl.6014.
- Bhatia A, Mehra R, Khan S, Egleston B, Alpaugh R, Lango M, Ridge J, Burtness B. Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2016, 34: 6027-6027. DOI: 10.1200/jco.2016.34.15_suppl.6027.
- Li S, Ferris R, Holsinger F, Weinstein G, Quon H, Mehra R, Garcia J, Chung C, Gillison M, Wagner L, Ringash J, Lewin J, Mendez E, Ridge J, Richmon J, Magnuson S, Bell R, Smith R, Thomas G, Burtness B. E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process. Journal Of Clinical Oncology 2016, 34: 6054-6054. DOI: 10.1200/jco.2016.34.15_suppl.6054.
- Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology 2016, 17: 717-726. PMID: 27157491, DOI: 10.1016/s1470-2045(16)00175-3.
- Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL. Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. Cancer 2016, 122: 1853-1860. PMID: 27019213, DOI: 10.1002/cncr.29962.
- Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 340-345. PMID: 24685886, PMCID: PMC4177955, DOI: 10.1097/coc.0000000000000068.
- Cohen E, Licitra L, Burtness B, Fayette J, Gauler T, Clement P, Grau J, del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1). International Journal Of Radiation Oncology • Biology • Physics 2016, 94: 868-869. DOI: 10.1016/j.ijrobp.2015.12.032.
- Husain ZA, Burtness BA, Decker RH. Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2015, 34: 396-398. PMID: 26644528, DOI: 10.1200/jco.2015.64.7586.
- Yen C, Klochikhin A, Cohen E, Vermorken J, Harrington K, Tahara M, Ge J, Geib J, Jin F, Burtness B. 342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.29.
- Tahara M, Cohen E, Haddad R, Fayette J, Licitra L, Clement P, Vermorken J, Gauler T, Cupissol D, Grau J, Guigay J, del Campo J, Okami K, Takahashi S, Burtness B, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. 314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1). Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.01.
- Machiels J, Shin S, Cohen E, Harrington K, Burtness B, Gause C, Swift A, Swaby R, Le Tourneau C. 343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial. Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.30.
- Lee J, Parameswaran J, Koo J, Burtness B. Abstract C172: Concomitant disruption of WEE1 and AurKA synergistically enhances anti-cancer effects in p53 mutated head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 2015, 14: c172-c172. DOI: 10.1158/1535-7163.targ-15-c172.
- Cohen E, Moore K, Slomovitz B, Chung C, Anderson M, Morris S, Mauro D, Burtness B. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p147. PMCID: PMC4645484, DOI: 10.1186/2051-1426-3-s2-p147.
- Klochikhin A, Greil R, Cohen E, Vermorken J, Harrington K, Tahara M, Ge J, Geib J, Jin F, Burtness B. 11TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals Of Oncology 2015, 26: viii5. DOI: 10.1093/annonc/mdv514.01.
- Harrington K, Machiels J, Shin S, Cohen E, Burtness B, Gause C, Swift A, Swaby R, Le Tourneau C. 13TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial. Annals Of Oncology 2015, 26: viii5. DOI: 10.1093/annonc/mdv514.03.
- Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.
- Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.
- Chow L, Mehra R, Haddad R, Gupta S, Weiss J, Berger R, Burtness B, Tahara M, Keam B, Le D, Cheng J, Heath K, Pathiraja K, Seiwert T. 2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012. European Journal Of Cancer 2015, 51: s579. DOI: 10.1016/s0959-8049(16)31604-5.
- Burtness B. Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer. Journal Of Clinical Oncology 2015, 33: 3845-3846. PMID: 26282638, DOI: 10.1200/jco.2015.62.8487.
- Peri S, Slifker M, Mehra R, Burtness B, Ross E, Golemis E. Abstract LB-178: Genomic analysis identifies a subset of laryngeal tumors with poor prognosis. Cancer Research 2015, 75: lb-178-lb-178. DOI: 10.1158/1538-7445.am2015-lb-178.
- Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. Journal Of The National Comprehensive Cancer Network 2015, 13: 847-55; quiz 856. PMID: 26150579, PMCID: PMC4976490, DOI: 10.6004/jnccn.2015.0102.
- Seiwert T, Haddad R, Gupta S, Mehra R, Tahara M, Berger R, Lee S, Burtness B, Le D, Heath K, Blum A, Dolled-Filhart M, Emancipator K, Pathiraja K, Cheng J, Chow L. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal Of Clinical Oncology 2015, 33: lba6008-lba6008. DOI: 10.1200/jco.2015.33.18_suppl.lba6008.
- Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R. Phospho- T356 RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget 2015, 6: 18863-18874. PMID: 26265441, PMCID: PMC4662460, DOI: 10.18632/oncotarget.4321.
- Seiwert T, Burtness B, Weiss J, Eder J, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford J, Mehra R, Heath K, Cheng J, Chow L. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. Journal Of Clinical Oncology 2015, 33: 6017-6017. DOI: 10.1200/jco.2015.33.15_suppl.6017.
- Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Murphy B, Galloway T, Burtness B. Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). Journal Of Clinical Oncology 2015, 33: 6021-6021. DOI: 10.1200/jco.2015.33.15_suppl.6021.
- Argiris A, Li S, Savvides P, Forastiere A, Burtness B. Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal Of Clinical Oncology 2015, 33: 6022-6022. DOI: 10.1200/jco.2015.33.15_suppl.6022.
- Cohen E, Licitra L, Fayette J, Gauler T, Clement P, Grau J, Del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Dupuis N, Burtness B, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). Journal Of Clinical Oncology 2015, 33: 6023-6023. DOI: 10.1200/jco.2015.33.15_suppl.6023.
- Seiwert T, Haddad R, Gupta S, Mehra R, Tahara M, Berger R, Lee S, Burtness B, Le D, Heath K, Blum A, Dolled-Filhart M, Emancipator K, Pathiraja K, Cheng J, Chow L. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal Of Clinical Oncology 2015, 33: lba6008-lba6008. DOI: 10.1200/jco.2015.33.15_suppl.lba6008.
- Cohen E, Machiels J, Harrington K, Burtness B, Shin S, Gause C, Swift A, Brown H, Perrone A, Cheng J, Swaby R, Le Tourneau C. KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. Journal Of Clinical Oncology 2015, 33: tps6084-tps6084. DOI: 10.1200/jco.2015.33.15_suppl.tps6084.
- Khan S, Bauman J, Burtness B, Frankel A, Harper J, Hughes R, Kurian P, Myers L, Nedzi L, Schwartz D, Sumer B, Truelson J, Zhu H. Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities. Journal Of Clinical Oncology 2015, 33: tps6085-tps6085. DOI: 10.1200/jco.2015.33.15_suppl.tps6085.
- Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, W. A, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 1566-1573. PMID: 25573383, PMCID: PMC6607903, DOI: 10.1158/1078-0432.ccr-14-2820.
- Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.
- Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen E. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 2014, 15: 469. PMID: 25432788, PMCID: PMC4289298, DOI: 10.1186/1745-6215-15-469.
- Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer. The Annals Of Thoracic Surgery 2014, 99: 270-276. PMID: 25440267, PMCID: PMC4284823, DOI: 10.1016/j.athoracsur.2014.08.033.
- Burtness B. On mentorship: lessons from my father. Journal Of The National Comprehensive Cancer Network 2014, 12: 1651-2. PMID: 25361809, DOI: 10.6004/jnccn.2014.0162.
- Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2014, 12: 1454-87. PMID: 25313184, DOI: 10.6004/jnccn.2014.0142.
- Mehra R, Yang D, Handorf E, Serebriiskii I, Ross E, Lango M, Ridge J, Golemis E, Burtness B. Abstract 4743: Analysis of a protein expression biomarkers in HPV negative SCCHN. 2014, 4743-4743. DOI: 10.1158/1538-7445.am2014-4743.
- Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clinical Cancer Research 2014, 20: 5041-5051. PMID: 25107914, PMCID: PMC4184913, DOI: 10.1158/1078-0432.ccr-14-0051.
- Scher E, Handorf E, Ridge J, Mehra R, Lango M, Burtness B, Liu J, Galloway T. Evaluation of Primary Treatment Technique for Squamous Cell Carcinoma of the Buccal Mucosa: A Single-Center Experience. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s507. DOI: 10.1016/j.ijrobp.2014.05.1558.
- Chow L, Burtness B, Weiss J, Berger R, Eder J, Gonzalez E, Pulini J, Johnson J, Dolled-Filhart M, Emancipator K, Lunceford J, Pathiraja K, Gause C, Cheng J, Seiwert T. LBA31 A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc). Annals Of Oncology 2014, 25: v1. DOI: 10.1093/annonc/mdu438.32.
- Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Human Genetics 2014, 134: 497-507. PMID: 25108461, PMCID: PMC4324386, DOI: 10.1007/s00439-014-1470-0.
- Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals Of Oncology 2014, 25: 2230-2236. PMID: 25081901, PMCID: PMC4207729, DOI: 10.1093/annonc/mdu367.
- Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer 2014, 120: 3353-3360. PMID: 25042524, DOI: 10.1002/cncr.28870.
- Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Annals Of Oncology 2014, 25: 2036-2041. PMID: 25009013, PMCID: PMC4176450, DOI: 10.1093/annonc/mdu248.
- Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.18_suppl.lba6006.
- Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clinical Cancer Research 2014, 20: 3023-3032. PMID: 24700741, PMCID: PMC4049169, DOI: 10.1158/1078-0432.ccr-14-0113.
- Cohen S, Feng Y, Catalano P, Mitchell E, O'Dwyer P, Lubner S, Fisher G, Mulcahy M, Burtness B, Benson A. E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. Journal Of Clinical Oncology 2014, 32: 4020-4020. DOI: 10.1200/jco.2014.32.15_suppl.4020.
- Seiwert T, Burtness B, Weiss J, Gluck I, Eder J, Pai S, Dolled-Filhart M, Emancipator K, Pathiraja K, Gause C, Iannone R, Brown H, Houp J, Cheng J, Chow L. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. Journal Of Clinical Oncology 2014, 32: 6011-6011. DOI: 10.1200/jco.2014.32.15_suppl.6011.
- Masica D, Li S, Douville C, Manola J, Ferris R, Burtness B, Forastiere A, Koch W, Karchin R, Chung C. Evaluation of computational tools to determine prognostic significance of TP53 mutation in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2014, 32: 6035-6035. DOI: 10.1200/jco.2014.32.15_suppl.6035.
- Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.15_suppl.lba6006.
- Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Annals Of Oncology 2014, 25: 1410-1416. PMID: 24799460, PMCID: PMC4071756, DOI: 10.1093/annonc/mdu167.
- Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.
- Burtness B, Ilson D, Iqbal S. New directions in perioperative management of locally advanced esophagogastric cancer. American Society Of Clinical Oncology Educational Book 2014, e172-8. PMID: 24857100, DOI: 10.14694/edbook_am.2014.34.e172.
- Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.
- Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC). PLOS ONE 2014, 9: e94273. PMID: 24722213, PMCID: PMC3983114, DOI: 10.1371/journal.pone.0094273.
- Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2014, 1-5. DOI: 10.1007/978-1-4614-8815-6_1.
- Burtness B. Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. Current Cancer Research 2014, 343-359. DOI: 10.1007/978-1-4614-8815-6_17.
- Galloway T, Davis K, Burtness B, Ferris R, Mehra R, Ridge J, Flieder D, Duvvuri U. HPV Association and the Increasing Incidence of Unknown Primary Head-and-Neck Squamous Cell Carcinoma Epidemiology and Prevention. International Journal Of Radiation Oncology • Biology • Physics 2014, 88: 494. DOI: 10.1016/j.ijrobp.2013.11.102.
- Thomay A, Su S, Friedant A, Ruth K, Astsaturov I, Burtness B, Denlinger C, Dotan E, Hall M, Meyer J, Shah P, Cohen S, Scott W. Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. Journal Of Clinical Oncology 2014, 32: 126-126. DOI: 10.1200/jco.2014.32.3_suppl.126.
- Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & Neck 2014, 36: 1677-1684. PMID: 24115269, PMCID: PMC3972378, DOI: 10.1002/hed.23514.
- Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer 2013, 120: 840-847. PMID: 24352973, PMCID: PMC3951722, DOI: 10.1002/cncr.28482.
- Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research 2013, 19: 6633-6643. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.ccr-13-0152.
- Jimeno A, Galloway T, Wirth L, Gilbert J, Saba N, Bauman J, Colevas D, Mehra R, Raben D, Lai C, Laliberte R, Voi M, Burtness B. Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. Molecular Cancer Therapeutics 2013, 12: b268-b268. DOI: 10.1158/1535-7163.targ-13-b268.
- Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein–Szanto A. Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. Head & Neck 2013, 36: 1113-1119. PMID: 23804308, PMCID: PMC4099415, DOI: 10.1002/hed.23421.
- Lemons J, Ruth K, Ridge J, Burtness B, Lango M, Mehra R, Liu J, Galloway T. Can It Stay or Should It Go? A Comparison of T4 Laryngeal Cancer Management. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s452. DOI: 10.1016/j.ijrobp.2013.06.1193.
- Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-1087. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.
- Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer. Journal Of Gastrointestinal Surgery 2013, 18: 69-74. PMID: 24002765, DOI: 10.1007/s11605-013-2329-8.
- Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid 2013, 23: 1099-1105. PMID: 23421588, PMCID: PMC3770240, DOI: 10.1089/thy.2013.0027.
- Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA. Aurora kinases in head and neck cancer. The Lancet Oncology 2013, 14: e425-e435. PMID: 23993387, PMCID: PMC4139969, DOI: 10.1016/s1470-2045(13)70128-1.
- Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. Journal Of The National Comprehensive Cancer Network 2013, 11: 917-23. PMID: 23946171, DOI: 10.6004/jnccn.2013.0113.
- Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.
- Boland PM, Burtness B. Esophageal carcinoma. Current Opinion In Oncology 2013, 25: 417-424. PMID: 23680713, DOI: 10.1097/cco.0b013e328362105e.
- Marur S, Li S, Cmelak A, Gillison M, Ferris R, Bauman J, Zhao W, Westra W, Chung C, Wagner L, Trevarthen D, Jahagirdar B, Colevas A, Burtness B. E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). Journal Of Clinical Oncology 2013, 31: 6005-6005. DOI: 10.1200/jco.2013.31.15_suppl.6005.
- Mehra R, Egloff A, Li S, Yang D, Wang L, Zhu F, Forastiere A, Burtness B, Argiris A. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal Of Clinical Oncology 2013, 31: 6006-6006. DOI: 10.1200/jco.2013.31.15_suppl.6006.
- Weidhaas J, Lee J, Slebos R, Howard J, Perez J, Gilbert J, Nallur S, Paranjape T, Garcia J, Burtness B, Forastiere A, Chung C. Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6016-6016. DOI: 10.1200/jco.2013.31.15_suppl.6016.
- Burtness B, Lee J, Yang D, Zhu F, Garcia J, Forastiere A, Chung C. Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. Journal Of Clinical Oncology 2013, 31: 6028-6028. DOI: 10.1200/jco.2013.31.15_suppl.6028.
- Psyrri A, Lee J, Vasilakopoulou M, Pectasides E, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303. Journal Of Clinical Oncology 2013, 31: 6081-6081. DOI: 10.1200/jco.2013.31.15_suppl.6081.
- Cohen E, Hong D, Pfister D, Salgia R, Burtness B, Cohen R, Ball D, Mehra R, Mangeshkar M, Yaron Y, Bentzien F, Kurzrock R. Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. Journal Of Clinical Oncology 2013, 31: 6090-6090. DOI: 10.1200/jco.2013.31.15_suppl.6090.
- Chun Y, Cohen S, Donohue J, Burtness B, Hall M, Nagorney D. 445 Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer. Gastroenterology 2013, 144: s-1048. DOI: 10.1016/s0016-5085(13)63901-3.
- Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal Of Clinical Oncology 2013, 31: 1405-1414. PMID: 23460714, PMCID: PMC3612594, DOI: 10.1200/jco.2012.45.4272.
- Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Annals Of Oncology 2013, 24: 2124-2131. PMID: 23406730, DOI: 10.1093/annonc/mdt013.
- Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation. Cancer Discovery 2013, 3: 96-111. PMID: 23125191, PMCID: PMC3546138, DOI: 10.1158/2159-8290.cd-12-0031.
- Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”. Science Signaling 2012, 5: lc5. PMID: 23233526, DOI: 10.1126/scisignal.2003734.
- Sopka D, Li T, Lango M, Mehra R, Burtness B, Flieder D, Ridge J, Galloway T. Dysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s205. DOI: 10.1016/j.ijrobp.2012.07.531.
- Keller L, Galloway T, Holdbrook T, Flieder D, Ruth K, Lango M, Mehra R, Burtness B, Ridge J. p16 Status, Pathologic and Clinical Characteristics, and Long-term Outcomes in Unknown Primary Carcinomas of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s514. DOI: 10.1016/j.ijrobp.2012.07.1370.
- Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinomaHusain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. The Laryngoscope 2012, 122: 2762-2768. PMID: 23086695, PMCID: PMC3574977, DOI: 10.1002/lary.23647.
- Burtness B. 59IN Strategies to Optimize EGFR Therapies. Annals Of Oncology 2012, 23: ix42. DOI: 10.1016/s0923-7534(20)32673-9.
- Mehra R, Ang KK, Burtness B. Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer. Seminars In Radiation Oncology 2012, 22: 194-197. PMID: 22687943, DOI: 10.1016/j.semradonc.2012.03.003.
- Marur S, Lee J, Cmelak A, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal Of Clinical Oncology 2012, 30: 5566-5566. DOI: 10.1200/jco.2012.30.15_suppl.5566.
- Psyrri A, Lee J, Pectasides E, Vassilakopoulou M, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2012, 30: 5576-5576. DOI: 10.1200/jco.2012.30.15_suppl.5576.
- Burtness B, Bourhis J, Vermorken J, Dai L, Lind C, Ehrnrooth E, Cohen E. LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. Journal Of Clinical Oncology 2012, 30: tps5599-tps5599. DOI: 10.1200/jco.2012.30.15_suppl.tps5599.
- Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.
- Khan S, Yang D, Zhu F, Dubyk C, Tejani M, Cohen S, Hoffman J, Burtness B. Abstract 714: Survivin expression in patients with resected pancreatic adenocarcinoma. Cancer Research 2012, 72: 714-714. DOI: 10.1158/1538-7445.am2012-714.
- Fidler C, Yang D, Zhu F, Mehra R, Astsaturov I, Ridge J, Golemis E, Burtness B. Abstract 721: Expression of Aurora A and Phospho-Aurora-A is predictive of survival in patients with head and neck cancer. Cancer Research 2012, 72: 721-721. DOI: 10.1158/1538-7445.am2012-721.
- Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. Mucosal melanoma of the head and neck. Journal Of The National Comprehensive Cancer Network 2012, 10: 320-38. PMID: 22393194, DOI: 10.6004/jnccn.2012.0033.
- Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational needs of head and neck cancer patients. Health And Technology 2012, 2: 57-62. PMID: 22518350, PMCID: PMC3327509, DOI: 10.1007/s12553-012-0020-9.
- Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head & Neck 2012, 35: 160-164. PMID: 22302641, PMCID: PMC4037756, DOI: 10.1002/hed.22929.
- Astsaturov I, Meyer J, Cheng J, Olszanski A, Dushkin H, Berger A, Davey M, Cohen S, Burtness B, Scott W. A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction. Journal Of Clinical Oncology 2012, 30: 74-74. DOI: 10.1200/jco.2012.30.4_suppl.74.
- Shaikh T, Ruth K, Scott W, Burtness B, Cohen S, Konski A, Cooper H, Astsaturov I, Meyer J. Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer. Journal Of Clinical Oncology 2012, 30: 84-84. DOI: 10.1200/jco.2012.30.4_suppl.84.
- Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study. Journal Of Gastrointestinal Cancer 2012, 43: 562-569. PMID: 22294255, PMCID: PMC3400721, DOI: 10.1007/s12029-012-9368-3.
- Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY. Psychological functioning of caregivers for head and neck cancer patients. Oral Oncology 2011, 48: 18-25. PMID: 22154127, PMCID: PMC3357183, DOI: 10.1016/j.oraloncology.2011.11.012.
- Sopka D, Chun Y, Cohen S, Zhu F, Milestone B, Cooper H, Freedman G, Burtness B, Hoffman J, Meyer J. Maximizing the Effect of Neoadjuvant Chemoradiation in Patients with Borderline Resectable Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s335. DOI: 10.1016/j.ijrobp.2011.06.1804.
- Galloway T, Turaka A, Ruth K, Mehra R, Lango M, Burtness B, Ridge J, Horwitz E. Low Rates of Gastrostomy Tube Dependence in Patients with T1-T2 Oropharynx Cancer Treated without Pharyngeal Constrictor Sparing. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s504. DOI: 10.1016/j.ijrobp.2011.06.1029.
- Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3601-3607. PMID: 21947697, DOI: 10.1245/s10434-011-2086-4.
- Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 2011, 14: 260-279. PMID: 21920801, PMCID: PMC3195944, DOI: 10.1016/j.drup.2011.08.002.
- Burtness B. Commentary. The Cancer Journal 2011, 17: 273-275. PMID: 21952274, DOI: 10.1097/ppo.0b013e3182326944.
- Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network 2011, 9: 596-650. PMID: 21636536, DOI: 10.6004/jnccn.2011.0053.
- Tejani M, Cai K, Zhu F, Dubyk C, Chun Y, Cohen S, Hoffman J, Burtness B. ERCC1 and RRM1 expression in resected pancreatic adenocarcinoma. Journal Of Clinical Oncology 2011, 29: e14606-e14606. DOI: 10.1200/jco.2011.29.15_suppl.e14606.
- Psyrri A, Ghebremichael M, Pectasides E, Dimou A, Burtness B, Rimm D, Wanebo H, Forastiere A. p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2011, 29: e16032-e16032. DOI: 10.1200/jco.2011.29.15_suppl.e16032.
- Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2011, 17: 2947-2954. PMID: 21355076, DOI: 10.1158/1078-0432.ccr-10-2040.
- Husain H, Psyrri A, Slebos R, Ross D, Burtness B, Chung C. Abstract 2254: Nuclear and cytoplasmic epidermal growth factor receptor and p16 expression as prognostic biomarkers in head and neck squamous cell carcinoma. Cancer Research 2011, 71: 2254-2254. DOI: 10.1158/1538-7445.am2011-2254.
- Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal Of Clinical Oncology 2011, 34: 70-75. PMID: 20458210, PMCID: PMC3030655, DOI: 10.1097/coc.0b013e3181d2734a.
- Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. Cancer 2011, 117: 3374-3382. PMID: 21246525, PMCID: PMC3135694, DOI: 10.1002/cncr.25852.
- Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal Of Clinical Oncology 2010, 33: 599-603. PMID: 21063195, DOI: 10.1097/coc.0b013e3181c4c3cc.
- Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. Head & Neck 2010, 33: 1433-1440. PMID: 21928415, DOI: 10.1002/hed.21615.
- Shanbhag S, Burtness B. Antibody-Based Therapies for Solid Tumors. Cancer Growth And Progression 2010, 245-256. DOI: 10.1007/978-90-481-9704-0_13.
- Richard C, Turaka A, Li T, Nicolaou N, Horwitz E, Lango M, Burtness B, Ridge J, Feigenberg S. Intensity Modulated Radiation Therapy (IMRT) for the Para-nasal Sinus (PNS) Malignancies. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s478-s479. DOI: 10.1016/j.ijrobp.2010.07.1122.
- Psyrri A, Burtness B. Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 2010, 7: 621-622. PMID: 20981127, DOI: 10.1038/nrclinonc.2010.156.
- Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals Of Surgical Oncology 2010, 17: 2832-2838. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.
- Turaka A, Weinberg B, Li T, Nicos N, Burtness B, Lango M, Ridge J, Feigenberg S. SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia. Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468568.
- Turaka A, Cattaneo R, Nicos N, Lango M, Burtness B, Ridge J, Feigenberg S. SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC). Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468570.
- Enzinger P, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson A, Mayer R, Goldberg R. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. Journal Of Clinical Oncology 2010, 28: 4006-4006. DOI: 10.1200/jco.2010.28.15_suppl.4006.
- Wanebo H, Ghebremichael M, Burtness B, Ridge J, Spencer S, Rosen F, Hancock M, Tolba K, Forastiere A. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal Of Clinical Oncology 2010, 28: 5513-5513. DOI: 10.1200/jco.2010.28.15_suppl.5513.
- Egloff A, Lee J, Vaezi A, Langer C, Forastiere A, Quon H, Burtness B, Grandis J. Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). Journal Of Clinical Oncology 2010, 28: 5537-5537. DOI: 10.1200/jco.2010.28.15_suppl.5537.
- Pectasides E, Fountzilas G, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Rimm D, Burtness B, Psyrri D. Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. Journal Of Clinical Oncology 2010, 28: 5538-5538. DOI: 10.1200/jco.2010.28.15_suppl.5538.
- Mehra R, Cai K, Zhu F, Weaver J, Nicolaou N, Cohen R, Lango M, Ridge J, Godwin A, Burtness B. Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. Journal Of Clinical Oncology 2010, 28: 5539-5539. DOI: 10.1200/jco.2010.28.15_suppl.5539.
- Fountzilas G, Pectasides E, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Pectasides D, Rimm D, Burtness B, Psyrri D. The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. Journal Of Clinical Oncology 2010, 28: 5550-5550. DOI: 10.1200/jco.2010.28.15_suppl.5550.
- Mehra R, Cai K, Zhu F, Weaver J, Nicolaou N, Lango M, Ridge J, Godwin A, Burtness B. Abstract 2804: ERCC1 (excision repair cross complementing group 1) is a predictive biomarker of survival in squamous cell carcinoma of the head and neck (SCCHN). Cancer Research 2010, 70: 2804-2804. DOI: 10.1158/1538-7445.am10-2804.
- Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research 2010, 16: 2427-2434. PMID: 20371693, PMCID: PMC3030188, DOI: 10.1158/1078-0432.ccr-09-2658.
- Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.
- Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: 1020-1025. PMID: 20231078, DOI: 10.1016/j.ijrobp.2009.09.003.
- Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 358-365. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.epi-09-0937.
- Turaka A, Li T, Nicolaou N, Lango M, Burtness B, Horwitz E, Ridge J, Feigenberg S. The use of a Low Neck Field (LNF) and Intensity-Modulated Radiation Therapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF during the Treatment of Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s427-s428. DOI: 10.1016/j.ijrobp.2009.07.978.
- Rusthoven K, Feigenberg S, Raben D, Kane M, Song J, Nicolaou N, Mehra R, Burtness B, Swing R, Chen C. Initial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-irradiation for Recurrent and New Primary Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s408. DOI: 10.1016/j.ijrobp.2009.07.935.
- Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets And Therapy 2009, Volume 3: 419-428. PMID: 19774209, PMCID: PMC2747340, DOI: 10.2147/btt.s3170.
- Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). Journal Of Clinical Oncology 2009, 27: 6011-6011. DOI: 10.1200/jco.2009.27.15_suppl.6011.
- Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A. Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. Journal Of Clinical Oncology 2009, 27: 6020-6020. DOI: 10.1200/jco.2009.27.15_suppl.6020.
- Psyrri D, Pectasides E, Weinberger P, Sasaki C, Burtness B, Fountzilas G. Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. Journal Of Clinical Oncology 2009, 27: 6031-6031. DOI: 10.1200/jco.2009.27.15_suppl.6031.
- Mehra R, Sherman E, Ruth K, Litwin S, Sylvester J, Tuttle H, Burtness B, Cohen R, Langer C. Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN). Journal Of Clinical Oncology 2009, 27: 6052-6052. DOI: 10.1200/jco.2009.27.15_suppl.6052.
- Pectasides E, Founztilas G, Sasaki C, Burtness B, Psyrri A. Assessment of phosphatidylinositol-3 kinase (PI3K) as a prognostic marker in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2009, 27: e17028-e17028. DOI: 10.1200/jco.2009.27.15_suppl.e17028.
- Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Annals Of Oncology 2009, 20: 1242-1248. PMID: 19429872, PMCID: PMC2699385, DOI: 10.1093/annonc/mdn787.
- Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal Of The National Comprehensive Cancer Network 2009, 7 Suppl 1: s5-21; quiz s22-4. PMID: 19470276, DOI: 10.6004/jnccn.2009.0074.
- Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling 2009, 21: 1255-1268. PMID: 19258037, PMCID: PMC2770888, DOI: 10.1016/j.cellsig.2009.02.021.
- Psyrri A, Burtness B, Harari PM, Vermorken JB, Licitra L, Sasaki CT. Head and Neck Cancer. Journal Of Oncology 2009, 2009: 358098. PMID: 20169126, PMCID: PMC2821645, DOI: 10.1155/2009/358098.
- Burtness B, Weiner L, Astsaturov I, Golemis E. 246 INVITED Targeting Her: Can resistance to EGFR inhibitors be overcome? European Journal Of Cancer Supplements 2008, 6: 80. DOI: 10.1016/s1359-6349(08)72178-5.
- Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clinical Advances In Hematology And Oncology 2008, 6: 742-50. PMID: 18997665, PMCID: PMC2745918.
- Psyrri A, Burtness B. Viruses in head and neck cancers: prevention and therapy. Expert Review Of Anticancer Therapy 2008, 8: 1365-1371. PMID: 18759688, DOI: 10.1586/14737140.8.9.1365.
- Forastiere A, Ang K, Brizel D, Brockstein B, Burtness B, Cmelak A, Colevas A, Dunphy F, Eisele D, Goepfert H, Hicks W, Kies M, Lydiatt W, Maghami E, Martins R, McCaffrey T, Mittal B, Pfister D, Pinto H, Posner M, Ridge J, Samant S, Schuller D, Shah J, Spencer S, Trotti A, Weber R, Wolf G, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network 2008, 6: 646-95. PMID: 18691457, DOI: 10.6004/jnccn.2008.0051.
- Psyrri A, Prezas L, Burtness B. Oropharyngeal cancer. Clinical Advances In Hematology And Oncology 2008, 6: 604-12. PMID: 18820604.
- Psyrri A, Egleston B, Pectasides E, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B. Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue Microarray. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 1486-1492. PMID: 18559565, DOI: 10.1158/1055-9965.epi-07-2684.
- Burtness B, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson A. Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19–9 results. Journal Of Clinical Oncology 2008, 26: 4642-4642. DOI: 10.1200/jco.2008.26.15_suppl.4642.
- Psyrri A, Sasaki C, Burtness B, Rampias T. Regulation of cytoplasmic and nuclear PTEN levels by human papillomavirus (HPV) type 16 E6 and E7 oncogenes in HPV16+ oropharyngeal cancer cell line. Journal Of Clinical Oncology 2008, 26: 6034-6034. DOI: 10.1200/jco.2008.26.15_suppl.6034.
- Molecular prognostic markers in squamous cell carcinoma of the head and neck: the role of E-cadherinKountourakis P, Pectasides E, Burtness B, Pectasides D, Psyrri A, Fountzilas G. Molecular prognostic markers in squamous cell carcinoma of the head and neck: the role of E-cadherin. Journal Of Clinical Oncology 2008, 26: 6040-6040. DOI: 10.1200/jco.2008.26.15_suppl.6040.
- Murphy B, Dietrich M, Cmelak A, Burtness B, Forastiere A. E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC). Journal Of Clinical Oncology 2008, 26: 6022-6022. DOI: 10.1200/jco.2008.26.15_suppl.6022.
- Pectasides E, Kountourakis P, Fountzilas G, Burtness B, Psyrri A. Evaluation of the prognostic significance of activated STAT3 expression levels in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2008, 26: 6015-6015. DOI: 10.1200/jco.2008.26.15_suppl.6015.
- Rampias T, Sasaki C, Burtness B, Psyrri A. Gene expression differences associated with silencing of E6 and E7 viral oncogenes in HPV16 + oropharyngeal cancer cell lines. Journal Of Clinical Oncology 2008, 26: 6009-6009. DOI: 10.1200/jco.2008.26.15_suppl.6009.
- Burtness BA. Advanced gastric cancer: new treatments raise new questions. Gastrointestinal Cancer Research : GCR 2008, 2: 158-9. PMID: 19259295, PMCID: PMC2633076.
- Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals Of Oncology 2008, 19: 977-983. PMID: 18296423, DOI: 10.1093/annonc/mdm591.
- Burtness B. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. Oncology 2007, 21: 964-70; discussion 970, 974, 976-7. PMID: 17715697.
- Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal 2007, 13: 257-262. PMID: 17762761, DOI: 10.1097/ppo.0b013e31813c1174.
- Burtness B, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson A. Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology. Journal Of Clinical Oncology 2007, 25: 4519-4519. DOI: 10.1200/jco.2007.25.18_suppl.4519.
- Wanebo H, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A, Ghebremichael M. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). Journal Of Clinical Oncology 2007, 25: 6015-6015. DOI: 10.1200/jco.2007.25.18_suppl.6015.
- Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.
- Psyrri A, Weinberger P, Yu Z, Sasaki C, Haffty B, Kowalski D, Burtness B. Correlates and determinants of nuclear epidermal growth factor receptor (EGFR) content in an oropharyngeal cancer tissue microarray. Journal Of Clinical Oncology 2007, 25: 6022-6022. DOI: 10.1200/jco.2007.25.18_suppl.6022.
- Weinberger P, Psyrri A, Kountourakis P, Rampias T, Sasaki C, Sasaki C, Haffty B, Kowalski D, Fountzilas G, Rimm D, Burtness B. Gene copy number of epidermal growth factor receptor (EGFR) by fluorescent in situ hybridization (FISH) in head and neck squamous cell carcinomas (HNSCC) is closely correlated with EGFR protein levels assessed by automated quantitative protein analysis (AQUA). Journal Of Clinical Oncology 2007, 25: 6023-6023. DOI: 10.1200/jco.2007.25.18_suppl.6023.
- Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal Population or Pathologist Artifact? Journal Of Clinical Oncology 2007, 25: 2487-2488. PMID: 17557963, DOI: 10.1200/jco.2006.07.7537.
- Burtness B. Her signaling in pancreatic cancer. Expert Opinion On Biological Therapy 2007, 7: 823-829. PMID: 17555368, DOI: 10.1517/14712598.7.6.823.
- Forastiere AA, Burtness BA. Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer—More Insights, but More Questions. Journal Of Clinical Oncology 2007, 25: 2152-2155. PMID: 17538157, DOI: 10.1200/jco.2007.10.9017.
- Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell CancerYu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 553-558. PMID: 17372251, DOI: 10.1158/1055-9965.epi-06-0121.
- Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.
- Burtness B, Manola J, Argiris A, Altieri D, Axelrod R, Forastiere A. 632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301. European Journal Of Cancer Supplements 2006, 4: 190-191. DOI: 10.1016/s1359-6349(06)70637-1.
- Landry J, Catalano P, Hoffman J, Staley C, Harris W, Burtness B, Frontiera M, Berlin J, Benson A. 2111 ECOG 1200: A Randomized Phase II Trial of Gemcitabine Plus Radiotherapy vs Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil in Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s272. DOI: 10.1016/j.ijrobp.2006.07.515.
- Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.
- Cohen SJ, Burtness BA. Novel targets in pancreatic cancer: focus on future paths to therapy. Expert Opinion On Therapeutic Targets 2006, 10: 771-775. PMID: 16981833, DOI: 10.1517/14728222.10.5.771.
- Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion On Biological Therapy 2006, 6: 951-962. PMID: 16918262, DOI: 10.1517/14712598.6.9.951.
- Arciero C, Salem R, Lacy J, Sigurdson E, Hoffman J, Watson J, Joseph N, Cooper H, Meropol N, Burtness B. Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases. Journal Of Clinical Oncology 2006, 24: 13523-13523. DOI: 10.1200/jco.2006.24.18_suppl.13523.
- Burtness B, Goldwasser M, Axelrod R, Argiris A, Forastiere A. A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. Journal Of Clinical Oncology 2006, 24: 5532-5532. DOI: 10.1200/jco.2006.24.18_suppl.5532.
- Argiris A, Goldwasser M, Burtness B, Deconti R, Axelrod R, Van Waes C, Forastiere A. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. Journal Of Clinical Oncology 2006, 24: 5573-5573. DOI: 10.1200/jco.2006.24.18_suppl.5573.
- Abu-Khalaf M, Kim R, Cohenuram M, Chung G, Digiovanna M, Haffty B, Carter D, Horvath L, Tavassoli F, Burtness B. Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC). Journal Of Clinical Oncology 2006, 24: 10721-10721. DOI: 10.1200/jco.2006.24.18_suppl.10721.
- Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer. The Cancer Journal 2006, 12: 212-221. PMID: 16803680, DOI: 10.1097/00130404-200605000-00010.
- Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106: 1677-1684. PMID: 16532435, DOI: 10.1002/cncr.21783.
- Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 2006, 24: 135-140. PMID: 16502351, DOI: 10.1007/s10637-006-5934-5.
- Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer. Oncology 2005, 69: 372-383. PMID: 16319508, DOI: 10.1159/000089991.
- Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. Journal Of Clinical Oncology 2005, 23: 8646-8654. PMID: 16314626, DOI: 10.1200/jco.2005.02.4646.
- Moss JE, Burtness B. Cetuximab-Associated Acneiform Eruption. New England Journal Of Medicine 2005, 353: e17. PMID: 16282170, DOI: 10.1056/nejmicm050560.
- Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin Induces a Delayed Immune-Mediated Hemolytic Anemia: A Case Report and Review of the Literature. Clinical Colorectal Cancer 2005, 5: 283-286. PMID: 16356307, DOI: 10.3816/ccc.2005.n.041.
- Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation. International Journal Of Surgical Pathology 2005, 13: 319-327. PMID: 16273187, DOI: 10.1177/106689690501300403.
- Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 2005, 11: 5856-5862. PMID: 16115926, DOI: 10.1158/1078-0432.ccr-05-0420.
- Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opinion On Biological Therapy 2005, 5: 1085-1093. PMID: 16050785, DOI: 10.1517/14712598.5.8.1085.
- Burtness B. Cetuximab and Cisplatin for Chemotherapy-Refractory Squamous Cell Cancer of the Head and Neck. Journal Of Clinical Oncology 2005, 23: 5440-5442. PMID: 16009959, DOI: 10.1200/jco.2005.02.002.
- Burtness B, Gibson M, Lacy J, Rowen E, Thomas L, Sipples R, McGurk M, Murren J, Forastiere A. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal Of Clinical Oncology 2005, 23: 4070-4070. DOI: 10.1200/jco.2005.23.16_suppl.4070.
- Psyrri A, Yu Z, Haffty B, Sasaki C, Weinberger P, Camp R, Rimm D, Burtness B. Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC). Journal Of Clinical Oncology 2005, 23: 5518-5518. DOI: 10.1200/jco.2005.23.16_suppl.5518.
- Yu Z, Weinberger P, Sasaki C, Haffty B, Camp R, Rimm D, Burtness B, Psyrri A. Molecular prognostic markers in oropharyngeal squamous cell carcinoma: The role of phospho-Akt. Journal Of Clinical Oncology 2005, 23: 5517-5517. DOI: 10.1200/jco.2005.23.16_suppl.5517.
- Psyrri A, Burtness B. Pregnancy-Associated Breast Cancer. The Cancer Journal 2005, 11: 83-95. PMID: 15969981, DOI: 10.1097/00130404-200503000-00001.
- Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Of Today 2005, 41: 107-27. PMID: 15821783, DOI: 10.1358/dot.2005.41.2.882662.
- Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates. Journal Of Clinical Oncology 2004, 23: 17-23. PMID: 15545666, DOI: 10.1200/jco.2005.09.048.
- Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL. Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up. Journal Of Clinical Oncology 2004, 22: 3061-3069. PMID: 15284256, DOI: 10.1200/jco.2004.01.108.
- Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere A. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal Of Clinical Oncology 2004, 22: 4032-4032. DOI: 10.1200/jco.2004.22.14_suppl.4032.
- Burtness B, Sipples R, Mirto G, Thomas L, Rahman Z, Kloss R, Murren J, Lacy J. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer. Journal Of Clinical Oncology 2004, 22: 4116-4116. DOI: 10.1200/jco.2004.22.14_suppl.4116.
- Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere A. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal Of Clinical Oncology 2004, 22: 4032-4032. DOI: 10.1200/jco.2004.22.90140.4032.
- Burtness B, Sipples R, Mirto G, Thomas L, Rahman Z, Kloss R, Murren J, Lacy J. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer. Journal Of Clinical Oncology 2004, 22: 4116-4116. DOI: 10.1200/jco.2004.22.90140.4116.
- Alvero AB, Burtness BA, Ercan AG, Sapi E. Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients. Laboratory Investigation 2004, 84: 658-661. PMID: 15105816, DOI: 10.1038/labinvest.3700086.
- Angelopoulou MK, Rinder H, Wang C, Burtness B, Cooper DL, Krause DS. A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftment. Transfusion 2004, 44: 555-566. PMID: 15043572, DOI: 10.1111/j.1537-2995.2004.03285.x.
- Burtness B. Chapter 23 Neoplastic Diseases. 2004, 479-504. DOI: 10.1016/b978-0-7216-0435-0.50027-4.
- Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clinical Cancer Research 2003, 9: 6461-8. PMID: 14695149.
- Bou‐Khalil J, Rose M, Psyrri A, D’Andrea E, Medoff E, Staugaard‐Hahn C, Holtkamp C, Gran S, Pezzimente J, Snyder E, Cooper D, Haffty B, Reiss M, Burtness B. Sequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer. The Breast Journal 2003, 9: 472-477. PMID: 14616941, DOI: 10.1046/j.1524-4741.2003.09604.x.
- Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 2003, 56: 328-334. PMID: 12738305, DOI: 10.1016/s0360-3016(02)04598-4.
- Knisely JP, Burtness BA, Salem RR. Surgical treatment of esophageal cancer. New England Journal Of Medicine 2003, 348: 1177-9; author reply 1177-9. PMID: 12647729.
- Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology 2003, 10: 132-139. PMID: 12673177, DOI: 10.1067/mnc.2003.7.
- Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer. Cancer Biology & Therapy 2002, 1: 646-651. PMID: 12642688, DOI: 10.4161/cbt.314.
- Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy 2002, 1: 130-135. PMID: 12170772, DOI: 10.4161/cbt.57.
- Burtness B. Head and Neck Cancer. 2002, 339-346. DOI: 10.1016/b0-12-227555-1/00096-4.
- Kleinberg L, Knisely J, Heitmiller R, Zahurak M, Yang S, Salem R, Heath E, Burtness B, Forastiere A. Mature survival results with preoperative cisplatin, protracted infusion 5-FU, and 45 GY radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 32. DOI: 10.1016/s0360-3016(01)01880-6.
- Gollerkeri A, Harrold L, Rose M, Jain D, Burtness B. Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience. International Journal Of Cancer 2001, 93: 139-141. PMID: 11391633, DOI: 10.1002/ijc.1295.
- Rich R, Argiris A, Peccerillo K, McKeon A, Gallipoli M, Burtness B, Murren J. Weekly chemotherapy with irinotecan plus a taxane in advanced non small cell lung cancer (NSCLC). Lung Cancer 2000, 29: 6. DOI: 10.1016/s0169-5002(00)80014-8.
- Snyder EL, Baril L, Cooper DL, Min K, Mechanic S, Stoddart L, Burtness B, Seagraves P, Debelak J, Gudino M, McCullough J. In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation. Transfusion 2000, 40: 961-967. PMID: 10960524, DOI: 10.1046/j.1537-2995.2000.40080961.x.
- Rose M, Lee F, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness B. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation 2000, 26: 133-139. PMID: 10918422, DOI: 10.1038/sj.bmt.1702449.
- Murren J, Peccerillo K, DiStasio S, Li X, Leffert J, Pizzorno G, Burtness B, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577, DOI: 10.1007/s002800000115.
- Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.
- Zhang Z, Burtness B, Zelterman D. The maximum negative binomial distribution. Journal Of Statistical Planning And Inference 2000, 87: 1-19. DOI: 10.1016/s0378-3758(99)00177-9.
- Heath E, Burtness B, Heitmiller R, Salem R, Kleinberg L, Knisely J, Yang S, Talamini M, Kaufman H, Canto M, Topazian M, Wu T, Olukayode K, Forastiere A. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. Journal Of Clinical Oncology 2000, 18: 868-76. PMID: 10673530, DOI: 10.1200/jco.2000.18.4.868.
- Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal Of Clinical Oncology 2000, 18: 904-14. PMID: 10673534, DOI: 10.1200/jco.2000.18.4.904.
- Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. The Cancer Journal 2000, 6: 309-15. PMID: 11079170.
- Horvath LJ, Burtness BA, McCarthy S, Johnson KM. Total-Body Echo-planar MR Imaging in the Staging of Breast Cancer: Comparison with Conventional Methods—Early Experience. Radiology 1999, 211: 119-128. PMID: 10189461, DOI: 10.1148/radiology.211.1.r99ap33119.
- Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.
- Burtness B, Psyrri A, Rose M, D’Andrea E, Staugaard-Hahn C, Henderson-Bakas M, Clark M, Mechanic S, Krause D, Snyder E, Cooper R, Abrantes J, Corringham R, Deisseroth A, Cooper D. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplantation 1999, 23: 311-315. PMID: 10100573, DOI: 10.1038/sj.bmt.1701589.
- Kleinberg L, Knisley J, Heitmiller R, Yang S, Zahurak M, Salem R, Burtness B, Heath E, Forastiere A. 83 Long term local control and survival with preoperative cisplatin, continuous infusion 5-FU, and 45 Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 189-190. DOI: 10.1016/s0360-3016(99)90101-3.
- Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty BG, Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. The Cancer Journal 1999, 5: 224-9. PMID: 10439168.
- Burtness B. High-dose chemotherapy for the treatment of high-risk and advanced breast cancer. Connecticut Medicine 1999, 63: 41-6. PMID: 10071438.
- Burtness BA. Preoperative chemoradiation for esophageal cancer. The Cancer Journal 1999, 5: 73-4. PMID: 10198727.
- Chabannon C, Cornetta K, Lotz J, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau J, Sledge G, Novakovitch G, Srour E, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-921. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.
- Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation. Blood 1998, 92: 672-682. PMID: 9657770, DOI: 10.1182/blood.v92.2.672.
- Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clinical Cancer Research 1998, 4: 1165-75. PMID: 9607574.
- Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal Of Clinical Oncology 1997, 15: 148-57. PMID: 8996136, DOI: 10.1200/jco.1997.15.1.148.
- Burtness BA. Histologic markers and long-term prognosis in breast cancer. The Cancer Journal 1997, 3: 211-2. PMID: 9263626.
- Haffty B, Burtness B, Papac R, Marsh J, Ward B, Farber L, Reiss M. 2036 The natural history of local regional breast cancer recurrence: Prognosis and implications for systemic therapy. International Journal Of Radiation Oncology • Biology • Physics 1997, 39: 258. DOI: 10.1016/s0360-3016(97)80804-8.
- Hanania E, Giles R, Kavanagh J, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove J, Bird R, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth A. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 15346-15351. PMID: 8986814, PMCID: PMC26407, DOI: 10.1073/pnas.93.26.15346.
- Burtness B. Oncology and hematology. JAMA 1995, 273: 1702-1703. DOI: 10.1001/jama.273.21.1702.
- Burtness BA. Oncology and Hematology. JAMA 1995, 273: 1702-1703. PMID: 7752426, DOI: 10.1001/jama.1995.03520450072037.
- Conner R, Burtness B, Ferguson K. Fatty acid desaturase specificity in tetrahymena. Lipids 1984, 19: 285-288. PMID: 6717257, DOI: 10.1007/bf02534456.
- Burtness B. Rape crisis centers. JAMA 1983, 250: 1391b-1391. DOI: 10.1001/jama.250.11.1391b.
- Burtness B. Rape Crisis Centers. JAMA 1983, 250: 1391-1391. PMID: 6887453, DOI: 10.1001/jama.1983.03340110015010.
Departments and Programs
Locations
Smilow Cancer Hospital Head and Neck Cancers Program
55 Park Street
Ste Phase I Clinical Trial Infusion Center
New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511
Biography
Barbara Burtness, MD, is a Yale Medicine medical oncologist who sees patients at Yale Cancer Center. She has made it her life’s mission to help people diagnosed with head and neck cancer, which can be a devastating disease even after it is cured—it can impact a person’s appearance, as well as the ability to speak, swallow, and eat.
“Patients often encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration, and feeding tube dependence,” says Dr. Burtness. “Younger patients may have to deal with these side effects for decades after cancer treatment.”
A careful treatment approach can help prevent these problems. She and her team evaluate the tumor location and decide which primary treatment (surgery or radiation therapy) will best cure the cancer and cause the fewest possible negative outcomes.
A professor of medicine at Yale School of Medicine, Dr. Burtness’ research lab is actively studying new cures for head and neck cancers. “We want to help improve these patients’ quality of life,” she says.
Titles
- Anthony N. Brady Professor of Medicine (Medical Oncology)
- Chief Translational Research Officer, Yale Cancer Center
- Chief, Head and Neck Cancers/Sarcoma
- Co-Leader, Developmental Therapeutics, Yale Cancer Center
- Associate Cancer Center Director for Translational Research, Yale Cancer Center
Education & Training
- FellowshipMemorial Sloan Kettering Cancer Center (1993)
- ResidencyYale-New Haven Hospital (1989)
- InternshipYale-New Haven Hospital (1987)
- MDSUNY at Stonybrook (1986)
- ABBryn Mawr College (1982)
Languages Spoken
- English
- Deutsch (German)
Additional Information
Honors & Recognitions
- Leadership in Diversity, Equity and Inclusion: Yale Cancer Center (2023)
- Yale Cancer Center Clinical Science Prize: Yale Cancer Center (2020)
- Wharton Lecturer: Princess Margaret Cancer Center (2019)
- Robert L. Krigel Award, Excellence in Teaching and Clinical Oncology: Fox Chase Cancer Center (2012)
- Top Doctor: U.S. News and World Report
- Best Doctors in America: Best Doctors
Board Certifications
- AB of Internal Medicine, Internal Medicine (1989)
Professional Service
- ECOG-ACRIN (2021 - Present): Chair, Task Force on Advancement of Women
- ECOG-ACRIN (2006 - Present): Chair of the ECOG-ACRIN Head and Neck Therapeutics Committee
Publications
- Dzienis M, Cundom J, Fuentes C, Spreafico A, Nordlinger M, Pastor A, Alesi E, Neki A, Fung A, Lima I, Oppelt P, da Cunha G, Burtness B, Franke F, Tseng J, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. Journal Of Clinical Oncology 2024, 42: 2989-2999. PMID: 39038265, PMCID: PMC11361359, DOI: 10.1200/jco.23.02625.
- Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse H, Su T, Cruz‐Gomez S, Lee S, Menges F, Parent L, Ratjen L, Burtness B, Fortner J, Zimmerman J. Multiplexable and Scalable Aqueous Synthesis Platform for Oleate‐Based, Bilayer‐Coated Gold Nanoparticles (Small 25/2024). Small 2024, 20 DOI: 10.1002/smll.202470191.
- Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'malley B, Ozer E, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2024, 42: 6009-6009. DOI: 10.1200/jco.2024.42.16_suppl.6009.
- Siu L, McQuarrie K, Bidadi B, Liu C, Black C, Wang A, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Harrington K, Machiels J. A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden. Journal Of Clinical Oncology 2024, 42: 11116-11116. DOI: 10.1200/jco.2024.42.16_suppl.11116.
- Long G, Haddad R, Robert C, Mortier L, Schadendorf D, Uppaluri R, Svane I, Saiag P, Lim A, Soria Rivas A, Scolyer R, Chaney M, Abildgaard C, Ahmad Q, Ringeisen F, McDowell D, Burtness B. A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors. Journal Of Clinical Oncology 2024, 42: tps2701-tps2701. DOI: 10.1200/jco.2024.42.16_suppl.tps2701.
- Colevas A, Chung C, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Worden F, Johnson F, Saba N, Burtness B, Julian R, Bauman J, Jotte R, Seiwert T, Dunn L, Chaney M, Margossian S, Levisetti M, Pai S. A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Journal Of Clinical Oncology 2024, 42: 6004-6004. DOI: 10.1200/jco.2024.42.16_suppl.6004.
- Bhatia A, Hayashi H, Kogawa T, Nishina T, Fountzilas C, Castillo D, McKean M, Colombo N, Smithy J, Fayette J, Chandra S, Powles T, Kudchadkar R, Sternberg D, Sullivan K, Yueh S, Clinthorne G, Burtness B. HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors. Journal Of Clinical Oncology 2024, 42: tps3164-tps3164. DOI: 10.1200/jco.2024.42.16_suppl.tps3164.
- Evans E, Fisher T, Mallow C, Foster A, Leonard J, Chaney M, Mekhail T, Seetharamu N, Steuer C, Saba N, Adkins D, Beck J, Algazi A, Burtness B, Baumgart M, Giampoli E, Hager S, Chay C, Spira A, Zauderer M. Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer. Journal Of Clinical Oncology 2024, 42: 2603-2603. DOI: 10.1200/jco.2024.42.16_suppl.2603.
- Shah H, Cohen O, Bourdillon A, Burtness B, Boffa D, Young M, Judson B, Mehra S. Identifying Opportunities to Deliver High‐Quality Cancer Care Across a Health System: A Clinical Responsibility. Otolaryngology 2024, 171: 445-456. PMID: 38606669, DOI: 10.1002/ohn.755.
- Colevas A, Chung C, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Margossian S, Pai S. A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e87. DOI: 10.1016/j.ijrobp.2024.01.192.
- Machiels J, TAO Y, Burtness B, Tahara M, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Black C, Norquist J, Gumuscu B, Bidadi B, Siu L. Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC). International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e39-e40. DOI: 10.1016/j.ijrobp.2024.01.091.
- Harrington K, Kim H, Salas S, Oliva M, Metcalf R, Bernsdorf M, Kim J, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, O'Hara K, Pathiraja K, Gumuscu B, Bidadi B, Burtness B. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e42. DOI: 10.1016/j.ijrobp.2024.01.095.
- Yarbrough W, Schrank T, Burtness B, Issaeva N. De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses 2024, 16: 536. PMID: 38675879, PMCID: PMC11053602, DOI: 10.3390/v16040536.
- Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple R, Shabbir Ahmed F, Schultz B, Flieder D, Connolly D, Psyrri A, Burtness B, Rimm D. An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers. Oral Oncology 2024, 152: 106750. PMID: 38547779, PMCID: PMC11060915, DOI: 10.1016/j.oraloncology.2024.106750.
- Hasan A, Demidova E, Czyzewicz P, Shah S, Devarajan K, Galloway T, Einarson M, Burtness B, Golemis E, Meyer J, Arora S. Abstract 5143: Molecular investigation of a polymorphic variant in JMJD1C that associates with chemoradiotherapy outcomes in locally advanced rectal and head and neck cancer. Cancer Research 2024, 84: 5143-5143. DOI: 10.1158/1538-7445.am2024-5143.
- Haider S, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann B, Judson B, Prasad M, Burtness B, Aboian M, Canis M, Reichel C, Baumeister P, Payabvash S. Impact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266637. PMID: 38514087, DOI: 10.2967/jnumed.123.266637.
- Contrera K, Patel M, Burtness B, Mehra R, Ferris R. The role of surgery and deescalation for HPV‐related oropharyngeal cancer. Cancer 2024 PMID: 38497569, DOI: 10.1002/cncr.35287.
- Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse H, Su T, Cruz‐Gomez S, Lee S, Menges F, Parent L, Ratjen L, Burtness B, Fortner J, Zimmerman J. Multiplexable and Scalable Aqueous Synthesis Platform for Oleate‐Based, Bilayer‐Coated Gold Nanoparticles. Small 2024, 20: e2309919. PMID: 38377304, DOI: 10.1002/smll.202309919.
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsBrahmer J, Long G, Hamid O, Garon E, Herbst R, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri T, Cohen E, Diaz L, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani P, Jafari N, Bird S, Snyder E, Gause C, Bracco O, Pietanza M, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. European Journal Of Cancer 2024, 199: 113530. PMID: 38295556, PMCID: PMC11227881, DOI: 10.1016/j.ejca.2024.113530.
- Argiris A, Flamand Y, Savvides P, Johnson J, Vathiotis I, Levine M, Li S, Forastiere A, Burtness B. A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305. European Journal Of Cancer 2023, 199: 113509. PMID: 38215573, PMCID: PMC11376484, DOI: 10.1016/j.ejca.2023.113509.
- Hasan A, Demidova E, Czyzewicz P, Shah S, Devarajan K, Galloway T, Einarson M, Burtness B, Golemis E, Meyer J, Arora S. Abstract PR013: Association of a polymorphic variant in JMJD1C with response to chemoradiotherapy in rectal cancer and head and neck cancer: Implications for a diverse population. Cancer Epidemiology Biomarkers & Prevention 2023, 32: pr013-pr013. DOI: 10.1158/1538-7755.disp23-pr013.
- Greil R, Burtness B, Laban S, Braña I, Nin R, Fuereder T, Bratland Å, Licitra L, Rordorf T, Psyrri A, Popovtzer A, Hughes B, Tahara M, Lin J, Gumuscu B, Lerman N, Harrington K. 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study. Immuno-Oncology Technology 2023, 20: 100578. DOI: 10.1016/j.iotech.2023.100578.
- Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.
- Harrington K, Cohen E, Soulières D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Swaby R, Lin J, Ge J, Lerman N, Tourneau C. Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncology 2023, 147: 106587. PMID: 37925894, DOI: 10.1016/j.oraloncology.2023.106587.
- Chung C, Adkins D, Dimitrios Colevas A, Rodriguez C, Park J, Gibson M, Sukari A, Burtness B, Johnson F, Julian R, Saba N, Worden F, Dunn L, Seiwert T, Jotte R, Haddad R, Gabrail N, Bauman J, Chaney M, Agensky L, Goel A, Quayle S, Margossian S, Levisetti M, Pai S. 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients. 2023, a764-a764. DOI: 10.1136/jitc-2023-sitc2023.0674.
- Fisher T, Evans E, Mallow C, Foster A, Leonard J, Chaney M, Mekhail T, Seetharamu N, Steuer C, Saba N, Adkins D, Thaddeus Beck J, Algazi A, Burtness B, Baumgart M, Hager S, Chay C, Spira A, Zauderer M. 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84). 2023, a767-a767. DOI: 10.1136/jitc-2023-sitc2023.0676.
- Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Redman R, Stokes W, Rudra S, Mell L, Sacco A, Spencer S, Nabell L, Yao M, Cury F, Mitchell D, Jones C, Firat S, Contessa J, Galloway T, Currey A, Harris J, Curran W, Le Q. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma. JAMA Oncology 2023, 9: 1565-1573. PMID: 37768670, PMCID: PMC10540060, DOI: 10.1001/jamaoncol.2023.3809.
- Tahara M, Machiels J, Tao Y, Burtness B, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Swaby R, Zhang Y, Bidadi B, Siu L. PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412. Annals Of Oncology 2023, 34: s1380. DOI: 10.1016/j.annonc.2023.09.109.
- Harrington K, Kim H, Salas S, Oliva M, Metcalf R, Bernsdorf M, Kim J, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, O'Hara K, Pathiraja K, Gumuscu B, Bidadi B, Burtness B. Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009. Clinical Cancer Research 2023, 29: po-003-po-003. DOI: 10.1158/1557-3265.aacrahns23-po-003.
- Hasan A, Demidova E, Shah S, Czyzewicz P, Devarajan K, Galloway T, Burtness B, Golemis E, Meyer J, Arora S. Abstract PO-032: Association of a polymorphic variant in JMJD1C with tumor recurrence after adjuvant chemoradiation therapy in head and neck squamous cell carcinoma. Clinical Cancer Research 2023, 29: po-032-po-032. DOI: 10.1158/1557-3265.aacrahns23-po-032.
- Schrank T, Kothari A, Weir W, Stepp W, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward M, Wu D, Burtness B, Anderson K, Baldwin A, Yarbrough W, Issaeva N. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2216532120. PMID: 37523561, PMCID: PMC10410762, DOI: 10.1073/pnas.2216532120.
- Snyder R, Burtness B, Cho M, Del Rivero J, Doroshow D, Hitchcock K, Kalyan A, Kim C, Lukovic J, Parikh A, Sanford N, Singh B, Shen C, Shroff R, Vijayvergia N, Goodman K, Kunz P. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership. Journal Of The National Cancer Institute 2023, 115: 1132-1138. PMID: 37364007, PMCID: PMC11009492, DOI: 10.1093/jnci/djad121.
- Stockton S, Catalano P, Cohen S, Burtness B, Mitchell E, Dotan E, Lubner S, Kumar P, Mulcahy M, Fisher G, Crandall T, Benson A. Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The Oncologist 2023, 28: 827-e822. PMID: 37104870, PMCID: PMC10485278, DOI: 10.1093/oncolo/oyad096.
- Kann B, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly H, Juliano A, Payabvash S, Guenette J, Uppaluri R, Margalit D, Schoenfeld J, Tishler R, Haddad R, Aerts H, Garcia J, Flamand Y, Subramaniam R, Burtness B, Ferris R. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. The Lancet Digital Health 2023, 5: e360-e369. PMID: 37087370, PMCID: PMC10245380, DOI: 10.1016/s2589-7500(23)00046-8.
- Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm D. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Research Communications 2023, 3: 558-563. PMID: 37057033, PMCID: PMC10088911, DOI: 10.1158/2767-9764.crc-22-0299.
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung C. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2023, 41: 3851-3862. PMID: 36977289, DOI: 10.1200/jco.22.01994.
- Burtness B. First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened? Journal Of Clinical Oncology 2023, 41: 2134-2137. PMID: 36877893, DOI: 10.1200/jco.22.02349.
- Belzer A, Pach J, Mortlock R, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal J. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD International 2023, 11: 174-175. PMID: 37252181, PMCID: PMC10213716, DOI: 10.1016/j.jdin.2023.02.007.
- Verma A, Burtness B. Top advances of the year: Head and neck cancer. Cancer 2023, 129: 1308-1312. PMID: 36692372, DOI: 10.1002/cncr.34654.
- Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J. Author Correction: Head and neck squamous cell carcinoma. Nature Reviews Disease Primers 2023, 9: 4. PMID: 36658129, DOI: 10.1038/s41572-023-00418-5.
- Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.
- Burtness B, Lin J, Souliéres D. Methodologic Concerns in Secondary Analysis of KEYNOTE-048. JAMA Oncology 2022, 8: 1853-1854. PMID: 36264563, DOI: 10.1001/jamaoncol.2022.5068.
- Qian D, Ulrich B, Peng G, Zhao H, Conneely K, Miller A, Bruner D, Eldridge R, Wommack E, Higgins K, Shin D, Saba N, Smith A, Burtness B, Park H, Stokes W, Beitler J, Xiao C. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood. International Journal Of Radiation Oncology • Biology • Physics 2022, 115: 1217-1228. PMID: 36410685, DOI: 10.1016/j.ijrobp.2022.11.009.
- Gavrielatou N, Warrell J, Aung T, Vathiotis L, Economopoulou P, Burtness B, Psyrri A, Rimm D. 133 Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma. 2022, a146-a146. DOI: 10.1136/jitc-2022-sitc2022.0133.
- Hutcheson K, Peterson C, Barbon C, Quon H, Mehra R, Ringash J, Lewin J, Flamand Y, Duvvuri U, Ozer E, Thomas G, Kupferman M, Koch W, Bell R, Saba N, Panwar A, Annino D, Wagner L, Ferris R, Burtness B. Reduced Aspiration Rates for 50 Gy Postoperative Radiation in HPV-Associated Oropharynx Cancer in E3311: A Trial of the ECOG-ACRIN Cancer Research Group. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s27-s28. DOI: 10.1016/j.ijrobp.2022.07.380.
- Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal Of Clinical Oncology 2022, 41: 790-802. PMID: 36219809, PMCID: PMC9902012, DOI: 10.1200/jco.21.02508.
- Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Journal Of The National Cancer Institute 2022, 114: 1619-1627. PMID: 36053203, PMCID: PMC9745425, DOI: 10.1093/jnci/djac163.
- Soulieres D, Harrington K, Le Tourneau C, Silva J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Lin J, Lerman N, Gumuscu B, Cohen E. 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Annals Of Oncology 2022, 33: s843. DOI: 10.1016/j.annonc.2022.07.782.
- Tahara M, Greil R, Rischin D, Harrington K, Burtness B, De Castro G, Psyrri A, Brana I, Neupane P, Bratland Å, Fuereder T, Hughes B, Nin R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Gumuscu B, Lerman N, Soulieres D. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Annals Of Oncology 2022, 33: s844. DOI: 10.1016/j.annonc.2022.07.783.
- Machiels J, Tao Y, Burtness B, Tahara M, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Swaby R, Zhang Y, Gumuscu B, Bidadi B, Siu L. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2022, 33: s1399. DOI: 10.1016/j.annonc.2022.08.029.
- Burtness B. Integrating Targeted Therapies in the Management of Head and Neck Cancers. The Cancer Journal 2022, 28: 329-330. PMID: 36165719, DOI: 10.1097/ppo.0000000000000624.
- Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404). Journal Of Clinical Oncology 2022, 40: 4240-4249. PMID: 35867947, PMCID: PMC9916043, DOI: 10.1200/jco.22.00229.
- Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society Of Clinical Oncology Educational Book 2022, 42: 1-14. PMID: 35486888, DOI: 10.1200/edbk_350442.
- Fisher T, Evans E, Mallow C, Foster A, Boise M, Smith E, Leonard J, Chaney M, Beck J, Hager S, Saba N, Steuer C, Adkins D, Burtness B, Zauderer M. Abstract CT111: Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84). Cancer Research 2022, 82: ct111-ct111. DOI: 10.1158/1538-7445.am2022-ct111.
- Chung C, Colevas A, Adkins D, Gibson M, Rodriguez C, Sukari A, Bauman J, Wirth L, Johnson F, Saba N, Burtness B, Dunn L, Seiwert T, Worden F, Muzaffar J, Margossian S, Moniz R, Quayle S, Levisetti M, Pai S. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Journal Of Clinical Oncology 2022, 40: 6045-6045. DOI: 10.1200/jco.2022.40.16_suppl.6045.
- Argiris A, Flamand Y, Savvides P, Johnson J, Li S, Forastiere A, Burtness B. A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. Journal Of Clinical Oncology 2022, 40: 6026-6026. DOI: 10.1200/jco.2022.40.16_suppl.6026.
- Fisher T, Evans E, Mallow C, Foster A, Boise M, Smith E, Leonard J, Chaney M, Beck J, Hager S, Mekhail T, Seetharamu N, Baumgart M, Saba N, Steuer C, Adkins D, Burtness B, Zauderer M. Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). Journal Of Clinical Oncology 2022, 40: e18033-e18033. DOI: 10.1200/jco.2022.40.16_suppl.e18033.
- Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.
- Mehra R, Flamand Y, Quon H, Garcia J, Weinstein G, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Gross N, Bell R, Saba N, Lango M, Bayon R, Burtness B, Ferris R. Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2022, 40: 6077-6077. DOI: 10.1200/jco.2022.40.16_suppl.6077.
- Haider S, Sharaf K, Zeevi T, Mahajan A, Forghani R, Judson B, Kann B, Burtness B, Reichel C, Baumeister P, Payabvash S. PET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients. Laryngo-Rhino-Otologie 2022, 101: s184-s184. DOI: 10.1055/s-0042-1746471.
- Haider S, Sharaf K, Zeevi T, Mahajan A, Forghani R, Judson B, Kann B, Burtness B, Reichel C, Baumeister P, Payabvash S. PET/CT-Radiomics zuzüglich zum UICC-Staging könnten die Prognostik des Progressionsfreien Überlebens (PFS) und Gesamtüberlebens (OS) beim Oropharyngealen Plattenepithelkarzinom (OPSCC) verbessern. Laryngo-Rhino-Otologie 2022, 101: s13-s13. DOI: 10.1055/s-0042-1747116.
- Fisher T, Evans E, Mallow C, Foster A, Boise M, Smith E, Leonard J, Chaney M, Beck J, Hager S, Saba N, Steuer C, Adkins D, Burtness B, Zauderer M. Phase 1/2 Study of Pepinemab in Combination with Pembrolizumab as First-Line Treatment of Advanced, Recurrent or Metastatic Head and Neck Cancer (KEYNOTE B84). International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e36. DOI: 10.1016/j.ijrobp.2021.12.084.
- Schoenfeld J, Cohen E, Nutting C, Licitra L, Burtness B, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Bourhis J. Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e20-e21. DOI: 10.1016/j.ijrobp.2021.12.046.
- Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e43-e44. DOI: 10.1016/j.ijrobp.2021.12.101.
- Yarbrough W, Schrank T, Blumberg J, Patel S, Hackman T, Lumley C, Burtness B, Issaeva N. Predictive Molecular Biomarkers for HPV-Associated Head and Neck Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e17-e18. DOI: 10.1016/j.ijrobp.2021.12.178.
- Chung C, Colevas A, Gibson M, Adkins D, Sukari A, Wirth L, Burtness B, Bauman J, Rodriguez C, Worden F, Saba N, Glisson B, Dunn L, Seiwert T, Agensky L, Levisetti M, Lynam R, Margossian S, Moniz R, Quayle S, Pienta K, Pai S. 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Journal For ImmunoTherapy Of Cancer 2021, 9: a468-a468. DOI: 10.1136/jitc-2021-sitc2021.438.
- Qian D, Ulrich B, Peng G, Zhao H, Conneely K, Miller A, Bruner D, Eldridge R, Wommack E, Higgins K, Shin D, Saba N, Smith A, Burtness B, Park H, Stokes W, Beitler J, Xiao C. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-Treatment DNA Methylation in Peripheral Blood. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s143-s144. DOI: 10.1016/j.ijrobp.2021.07.323.
- Harrington K, Siu L, Burtness B, Cohen E, Licitra L, Rischin D, Zhu Y, Okpara C, Pinheiro C, Swaby R, Machiels J, Tahara M. P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study. Oral Oncology 2021, 118: 7-8. DOI: 10.1016/s1368-8375(21)00375-4.
- Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology 2021, 118: 10-11. DOI: 10.1016/s1368-8375(21)00381-x.
- Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable? Journal Of Clinical Oncology 2021, 39: 2732-2733. PMID: 34043410, DOI: 10.1200/jco.21.00594.
- Xiao C, Beitler JJ, Peng G, Levine ME, Conneely KN, Zhao H, Felger JC, Wommack EC, Chico CE, Jeon S, Higgins KA, Shin DM, Saba NF, Burtness BA, Bruner DW, Miller AH. Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study. Cancer 2021, 127: 3361-3371. PMID: 34027995, DOI: 10.1002/cncr.33641.
- Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia J, Ringash J, Lewin J, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Kupferman M, Bell R, Saba N, Lango M, Wagner L, Burtness B. Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). Journal Of Clinical Oncology 2021, 39: 6010-6010. DOI: 10.1200/jco.2021.39.15_suppl.6010.
- Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Mell L, Spencer S, Stokes W, Yao M, Mitchell D, Harris J, Curran W, Le Q. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal Of Clinical Oncology 2021, 39: 6014-6014. DOI: 10.1200/jco.2021.39.15_suppl.6014.
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Saboda K, Obara S, Chung C. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6015-6015. DOI: 10.1200/jco.2021.39.15_suppl.6015.
- Forman R, Bhatia A, Burtness B. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. Journal Of Clinical Oncology 2021, 39: 6042-6042. DOI: 10.1200/jco.2021.39.15_suppl.6042.
- Bourhis J, Burtness B, Licitra L, Nutting C, Schoenfeld J, Sarkouh R, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen E. TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer. Journal Of Clinical Oncology 2021, 39: tps6091-tps6091. DOI: 10.1200/jco.2021.39.15_suppl.tps6091.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Entwicklung bildbasierter Radiomics-Biomarker für den Humanen Papillomavirus (HPV)-Status beim oropharyngealen Plattenepithelkarzinom (OPSCC) mittels Machine-Learning-Algorithmen. Laryngo-Rhino-Otologie 2021, 100: s65. DOI: 10.1055/s-0041-1727786.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Devising novel imaging biomarkers for Human Papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC): applying radiomics and machine learning algorithms. Laryngo-Rhino-Otologie 2021, 100: s99. DOI: 10.1055/s-0041-1727889.
- Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.
- Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.
- Petit C, Lacas B, Pignon J, Le Q, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar M, Lee J, Ghi M, Sanguineti G, Temam S, Cheugoua-Zanetsie M, O'Sullivan B, Posner M, Vokes E, Hernandez J, Szutkowski Z, Lartigau E, Budach V, Suwiński R, Poulsen M, Kumar S, Laskar S, Mazeron J, Jeremic B, Simes J, Zhong L, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P, Groups M, Adelstein D, Agarwal J, Alfonsi M, Argiris A, Aupérin A, Bacigalupo A, Bar-Ad V, Bartelink H, Beadle B, Belkacemi Y, Bensadoun R, Bernier J, Blanchard P, Bourhis J, Bratland Å, Brizel D, Budach V, Budach W, Burtness B, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Cheugoua-Zanetsie M, Cho K, Choussy O, Hernandez J, Denham J, Dobrowsky W, Dominello M, Driessen C, Fallai C, Forastiere A, Fortpied C, Fountzilas G, Garaud P, Garden A, Gery B, Ghadjar P, Ghi M, Laskar S, Graff-Cailleaud P, Grau C, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hay J, Hayoz S, Horiot J, Hitt R, Jeremic B, Johansen J, Jones C, Julieron M, Kristensen C, Kumar S, Lacas B, Langendijk J, Lapeyre M, Lartigau E, Licitra L, Le Q, Lee J, Lee P, Lewin F, Li Y, Lopes A, Lotayef M, Maciejewski B, Mazeron J, Mehta S, Michalski W, Moon J, Moon S, Moyal E, Nankivell M, Nilsson P, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Parmar M, Petit C, Pignon J, Pointreau Y, Posner M, Poulsen M, Quon H, Racadot S, Rosenthal D, Rovea P, Redda M, Sanguineti G, Shenouda G, Simes J, Sharma A, Simon C, Sire C, Skladowski K, Spencer S, Staar S, Strojan P, Stromberger C, Suwinski R, Szutkowski Z, Takácsi-Nagy Z, Tao Y, Temam S, Thomson D, Tobias J, Torres-Saavedra P, Torri V, Tripcony L, Trotti A, Tseroni V, van Herpen C, van Tinteren H, Vermorken J, Viegas C, Vokes E, Waldron J, Wernecke K, Widder J, Wolf G, Wong S, Wu J, Yamazaki H, Zaktonik B, Zackrisson B, Zhong L. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. The Lancet Oncology 2021, 22: 727-736. PMID: 33862002, DOI: 10.1016/s1470-2045(21)00076-0.
- Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Redda M, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP, Group M, Adelstein D, Alfonsi M, Belkacemi Y, Bar-Ad V, Bernier J, Bratland Å, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Choi K, Choussy O, Collette L, Cruz J, Dani C, Dauzier E, Forastiere A, Garaud P, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hayoz S, Horiot J, Jeremic B, Karrison T, Langendijk J, Lapeyre M, Lartigau E, Leong T, Le Q, Lee P, Lewin F, Lin A, Lopes A, Mehta S, Moon J, Moyal E, Occéan B, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Petit C, Quon H, Sanguineti G, Satar T, Simes J, Simon C, Sire C, Staar S, Stromberger C, Strojan P, Temam S, Thomson D, Timochenko A, Torri V, Tseroni V, Vermorken J, Vokes E, Waldron J, Wernecke K, Widder J, Zackrisson B. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy And Oncology 2021, 156: 281-293. PMID: 33515668, PMCID: PMC8386522, DOI: 10.1016/j.radonc.2021.01.013.
- Burtness B, Contessa J. Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer. Journal Of The National Cancer Institute 2021, 113: 652-653. PMID: 33429429, PMCID: PMC8168139, DOI: 10.1093/jnci/djaa187.
- Cmelak A, Dietrich MS, Li S, Ridner S, Forastiere A, Burtness BA, Cella D, Murphy BA. ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer. Cancers Of The Head & Neck 2020, 5: 12. PMID: 33353553, PMCID: PMC7756946, DOI: 10.1186/s41199-020-00059-1.
- Zandberg D, Ferris R, Laux D, Mehra R, Nabell L, Kaczmar J, Gibson M, Kim Y, Neupane P, Bauman J, Julian R, Adkins D, Cohen E, Burtness B, Bermingham C, Dupage A, Desbien A, Loi A, Nuyten D, Saba N. 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. Annals Of Oncology 2020, 31: s1446-s1447. DOI: 10.1016/j.annonc.2020.10.559.
- Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers 2020, 6: 92. PMID: 33243986, PMCID: PMC7944998, DOI: 10.1038/s41572-020-00224-3.
- Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Swaby R. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology 2020, 34: 532-541. PMID: 33239737, DOI: 10.1038/s41379-020-00710-9.
- Khan SA, Burke M, Zhu F, Yang DH, Dubyk C, Mehra R, Lango MJ, Ridge JA, Sher DJ, Burtness B. Survivin expression and impact on head and neck cancer outcomes. Oral Oncology 2020, 112: 105049. PMID: 33221541, PMCID: PMC10916757, DOI: 10.1016/j.oraloncology.2020.105049.
- Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Journal For ImmunoTherapy Of Cancer 2020, 8: a376-a376. DOI: 10.1136/jitc-2020-sitc2020.0351.
- Pai S, Adkins D, Wirth L, Chung C, Gibson M, Sukari A, Worden F, Colevas D, Saba N, Burtness B, Rodriguez C, Bauman J, Glisson B, Dunn L, Suri A, Haydock M, Quayle S, Cemerski S, Leader M, Brown J, Pienta K, Simcox M. 354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer. 2020, a216.1-a216. DOI: 10.1136/jitc-2020-sitc2020.0354.
- Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.
- Haider SP, Sharaf K, Zeevi T, Baumeister P, Reichel C, Forghani R, Kann BH, Petukhova A, Judson BL, Prasad ML, Liu C, Burtness B, Mahajan A, Payabvash S. Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics. Translational Oncology 2020, 14: 100906. PMID: 33075658, PMCID: PMC7568193, DOI: 10.1016/j.tranon.2020.100906.
- Burtness B, Ge J. Reply to “Keynote 48: Is it really for everyone?”. Oral Oncology 2020, 112: 104983. PMID: 33032941, DOI: 10.1016/j.oraloncology.2020.104983.
- Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le Q, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtness BA, Ghi MG, Sanguineti G, O’Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon J, Mell LK, Intergroup F. Predictive classifier for intensive treatment of head and neck cancer. Cancer 2020, 126: 5263-5273. PMID: 33017867, DOI: 10.1002/cncr.33212.
- Siu L, Burtness B, Cohen E, Harrington K, Licitra L, Rischin D, Zhu Y, Okpara C, Pinheiro C, Swaby R, Machiels J, Tahara M. LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2020, 31: s683-s684. DOI: 10.1016/j.annonc.2020.08.1088.
- Greil R, Rischin D, Harrington K, Soulières D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Swaby R, Gumuscu B, Burtness B. Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2020, 31: s660-s661. DOI: 10.1016/j.annonc.2020.08.1030.
- Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. Cancer Research 2020, 80: lb-258-lb-258. DOI: 10.1158/1538-7445.am2020-lb-258.
- Burtness B, Zhang Y, Harrington KJ, Rischin D. Further clinical interpretation and implications of KEYNOTE-048 findings – Authors' reply. The Lancet 2020, 396: 379-380. PMID: 32771104, DOI: 10.1016/s0140-6736(20)30900-4.
- Ferris RL, Flamand Y, Holsinger FC, Weinstein GS, Quon H, Mehra R, Garcia JJ, Hinni ML, Gross ND, Sturgis EM, Duvvuri U, Méndez E, Ridge JA, Magnuson JS, Higgins KA, Patel MR, Smith RB, Karakla DW, Kupferman ME, Malone JP, Judson BL, Richmon J, Boyle JO, Bayon R, O'Malley BW, Ozer E, Thomas GR, Koch WM, Bell RB, Saba NF, Li S, Sigurdson ER, Burtness B. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncology 2020, 110: 104797. PMID: 32679405, PMCID: PMC7771718, DOI: 10.1016/j.oraloncology.2020.104797.
- Haider SP, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kann BH, Judson BL, Prasad ML, Burtness B, Mahajan A, Payabvash S. Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma. Cancers 2020, 12: 1778. PMID: 32635216, PMCID: PMC7407414, DOI: 10.3390/cancers12071778.
- Husain ZA, Burtness BA. High Dose Cisplatin: Still the One? International Journal Of Radiation Oncology • Biology • Physics 2020, 107: 615-616. PMID: 32589986, DOI: 10.1016/j.ijrobp.2019.09.026.
- Ridge J, Ringash J, Yao M, Blakaj D, Razaq M, Colevas A, Beitler J, Jones C, Dunlap N, Seaward S, Spencer S, Galloway T, Dignam J, Le Q, Gillison M, Sturgis E, Phan J, Trotti A, Harris J, Eisbruch A, Harari P, Adelstein D, Koyfman S, Burtness B. Abstract IA20: Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial*. Clinical Cancer Research 2020, 26: ia20-ia20. DOI: 10.1158/1557-3265.aacrahns19-ia20.
- Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, Alves GV, Lima I, Pointreau Y, Hughes B, Aksoy S, Hetnal M, Ge JY, Brown H, Cheng J, Bidadi B, Siu LL. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncology 2020, 16: 1235-1243. PMID: 32490686, DOI: 10.2217/fon-2020-0184.
- Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia J, Chung C, Gillison M, Duvvuri U, O'malley B, Ozer E, Thomas G, Koch W, Kupferman M, Bell R, Saba N, Lango M, Mendez E, Burtness B. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). Journal Of Clinical Oncology 2020, 38: 6500-6500. DOI: 10.1200/jco.2020.38.15_suppl.6500.
- Harrington K, Rischin D, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Gumuscu B, Swaby R, Burtness B. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6505-6505. DOI: 10.1200/jco.2020.38.15_suppl.6505.
- Rischin D, Harrington K, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Burtness B. Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. Journal Of Clinical Oncology 2020, 38: 6530-6530. DOI: 10.1200/jco.2020.38.15_suppl.6530.
- Burtness B, Deneka A, Baca Y, Serebriiskii I, Parker M, Nicolas E, Lee J, Wise-Draper T, Sukari A, Somer B, Golemis E. Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6552-6552. DOI: 10.1200/jco.2020.38.15_suppl.6552.
- Siu L, Burtness B, Cohen E, Harrington K, Licitra L, Rischin D, Zhu Y, Lee C, Pinheiro C, Swaby R, Machiels J, Tahara M. Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6589-tps6589. DOI: 10.1200/jco.2020.38.15_suppl.tps6589.
- Bauman J, Roe D, Saba N, Bauman J, Kaczmar J, Burtness B, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Bhatia A, Giri A, Caulin C, Stabile L, Centuori S, Chung C. Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6594-tps6594. DOI: 10.1200/jco.2020.38.15_suppl.tps6594.
- Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal Of The National Cancer Institute 2020, 113: 171-181. PMID: 32407532, PMCID: PMC7850527, DOI: 10.1093/jnci/djaa063.
- Haider SP, Mahajan A, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kucukkaya AS, Kann BH, Judson BL, Prasad ML, Burtness B, Payabvash S. PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2978-2991. PMID: 32399621, DOI: 10.1007/s00259-020-04839-2.
- Haider SP, Burtness B, Yarbrough WG, Payabvash S. Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. Cancers Of The Head & Neck 2020, 5: 6. PMID: 32391171, PMCID: PMC7197186, DOI: 10.1186/s41199-020-00053-7.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Devising novel imaging biomarkers for Human Papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC): applying radiomics and machine learning algorithms. Laryngo-Rhino-Otologie 2020, 99: s163. DOI: 10.1055/s-0040-1711024.
- Haider S, Mahajan A, Zeevi T, Forghani R, Kann B, Judson B, Burtness B, Sharaf K, Reichel C, Baumeister P, Payabvash S. Entwicklung bildbasierter Radiomics-Biomarker für den Humanen Papillomavirus (HPV)-Status beim oropharyngealen Plattenepithelkarzinom (OPSCC) mittels Machine-Learning-Algorithmen. Laryngo-Rhino-Otologie 2020, 99: s116. DOI: 10.1055/s-0040-1711657.
- Jacobs D, Park H, Young M, Olino K, Rahmati R, Mehra S, Burtness B, Judson B. Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1191-1192. DOI: 10.1016/j.ijrobp.2019.11.099.
- Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancerSaeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.
- Deneka AY, Einarson MB, Bennett J, Nikonova AS, Elmekawy M, Zhou Y, Lee JW, Burtness BA, Golemis EA. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers 2020, 12: 306. PMID: 32012873, PMCID: PMC7072436, DOI: 10.3390/cancers12020306.
- Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.
- Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. Journal Of Clinical Oncology 2019, 38: 472-479. PMID: 31815582, PMCID: PMC7007287, DOI: 10.1200/jco.19.00925.
- Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S. Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal Of Clinical Oncology 2019, 38: 1304-1311. PMID: 31815574, DOI: 10.1200/jco.19.02031.
- Baro M, Lopez Sambrooks C, Burtness BA, Lemmon MA, Contessa JN. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics 2019, 18: 2124-2134. PMID: 31387891, PMCID: PMC6825559, DOI: 10.1158/1535-7163.mct-19-0163.
- Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak W, Hong RL, Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D, Investigators K, Lerzo G, Tatangelo M, Varela M, Zarba J, Boyer M, Gan H, Gao B, Hughes B, Mallesara G, Rischin D, Taylor A, Burian M, Fuereder T, Greil R, Barrios C, de Castro D, Castro G, Franke F, Girotto G, Lima I, Nicolau U, Pinto G, Santos L, Victorino A, Chua N, Couture F, Gregg R, Hansen A, Hilton J, McCarthy J, Soulieres D, Ascui R, Gonzalez P, Villanueva L, Torregroza M, Zambrano A, Holeckova P, Kral Z, Melichar B, Prausova J, Vosmik M, Andersen M, Gyldenkerne N, Jurgens H, Putnik K, Reinikainen P, Gruenwald V, Laban S, Aravantinos G, Boukovinas I, Georgoulias V, Psyrri A, Kwong D, Al-Farhat Y, Csoszi T, Erfan J, Horvai G, Landherr L, Remenar E, Ruzsa A, Szota J, Billan S, Gluck I, Gutfeld O, Popovtzer A, Benasso M, Bui S, Ferrari V, Licitra L, Nole F, Fujii T, Fujimoto Y, Hanai N, Hara H, Matsumoto K, Mitsugi K, Monden N, Nakayama M, Okami K, Oridate N, Shiga K, Shimizu Y, Sugasawa M, Tahara M, Takahashi M, Takahashi S, Tanaka K, Ueda T, Yamaguchi H, Yamazaki T, Yasumatsu R, Yokota T, Yoshizaki T, Kudaba I, Stara Z, Ishak W, Cheah S, Ponce J, Mendoza R, Hernandez C, Soto F, Buter J, Hoeben A, Oosting S, Suijkerbuijk K, Bratland A, Brydoey M, Alvarez R, Mas L, Caguioa P, Querol J, Regala E, Tamayo M, Villegas E, Kawecki A, Karpenko A, Klochikhin A, Smolin A, Zarubenkov O, Goh B, Cohen G, du Toit J, Jordaan C, Landers G, Ruff P, Szpak W, Tabane N, Brana I, Docampo L, Lavernia J, Mesia R, Abel E, Muratidu V, Nielsen N, Cristina V, Rordorf T, Rothschild S, Hong R, Wang H, Yang M, Yeh S, Yen C, Ngamphaiboon N, Soparattanapaisarn N, Sriuranpong V, Aksoy S, Cicin I, Ekenel M, Harputluoglu H, Ozyilkan O, Harrington K, Agarwala S, Ali H, Alter R, Anderson D, Bruce J, Burtness B, Campbell N, Conde M, Deeken J, Edenfield W, Feldman L, Gaughan E, Goueli B, Halmos B, Hegde U, Hunis B, Jotte R, Karnad A, Khan S, Laudi N, Laux D, Martincic D, McCune S, McGaughey D, Misiukiewicz K, Mulford D, Nadler E, Neupane P, Nunnink J, Ohr J, O'Malley M, Patson B, Paul D, Popa E, Powell S, Redman R, Rella V, Lima C, Sivapiragasam A, Su Y, Sukari A, Wong S, Yilmaz E, Yorio J. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 2019, 394: 1915-1928. PMID: 31679945, DOI: 10.1016/s0140-6736(19)32591-7.
- Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncology 2019, 99: 104460. PMID: 31683169, PMCID: PMC7749717, DOI: 10.1016/j.oraloncology.2019.104460.
- Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.
- Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2019, 37: 3266-3274. PMID: 31618129, PMCID: PMC6980834, DOI: 10.1200/jco.19.00555.
- Cohen E, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Bal T, Juco J, Aurora-Garg D, Huang L, Swaby R, Emancipator K. 1115PD Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040. Annals Of Oncology 2019, 30: v452-v453. DOI: 10.1093/annonc/mdz252.007.
- Husain Z, Lee N, Eskander A, Park H, mehra S, Burtness B. 1149P Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Annals Of Oncology 2019, 30: v466. DOI: 10.1093/annonc/mdz252.041.
- Yu J, Tsay C, Sasaki C, Son Y, Decker R, Mehra S, Burtness B. 1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Annals Of Oncology 2019, 30: v457. DOI: 10.1093/annonc/mdz252.019.
- Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant TherapyLOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.
- Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant TherapyLoganadane G, Kann B, Park H, Johnson S, Mehra S, Judson B, Bhatia A, Belkacemi Y, Yarbrough W, Burtness B, Husain Z. Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e375-e376. DOI: 10.1016/j.ijrobp.2019.06.1628.
- Kann B, Hicks D, Payabvash S, Mahajan A, Gupta V, Burtness B, Husain Z, Aneja S. External Validation and Radiologist Comparison of a Deep Learning Model (DLM) to Identify Extranodal Extension (ENE) in Head and Neck Squamous Cell Carcinoma (HNSCC) with Pretreatment Computed Tomography (CT) Imaging. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s71. DOI: 10.1016/j.ijrobp.2019.06.525.
- Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology 2019, 5: 1170-1180. PMID: 31194247, PMCID: PMC6567846, DOI: 10.1001/jamaoncol.2019.1146.
- Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Journal For ImmunoTherapy Of Cancer 2019, 7: 184. PMID: 31307547, PMCID: PMC6632213, DOI: 10.1186/s40425-019-0662-5.
- Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology 2019, 16: 669-683. PMID: 31189965, DOI: 10.1038/s41571-019-0227-z.
- Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2019, 25: 3430-3442. PMID: 30755439, PMCID: PMC6548643, DOI: 10.1158/1078-0432.ccr-18-0440.
- Rischin D, Harrington K, Greil R, Soulieres D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland A, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Jin F, Gumuscu B, Burtness B. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal Of Clinical Oncology 2019, 37: 6000-6000. DOI: 10.1200/jco.2019.37.15_suppl.6000.
- Ho A, Foster N, Zoroufy A, Worden F, Price K, Adkins D, Bowles D, Kang H, Burtness B, Sherman E, Morton R, Katabi N, Munster P, Schwartz G. Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. Journal Of Clinical Oncology 2019, 37: 6020-6020. DOI: 10.1200/jco.2019.37.15_suppl.6020.
- Harrington K, Cohen E, Soulieres D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Lin J, Cheng J, Swaby R, Le Tourneau C. Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state. Journal Of Clinical Oncology 2019, 37: 6026-6026. DOI: 10.1200/jco.2019.37.15_suppl.6026.
- Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.
- Lee NCJ, Eskander A, Park HS, Mehra S, Burtness BA, Husain Z. Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Cancer 2019, 125: 2975-2983. PMID: 31090934, DOI: 10.1002/cncr.32161.
- Benchetrit L, Torabi SJ, Tate JP, Mehra S, Osborn HA, Young MR, Burtness B, Judson BL. Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment. Oral Oncology 2019, 94: 32-40. PMID: 31178210, DOI: 10.1016/j.oraloncology.2019.05.009.
- Xiang JJ, Uy NF, Minja FJ, Verter EE, Burtness BA. Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report. The Laryngoscope 2019, 130: 907-910. PMID: 31058321, DOI: 10.1002/lary.28042.
- Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal Of Clinical Oncology 2019, 37: jco.19.00441. PMID: 31021656, DOI: 10.1200/jco.19.00441.
- Miccio J, Kelly J, Kann B, An Y, Park H, Verma V, Mehra S, Judson B, Burtness B, Husain Z. OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e1. DOI: 10.1016/s0360-3016(19)30402-x.
- Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncology 2019, 91: 69-78. PMID: 30926065, PMCID: PMC6855599, DOI: 10.1016/j.oraloncology.2019.02.026.
- Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head & Neck 2019, 41: 1928-1934. PMID: 30758123, PMCID: PMC6542589, DOI: 10.1002/hed.25634.
- Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, Husain ZA. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019, 125: 2018-2026. PMID: 30748002, PMCID: PMC6541535, DOI: 10.1002/cncr.32001.
- Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene 2019, 38: 3475-3487. PMID: 30647454, PMCID: PMC6499643, DOI: 10.1038/s41388-018-0657-6.
- Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ, investigators K, Acosta-Rivera M, Adkins D, Aghmesheh M, Ahn M, Airoldi M, Aleknavicius E, Al-Farhat Y, Algazi A, Almokadem S, Alyasova A, Bauman J, Benasso M, Berrocal A, Bray V, Burtness B, Caponigro F, Castro A, Cescon T, Chan K, Chaudhry A, Chauffert B, Cohen E, Csoszi T, De Boer J, Delord J, Dietz A, Dinis J, Dupuis C, Digue L, Erfan J, Alvarez Y, Evans M, Fidler M, Forster M, Friesland S, Ganti A, Geoffrois L, Grant C, Gruenwald V, Harrington K, Hoffmann T, Horvai G, Inciura A, Jang R, Jankowska P, Jimeno A, Joseph M, Ramiro A, Karaszewska B, Kawecki A, Keilholz U, Keller U, Kim S, Kocsis J, Kotecki N, Kozloff M, Lambea J, Landherr L, Lantsukhay Y, Lazarev S, Lee L, Le Tourneau C, Licitra L, Lifirenko I, Mach N, Martincic D, Matorin O, McGrath M, Machiels J, Mehra R, Misiukiewicz K, Morris J, Mufazalov F, Niu J, Srinivasan D, Segura P, Rauch D, Ribeiro M, Rodriguez C, Rolland F, Russo A, Ruzsa A, Sanches F, Shin S, Shtiveland M, Soulieres D, Soria A, Specenier P, Szekanecz E, Szota J, van Herpen C, Velez-Cortes H, Walsh W, Wilop S, Winterhalder R, Wojtukiewicz M, Wong D, Zandberg D. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet 2018, 393: 156-167. PMID: 30509740, DOI: 10.1016/s0140-6736(18)31999-8.
- Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet 2018, 393: 40-50. PMID: 30449625, PMCID: PMC6541928, DOI: 10.1016/s0140-6736(18)32779-x.
- Kann B, Aneja S, Loganadane G, Kelly J, Smith S, Decker R, Yarbrough W, Malhotra A, Burtness B, Husain Z. Successful Identification of Head and Neck Cancer (HNC) Nodal Metastasis (NM) and Extranodal Extension (ENE) Using Deep Learning Neural Networks. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s60. DOI: 10.1016/j.ijrobp.2018.06.169.
- Le Tourneau C, Cohen E, Harrington K, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Soulières D. 1047PD Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. Annals Of Oncology 2018, 29: viii373-viii374. DOI: 10.1093/annonc/mdy287.003.
- Zakeri K, Rotolo F, Lacas B, Vitzthum L, Le Q, Gregoire V, Overgaard J, Tobias J, Zackrisson B, Parmar M, Burtness B, Ghi M, Sanguineti G, O'Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Pignon J, Mell L. 1052PD Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). Annals Of Oncology 2018, 29: viii375-viii376. DOI: 10.1093/annonc/mdy287.008.
- Machiels J, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, Delord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 1121TiP KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2018, 29: viii398. DOI: 10.1093/annonc/mdy287.078.
- Burtness B, Harrington K, Greil R, Soulières D, Tahara M, De Castro G, Psyrri A, Rotllan N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Roy A, Cheng J, Jin F, Rischin D. LBA8_PR KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals Of Oncology 2018, 29: viii729. DOI: 10.1093/annonc/mdy424.045.
- Kann BH, Aneja S, Loganadane GV, Kelly JR, Smith SM, Decker RH, Yu JB, Park HS, Yarbrough WG, Malhotra A, Burtness BA, Husain ZA. Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. Scientific Reports 2018, 8: 14036. PMID: 30232350, PMCID: PMC6145900, DOI: 10.1038/s41598-018-32441-y.
- Cheraghlou S, Torabi SJ, Husain ZA, Otremba MD, Osborn HA, Mehra S, Yarbrough WG, Burtness BA, Judson BL. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. The Laryngoscope 2018, 129: 684-691. PMID: 30151832, DOI: 10.1002/lary.27475.
- Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.
- Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2018, 1-5. DOI: 10.1007/978-3-319-78762-6_1.
- Kiseleva A, Beck T, Serebriiskii I, Liu H, Burtness B, Golemis E. Targeting the ErbB Family in Head and Neck Cancer. Current Cancer Research 2018, 7-61. DOI: 10.1007/978-3-319-78762-6_2.
- Parameswaran J, Burtness B. P53 in Head and Neck Squamous Cell Carcinoma. Current Cancer Research 2018, 249-274. DOI: 10.1007/978-3-319-78762-6_9.
- Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations. Otolaryngology 2018, 159: 987-997. PMID: 30060700, DOI: 10.1177/0194599818779052.
- Deneka A, Einarson M, Lee J, Nikonova A, Burtness B, Golemis E. Abstract 5814: Synthetic lethal therapy to overcome resistance to AURKA inhibition in HPV-negative head and neck cancer. Cancer Research 2018, 78: 5814-5814. DOI: 10.1158/1538-7445.am2018-5814.
- Soulieres D, Cohen E, Tourneau C, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Harrington K. Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. Cancer Research 2018, 78: ct115-ct115. DOI: 10.1158/1538-7445.am2018-ct115.
- Cohen R, Fayette J, Posner M, Lefebvre G, Bauman J, Salas S, Even C, Seiwert T, Colevas D, Jimeno A, Saada E, Burtness B, André P, Paturel C, Bonnafous C, Soulié A, Tirouvanziam-Martin A, Zerbib R, Boyer-Chammard A. Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy. Cancer Research 2018, 78: ct158-ct158. DOI: 10.1158/1538-7445.am2018-ct158.
- Siu L, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, DeLord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Machiels J. Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. Cancer Research 2018, 78: ct163-ct163. DOI: 10.1158/1538-7445.am2018-ct163.
- Seiwert T, Haddad R, Bauml J, Weiss J, Pfister D, Gupta S, Mehra R, Gluck I, Kang H, Worden F, Eder J, Tahara M, Burtness B, Liu S, Webber A, Huang L, Mogg R, Cristescu R, Cheng J, Chow L. Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). Cancer Research 2018, 78: lb-339-lb-339. DOI: 10.1158/1538-7445.am2018-lb-339.
- Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal Of Cancer 2018, 119: 153-159. PMID: 29955135, PMCID: PMC6048158, DOI: 10.1038/s41416-018-0131-9.
- Kluwe C, Cmelak A, Burtness B. Oropharyngeal Cancer: HPV-Positive Disease. 2018 DOI: 10.1891/9780826137784.0013.
- Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncology 2018, 82: 122-130. PMID: 29909886, DOI: 10.1016/j.oraloncology.2018.02.010.
- Cohen E, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Ellison M, Cheng J, Chirovsky D, Swaby R, Harrington K. Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040. Journal Of Clinical Oncology 2018, 36: 6013-6013. DOI: 10.1200/jco.2018.36.15_suppl.6013.
- Machiels J, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, Delord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. Journal Of Clinical Oncology 2018, 36: tps6094-tps6094. DOI: 10.1200/jco.2018.36.15_suppl.tps6094.
- Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.
- Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 479-490. PMID: 29752322, DOI: 10.6004/jnccn.2018.0026.
- Bhatia AK, Burtness BA, Decker RH. Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2018, 36: jco.2018.77.798. PMID: 29547345, DOI: 10.1200/jco.2018.77.7987.
- Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncology 2018, 79: 64-70. PMID: 29598952, DOI: 10.1016/j.oraloncology.2018.02.017.
- Machiels J, Yen C, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 96TiP Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: xi28. DOI: 10.1093/annonc/mdx711.077.
- Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.
- Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.
- Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Response. Journal Of The National Cancer Institute 2017, 110: 433-434. PMID: 29121329, DOI: 10.1093/jnci/djx230.
- Yen C, Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 373TiP KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: x110. DOI: 10.1093/annonc/mdx665.036.
- Burtness B. The tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets? Cancer 2017, 124: 14-17. PMID: 29053184, DOI: 10.1002/cncr.31059.
- Kelly J, An Y, Park H, Yarbrough W, Burtness B, Husain Z. Evaluation of Pathology-Based Staging for HPV-Associated Squamous Cell Carcinoma of the Oropharynx in a Large National Sample. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e347. DOI: 10.1016/j.ijrobp.2017.06.1430.
- Kelly J, An Y, Park H, Yarbrough W, Burtness B, Husain Z. Survival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s43-s44. DOI: 10.1016/j.ijrobp.2017.06.114.
- Cohen E, Harrington K, Le Tourneau C, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Wang Y, Tuozzo A, Swaby R, Soulieres D. LBA45_PR Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Annals Of Oncology 2017, 28: v628. DOI: 10.1093/annonc/mdx440.040.
- Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Grégoire V, Shekar T, Brown H, Cheng J, Siu L. 1105TiP Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial. Annals Of Oncology 2017, 28: v392. DOI: 10.1093/annonc/mdx374.056.
- Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.
- Eze N, Lo YC, Burtness B. Biomarker driven treatment of head and neck squamous cell cancer. Cancers Of The Head & Neck 2017, 2: 6. PMID: 31093353, PMCID: PMC6460531, DOI: 10.1186/s41199-017-0025-1.
- Bhatia AK, Lee J, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez‐Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.
- Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer. American Journal Of Clinical Oncology 2017, 40: 393-398. PMID: 26986978, PMCID: PMC5026539, DOI: 10.1097/coc.0000000000000171.
- Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z. Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study. JAMA Oncology 2017, 3: 1107-1111. PMID: 28056116, PMCID: PMC5824218, DOI: 10.1001/jamaoncol.2016.5769.
- Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals Of Oncology 2017, 28: 2526-2532. PMID: 28961833, PMCID: PMC5834024, DOI: 10.1093/annonc/mdx344.
- Parameswaran J, Burtness B. Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 969-973. PMID: 28721906, DOI: 10.1016/j.ijrobp.2017.03.003.
- Mufson J, Handorf E, Weidhaas J, Lango M, Burtness B, Golemis E, Ridge J, Mehra R. Abstract 4732: Analysis of KRAS variant in a cohort of resected HPV negative HNSCC. Cancer Research 2017, 77: 4732-4732. DOI: 10.1158/1538-7445.am2017-4732.
- Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Ent Instructions for Authors. Ear, Nose & Throat Journal 2017, 96: 271-272. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.
- Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.
- Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 761-770. PMID: 28596256, DOI: 10.6004/jnccn.2017.0101.
- Lee N, Kelly J, Park H, Yarbrough W, Burtness B, Husain Z. (S040) The Risk of Level IB Nodal Involvement in Oropharynx Cancer: Guidance for Submandibular Gland Sparing Irradiation. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e12. DOI: 10.1016/j.ijrobp.2017.02.076.
- Bledsoe T, Park H, Stahl J, Yarbrough W, Burtness B, Decker R, Husain Z. (S027) Hypofractionated Radiotherapy Is associated With Improved Overall Survival Among Patients With Early-Stage Glottic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e8-e9. DOI: 10.1016/j.ijrobp.2017.02.063.
- Iqbal S, McDonough S, Lenz H, Ilson D, Burtness B, Nangia C, Barzi A, Schneider C, Liu J, Dotan E, Guthrie K, Hochster H. A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. Journal Of Clinical Oncology 2017, 35: 4009-4009. DOI: 10.1200/jco.2017.35.15_suppl.4009.
- Argiris A, Li S, Savvides P, Ohr J, Gilbert J, Levine M, Haigentz M, Saba N, Chakravarti A, Ikpeazu C, Schneider C, Pinto H, Forastiere A, Burtness B. Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. Journal Of Clinical Oncology 2017, 35: 6000-6000. DOI: 10.1200/jco.2017.35.15_suppl.6000.
- Burtness B, Haddad R, Dinis J, Trigo Perez J, Yokota T, Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia C, Chaves-Conde M, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen E. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal Of Clinical Oncology 2017, 35: 6001-6001. DOI: 10.1200/jco.2017.35.15_suppl.6001.
- Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I, Eder J, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Huang L, Ayers M, Mogg R, Cristescu R, Cheng J, Mehra R. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2017, 35: 6009-6009. DOI: 10.1200/jco.2017.35.15_suppl.6009.
- Wirth L, Burtness B, Mehra R, Bauman J, Lee J, Smith N, Lefranc-Torres A, Westra W, Bishop J, Faquin W, Lin D, Pai S. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. Journal Of Clinical Oncology 2017, 35: 6053-6053. DOI: 10.1200/jco.2017.35.15_suppl.6053.
- Cmelak A, Flamand Y, Li S, Marur S, Murphy B, Cella D, Forastiere A, Burtness B. Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies. Journal Of Clinical Oncology 2017, 35: 6074-6074. DOI: 10.1200/jco.2017.35.15_suppl.6074.
- Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Shekar T, Brown H, Cheng J, Siu L. KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Journal Of Clinical Oncology 2017, 35: tps6090-tps6090. DOI: 10.1200/jco.2017.35.15_suppl.tps6090.
- Tawfik B, Gerber D, Burtness B, Hughes R, Myers L, Sumer B, Truelson J, Strom T, Kurian P, Saleem S, Pearson J, Zhu H, Khan S. Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). Journal Of Clinical Oncology 2017, 35: tps6098-tps6098. DOI: 10.1200/jco.2017.35.15_suppl.tps6098.
- Parameswaran J, Lee J, Sandoval-Schaefer T, Koo J, Burtness B. Combination of WEE1 and AURKA inhibition in HPV negative head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2017, 35: e14105-e14105. DOI: 10.1200/jco.2017.35.15_suppl.e14105.
- Eze N, Chung C, Neumeister V, Sandoval-Schaefer T, Lee J, Burtness B. PTEN loss as a predictive biomarker in head and neck squamous cell cancer (HNSCC) patients treated with cetuximab (C). Journal Of Clinical Oncology 2017, 35: e17520-e17520. DOI: 10.1200/jco.2017.35.15_suppl.e17520.
- Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109: djx042. PMID: 28521361, DOI: 10.1093/jnci/djx042.
- Marur S, Cmelak AJ, Burtness B. Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials. Journal Of Clinical Oncology 2017, 35: jco.2017.72.291. PMID: 28430529, DOI: 10.1200/jco.2017.72.2918.
- Marur S, Li S, Cmelak A, Burtness B. Reply to A. Garden et al. Journal Of Clinical Oncology 2017, 35: jco.2017.72.827. PMID: 28430530, DOI: 10.1200/jco.2017.72.8279.
- An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma. Cancer 2017, 123: 2762-2772. PMID: 28323338, DOI: 10.1002/cncr.30598.
- Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.
- Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 358-365. PMID: 27737449, DOI: 10.1001/jamaoncol.2016.4581.
- Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. Practical Radiation Oncology 2017, 7: e317-e321. PMID: 28356201, DOI: 10.1016/j.prro.2017.02.004.
- Psyrri A, Rampias T, Burtness B. Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 125. PMID: 27607105, DOI: 10.1001/jamaoncol.2016.3409.
- Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2016, 35: 490-497. PMID: 28029303, PMCID: PMC5455313, DOI: 10.1200/jco.2016.68.3300.
- Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le Q, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2016, 123: 1259-1271. PMID: 27906454, PMCID: PMC5705038, DOI: 10.1002/cncr.30449.
- Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncology 2016, 62: 147-148. PMID: 27776933, DOI: 10.1016/j.oraloncology.2016.10.007.
- Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.
- Blanchard P, Landais C, Petit C, Zhang Q, Grégoire V, Tobias J, Burtness B, Ghi M, Janot F, Overgaard J, Wolf G, Lewin F, Hitt R, Corvo R, Budach V, Trotti A, Fortpied C, Hackshaw A, Bourhis J, Pignon J. 950O Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group. Annals Of Oncology 2016, 27: vi328. DOI: 10.1093/annonc/mdw376.02.
- Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Molecular Cancer Therapeutics 2016, 15: 2486-2497. PMID: 27507850, PMCID: PMC5522587, DOI: 10.1158/1535-7163.mct-16-0243.
- Kelly J, Park H, An Y, Decker R, Contessa J, Yarbrough W, Burtness B, Judson B, Husain Z. Comparison of Upfront Surgery Versus Chemoradiation for cT1-2 N1-2b Oropharynx Squamous Cell Carcinoma Based on Human Papillomavirus Status. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e327. DOI: 10.1016/j.ijrobp.2016.06.1451.
- Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal Of Clinical Oncology 2016, 34: 3838-3845. PMID: 27646946, PMCID: PMC6804896, DOI: 10.1200/jco.2016.68.1478.
- Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL. Proposing prognostic thresholds for lymph node yield in clinically lymph node‐negative and lymph node‐positive cancers of the oral cavity. Cancer 2016, 122: 3624-3631. PMID: 27479645, DOI: 10.1002/cncr.30227.
- Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal Of Clinical Oncology 2016, 34: 2736-2742. PMID: 27382098, PMCID: PMC5019745, DOI: 10.1200/jco.2015.65.5092.
- Subramanian HE, Park HS, Barbieri A, Mahajan A, Judson BL, Mehra S, Yarbrough WG, Burtness BA, Husain ZA. Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study. Cancers Of The Head & Neck 2016, 1: 7. PMID: 31093337, PMCID: PMC6460847, DOI: 10.1186/s41199-016-0008-7.
- Burtness B. Introducing cancers of the head and neck, a new open access journal. Cancers Of The Head & Neck 2016, 1: 3. PMID: 31093333, PMCID: PMC6457142, DOI: 10.1186/s41199-016-0001-1.
- L K, B B, A F, RF H, E H, MK G. Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer. Journal Of Cancer Science And Clinical Oncology 2016, 3 DOI: 10.15744/2394-6520.3.105.
- Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. The Lancet Oncology 2016, 17: 956-965. PMID: 27247226, DOI: 10.1016/s1470-2045(16)30066-3.
- Bhatia A, Lee J, Pinto H, Jacobs C, Limburg P, Arusell R, Dunphy E, Khandekar J, Reiner S, Baez-Diaz L, Celano P, Li S, Li Y, Burtness B, Pandya K. Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590). Journal Of Clinical Oncology 2016, 34: 1507-1507. DOI: 10.1200/jco.2016.34.15_suppl.1507.
- Chow L, Mehra R, Haddad R, Mahipal A, Weiss J, Berger R, Eder J, Burtness B, Tahara M, Keam B, Le D, Muro K, Geva R, Chung H, Lin C, Ayers M, Aurora-Garg D, Lunceford J, Cheng J, Seiwert T. Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal Of Clinical Oncology 2016, 34: 6010-6010. DOI: 10.1200/jco.2016.34.15_suppl.6010.
- Mehra R, Seiwert T, Mahipal A, Weiss J, Berger R, Eder J, Burtness B, Tahara M, Keam B, Le D, Muro K, Geva R, Chung H, Lin C, Meister A, Hille D, Cheng J, Chow L, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. Journal Of Clinical Oncology 2016, 34: 6012-6012. DOI: 10.1200/jco.2016.34.15_suppl.6012.
- Khan S, Ci B, Gerber D, McFadden D, Beg M, Xie Y, Kurian P, Cabanillas M, Busaidy N, Sherman S, Heilmann A, Ross J, Bailey M, Burtness B, Ali S. Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). Journal Of Clinical Oncology 2016, 34: 6014-6014. DOI: 10.1200/jco.2016.34.15_suppl.6014.
- Bhatia A, Mehra R, Khan S, Egleston B, Alpaugh R, Lango M, Ridge J, Burtness B. Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2016, 34: 6027-6027. DOI: 10.1200/jco.2016.34.15_suppl.6027.
- Li S, Ferris R, Holsinger F, Weinstein G, Quon H, Mehra R, Garcia J, Chung C, Gillison M, Wagner L, Ringash J, Lewin J, Mendez E, Ridge J, Richmon J, Magnuson S, Bell R, Smith R, Thomas G, Burtness B. E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process. Journal Of Clinical Oncology 2016, 34: 6054-6054. DOI: 10.1200/jco.2016.34.15_suppl.6054.
- Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology 2016, 17: 717-726. PMID: 27157491, DOI: 10.1016/s1470-2045(16)00175-3.
- Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL. Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. Cancer 2016, 122: 1853-1860. PMID: 27019213, DOI: 10.1002/cncr.29962.
- Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 340-345. PMID: 24685886, PMCID: PMC4177955, DOI: 10.1097/coc.0000000000000068.
- Cohen E, Licitra L, Burtness B, Fayette J, Gauler T, Clement P, Grau J, del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1). International Journal Of Radiation Oncology • Biology • Physics 2016, 94: 868-869. DOI: 10.1016/j.ijrobp.2015.12.032.
- Husain ZA, Burtness BA, Decker RH. Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2015, 34: 396-398. PMID: 26644528, DOI: 10.1200/jco.2015.64.7586.
- Yen C, Klochikhin A, Cohen E, Vermorken J, Harrington K, Tahara M, Ge J, Geib J, Jin F, Burtness B. 342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.29.
- Tahara M, Cohen E, Haddad R, Fayette J, Licitra L, Clement P, Vermorken J, Gauler T, Cupissol D, Grau J, Guigay J, del Campo J, Okami K, Takahashi S, Burtness B, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. 314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1). Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.01.
- Machiels J, Shin S, Cohen E, Harrington K, Burtness B, Gause C, Swift A, Swaby R, Le Tourneau C. 343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial. Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.30.
- Lee J, Parameswaran J, Koo J, Burtness B. Abstract C172: Concomitant disruption of WEE1 and AurKA synergistically enhances anti-cancer effects in p53 mutated head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 2015, 14: c172-c172. DOI: 10.1158/1535-7163.targ-15-c172.
- Cohen E, Moore K, Slomovitz B, Chung C, Anderson M, Morris S, Mauro D, Burtness B. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p147. PMCID: PMC4645484, DOI: 10.1186/2051-1426-3-s2-p147.
- Klochikhin A, Greil R, Cohen E, Vermorken J, Harrington K, Tahara M, Ge J, Geib J, Jin F, Burtness B. 11TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals Of Oncology 2015, 26: viii5. DOI: 10.1093/annonc/mdv514.01.
- Harrington K, Machiels J, Shin S, Cohen E, Burtness B, Gause C, Swift A, Swaby R, Le Tourneau C. 13TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial. Annals Of Oncology 2015, 26: viii5. DOI: 10.1093/annonc/mdv514.03.
- Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.
- Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.
- Chow L, Mehra R, Haddad R, Gupta S, Weiss J, Berger R, Burtness B, Tahara M, Keam B, Le D, Cheng J, Heath K, Pathiraja K, Seiwert T. 2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012. European Journal Of Cancer 2015, 51: s579. DOI: 10.1016/s0959-8049(16)31604-5.
- Burtness B. Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer. Journal Of Clinical Oncology 2015, 33: 3845-3846. PMID: 26282638, DOI: 10.1200/jco.2015.62.8487.
- Peri S, Slifker M, Mehra R, Burtness B, Ross E, Golemis E. Abstract LB-178: Genomic analysis identifies a subset of laryngeal tumors with poor prognosis. Cancer Research 2015, 75: lb-178-lb-178. DOI: 10.1158/1538-7445.am2015-lb-178.
- Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. Journal Of The National Comprehensive Cancer Network 2015, 13: 847-55; quiz 856. PMID: 26150579, PMCID: PMC4976490, DOI: 10.6004/jnccn.2015.0102.
- Seiwert T, Haddad R, Gupta S, Mehra R, Tahara M, Berger R, Lee S, Burtness B, Le D, Heath K, Blum A, Dolled-Filhart M, Emancipator K, Pathiraja K, Cheng J, Chow L. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal Of Clinical Oncology 2015, 33: lba6008-lba6008. DOI: 10.1200/jco.2015.33.18_suppl.lba6008.
- Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R. Phospho- T356 RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget 2015, 6: 18863-18874. PMID: 26265441, PMCID: PMC4662460, DOI: 10.18632/oncotarget.4321.
- Seiwert T, Burtness B, Weiss J, Eder J, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford J, Mehra R, Heath K, Cheng J, Chow L. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. Journal Of Clinical Oncology 2015, 33: 6017-6017. DOI: 10.1200/jco.2015.33.15_suppl.6017.
- Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Murphy B, Galloway T, Burtness B. Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). Journal Of Clinical Oncology 2015, 33: 6021-6021. DOI: 10.1200/jco.2015.33.15_suppl.6021.
- Argiris A, Li S, Savvides P, Forastiere A, Burtness B. Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal Of Clinical Oncology 2015, 33: 6022-6022. DOI: 10.1200/jco.2015.33.15_suppl.6022.
- Cohen E, Licitra L, Fayette J, Gauler T, Clement P, Grau J, Del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Dupuis N, Burtness B, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). Journal Of Clinical Oncology 2015, 33: 6023-6023. DOI: 10.1200/jco.2015.33.15_suppl.6023.
- Seiwert T, Haddad R, Gupta S, Mehra R, Tahara M, Berger R, Lee S, Burtness B, Le D, Heath K, Blum A, Dolled-Filhart M, Emancipator K, Pathiraja K, Cheng J, Chow L. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal Of Clinical Oncology 2015, 33: lba6008-lba6008. DOI: 10.1200/jco.2015.33.15_suppl.lba6008.
- Cohen E, Machiels J, Harrington K, Burtness B, Shin S, Gause C, Swift A, Brown H, Perrone A, Cheng J, Swaby R, Le Tourneau C. KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. Journal Of Clinical Oncology 2015, 33: tps6084-tps6084. DOI: 10.1200/jco.2015.33.15_suppl.tps6084.
- Khan S, Bauman J, Burtness B, Frankel A, Harper J, Hughes R, Kurian P, Myers L, Nedzi L, Schwartz D, Sumer B, Truelson J, Zhu H. Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities. Journal Of Clinical Oncology 2015, 33: tps6085-tps6085. DOI: 10.1200/jco.2015.33.15_suppl.tps6085.
- Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, W. A, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 1566-1573. PMID: 25573383, PMCID: PMC6607903, DOI: 10.1158/1078-0432.ccr-14-2820.
- Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.
- Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen E. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 2014, 15: 469. PMID: 25432788, PMCID: PMC4289298, DOI: 10.1186/1745-6215-15-469.
- Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer. The Annals Of Thoracic Surgery 2014, 99: 270-276. PMID: 25440267, PMCID: PMC4284823, DOI: 10.1016/j.athoracsur.2014.08.033.
- Burtness B. On mentorship: lessons from my father. Journal Of The National Comprehensive Cancer Network 2014, 12: 1651-2. PMID: 25361809, DOI: 10.6004/jnccn.2014.0162.
- Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2014, 12: 1454-87. PMID: 25313184, DOI: 10.6004/jnccn.2014.0142.
- Mehra R, Yang D, Handorf E, Serebriiskii I, Ross E, Lango M, Ridge J, Golemis E, Burtness B. Abstract 4743: Analysis of a protein expression biomarkers in HPV negative SCCHN. 2014, 4743-4743. DOI: 10.1158/1538-7445.am2014-4743.
- Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clinical Cancer Research 2014, 20: 5041-5051. PMID: 25107914, PMCID: PMC4184913, DOI: 10.1158/1078-0432.ccr-14-0051.
- Scher E, Handorf E, Ridge J, Mehra R, Lango M, Burtness B, Liu J, Galloway T. Evaluation of Primary Treatment Technique for Squamous Cell Carcinoma of the Buccal Mucosa: A Single-Center Experience. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s507. DOI: 10.1016/j.ijrobp.2014.05.1558.
- Chow L, Burtness B, Weiss J, Berger R, Eder J, Gonzalez E, Pulini J, Johnson J, Dolled-Filhart M, Emancipator K, Lunceford J, Pathiraja K, Gause C, Cheng J, Seiwert T. LBA31 A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc). Annals Of Oncology 2014, 25: v1. DOI: 10.1093/annonc/mdu438.32.
- Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Human Genetics 2014, 134: 497-507. PMID: 25108461, PMCID: PMC4324386, DOI: 10.1007/s00439-014-1470-0.
- Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals Of Oncology 2014, 25: 2230-2236. PMID: 25081901, PMCID: PMC4207729, DOI: 10.1093/annonc/mdu367.
- Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer 2014, 120: 3353-3360. PMID: 25042524, DOI: 10.1002/cncr.28870.
- Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Annals Of Oncology 2014, 25: 2036-2041. PMID: 25009013, PMCID: PMC4176450, DOI: 10.1093/annonc/mdu248.
- Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.18_suppl.lba6006.
- Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clinical Cancer Research 2014, 20: 3023-3032. PMID: 24700741, PMCID: PMC4049169, DOI: 10.1158/1078-0432.ccr-14-0113.
- Cohen S, Feng Y, Catalano P, Mitchell E, O'Dwyer P, Lubner S, Fisher G, Mulcahy M, Burtness B, Benson A. E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. Journal Of Clinical Oncology 2014, 32: 4020-4020. DOI: 10.1200/jco.2014.32.15_suppl.4020.
- Seiwert T, Burtness B, Weiss J, Gluck I, Eder J, Pai S, Dolled-Filhart M, Emancipator K, Pathiraja K, Gause C, Iannone R, Brown H, Houp J, Cheng J, Chow L. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. Journal Of Clinical Oncology 2014, 32: 6011-6011. DOI: 10.1200/jco.2014.32.15_suppl.6011.
- Masica D, Li S, Douville C, Manola J, Ferris R, Burtness B, Forastiere A, Koch W, Karchin R, Chung C. Evaluation of computational tools to determine prognostic significance of TP53 mutation in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2014, 32: 6035-6035. DOI: 10.1200/jco.2014.32.15_suppl.6035.
- Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.15_suppl.lba6006.
- Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Annals Of Oncology 2014, 25: 1410-1416. PMID: 24799460, PMCID: PMC4071756, DOI: 10.1093/annonc/mdu167.
- Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.
- Burtness B, Ilson D, Iqbal S. New directions in perioperative management of locally advanced esophagogastric cancer. American Society Of Clinical Oncology Educational Book 2014, e172-8. PMID: 24857100, DOI: 10.14694/edbook_am.2014.34.e172.
- Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.
- Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC). PLOS ONE 2014, 9: e94273. PMID: 24722213, PMCID: PMC3983114, DOI: 10.1371/journal.pone.0094273.
- Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2014, 1-5. DOI: 10.1007/978-1-4614-8815-6_1.
- Burtness B. Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. Current Cancer Research 2014, 343-359. DOI: 10.1007/978-1-4614-8815-6_17.
- Galloway T, Davis K, Burtness B, Ferris R, Mehra R, Ridge J, Flieder D, Duvvuri U. HPV Association and the Increasing Incidence of Unknown Primary Head-and-Neck Squamous Cell Carcinoma Epidemiology and Prevention. International Journal Of Radiation Oncology • Biology • Physics 2014, 88: 494. DOI: 10.1016/j.ijrobp.2013.11.102.
- Thomay A, Su S, Friedant A, Ruth K, Astsaturov I, Burtness B, Denlinger C, Dotan E, Hall M, Meyer J, Shah P, Cohen S, Scott W. Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. Journal Of Clinical Oncology 2014, 32: 126-126. DOI: 10.1200/jco.2014.32.3_suppl.126.
- Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & Neck 2014, 36: 1677-1684. PMID: 24115269, PMCID: PMC3972378, DOI: 10.1002/hed.23514.
- Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer 2013, 120: 840-847. PMID: 24352973, PMCID: PMC3951722, DOI: 10.1002/cncr.28482.
- Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research 2013, 19: 6633-6643. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.ccr-13-0152.
- Jimeno A, Galloway T, Wirth L, Gilbert J, Saba N, Bauman J, Colevas D, Mehra R, Raben D, Lai C, Laliberte R, Voi M, Burtness B. Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. Molecular Cancer Therapeutics 2013, 12: b268-b268. DOI: 10.1158/1535-7163.targ-13-b268.
- Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein–Szanto A. Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. Head & Neck 2013, 36: 1113-1119. PMID: 23804308, PMCID: PMC4099415, DOI: 10.1002/hed.23421.
- Lemons J, Ruth K, Ridge J, Burtness B, Lango M, Mehra R, Liu J, Galloway T. Can It Stay or Should It Go? A Comparison of T4 Laryngeal Cancer Management. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s452. DOI: 10.1016/j.ijrobp.2013.06.1193.
- Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-1087. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.
- Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer. Journal Of Gastrointestinal Surgery 2013, 18: 69-74. PMID: 24002765, DOI: 10.1007/s11605-013-2329-8.
- Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid 2013, 23: 1099-1105. PMID: 23421588, PMCID: PMC3770240, DOI: 10.1089/thy.2013.0027.
- Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA. Aurora kinases in head and neck cancer. The Lancet Oncology 2013, 14: e425-e435. PMID: 23993387, PMCID: PMC4139969, DOI: 10.1016/s1470-2045(13)70128-1.
- Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. Journal Of The National Comprehensive Cancer Network 2013, 11: 917-23. PMID: 23946171, DOI: 10.6004/jnccn.2013.0113.
- Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.
- Boland PM, Burtness B. Esophageal carcinoma. Current Opinion In Oncology 2013, 25: 417-424. PMID: 23680713, DOI: 10.1097/cco.0b013e328362105e.
- Marur S, Li S, Cmelak A, Gillison M, Ferris R, Bauman J, Zhao W, Westra W, Chung C, Wagner L, Trevarthen D, Jahagirdar B, Colevas A, Burtness B. E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). Journal Of Clinical Oncology 2013, 31: 6005-6005. DOI: 10.1200/jco.2013.31.15_suppl.6005.
- Mehra R, Egloff A, Li S, Yang D, Wang L, Zhu F, Forastiere A, Burtness B, Argiris A. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal Of Clinical Oncology 2013, 31: 6006-6006. DOI: 10.1200/jco.2013.31.15_suppl.6006.
- Weidhaas J, Lee J, Slebos R, Howard J, Perez J, Gilbert J, Nallur S, Paranjape T, Garcia J, Burtness B, Forastiere A, Chung C. Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6016-6016. DOI: 10.1200/jco.2013.31.15_suppl.6016.
- Burtness B, Lee J, Yang D, Zhu F, Garcia J, Forastiere A, Chung C. Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. Journal Of Clinical Oncology 2013, 31: 6028-6028. DOI: 10.1200/jco.2013.31.15_suppl.6028.
- Psyrri A, Lee J, Vasilakopoulou M, Pectasides E, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303. Journal Of Clinical Oncology 2013, 31: 6081-6081. DOI: 10.1200/jco.2013.31.15_suppl.6081.
- Cohen E, Hong D, Pfister D, Salgia R, Burtness B, Cohen R, Ball D, Mehra R, Mangeshkar M, Yaron Y, Bentzien F, Kurzrock R. Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. Journal Of Clinical Oncology 2013, 31: 6090-6090. DOI: 10.1200/jco.2013.31.15_suppl.6090.
- Chun Y, Cohen S, Donohue J, Burtness B, Hall M, Nagorney D. 445 Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer. Gastroenterology 2013, 144: s-1048. DOI: 10.1016/s0016-5085(13)63901-3.
- Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal Of Clinical Oncology 2013, 31: 1405-1414. PMID: 23460714, PMCID: PMC3612594, DOI: 10.1200/jco.2012.45.4272.
- Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Annals Of Oncology 2013, 24: 2124-2131. PMID: 23406730, DOI: 10.1093/annonc/mdt013.
- Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation. Cancer Discovery 2013, 3: 96-111. PMID: 23125191, PMCID: PMC3546138, DOI: 10.1158/2159-8290.cd-12-0031.
- Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”. Science Signaling 2012, 5: lc5. PMID: 23233526, DOI: 10.1126/scisignal.2003734.
- Sopka D, Li T, Lango M, Mehra R, Burtness B, Flieder D, Ridge J, Galloway T. Dysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s205. DOI: 10.1016/j.ijrobp.2012.07.531.
- Keller L, Galloway T, Holdbrook T, Flieder D, Ruth K, Lango M, Mehra R, Burtness B, Ridge J. p16 Status, Pathologic and Clinical Characteristics, and Long-term Outcomes in Unknown Primary Carcinomas of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s514. DOI: 10.1016/j.ijrobp.2012.07.1370.
- Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinomaHusain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. The Laryngoscope 2012, 122: 2762-2768. PMID: 23086695, PMCID: PMC3574977, DOI: 10.1002/lary.23647.
- Burtness B. 59IN Strategies to Optimize EGFR Therapies. Annals Of Oncology 2012, 23: ix42. DOI: 10.1016/s0923-7534(20)32673-9.
- Mehra R, Ang KK, Burtness B. Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer. Seminars In Radiation Oncology 2012, 22: 194-197. PMID: 22687943, DOI: 10.1016/j.semradonc.2012.03.003.
- Marur S, Lee J, Cmelak A, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal Of Clinical Oncology 2012, 30: 5566-5566. DOI: 10.1200/jco.2012.30.15_suppl.5566.
- Psyrri A, Lee J, Pectasides E, Vassilakopoulou M, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2012, 30: 5576-5576. DOI: 10.1200/jco.2012.30.15_suppl.5576.
- Burtness B, Bourhis J, Vermorken J, Dai L, Lind C, Ehrnrooth E, Cohen E. LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. Journal Of Clinical Oncology 2012, 30: tps5599-tps5599. DOI: 10.1200/jco.2012.30.15_suppl.tps5599.
- Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.
- Khan S, Yang D, Zhu F, Dubyk C, Tejani M, Cohen S, Hoffman J, Burtness B. Abstract 714: Survivin expression in patients with resected pancreatic adenocarcinoma. Cancer Research 2012, 72: 714-714. DOI: 10.1158/1538-7445.am2012-714.
- Fidler C, Yang D, Zhu F, Mehra R, Astsaturov I, Ridge J, Golemis E, Burtness B. Abstract 721: Expression of Aurora A and Phospho-Aurora-A is predictive of survival in patients with head and neck cancer. Cancer Research 2012, 72: 721-721. DOI: 10.1158/1538-7445.am2012-721.
- Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. Mucosal melanoma of the head and neck. Journal Of The National Comprehensive Cancer Network 2012, 10: 320-38. PMID: 22393194, DOI: 10.6004/jnccn.2012.0033.
- Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational needs of head and neck cancer patients. Health And Technology 2012, 2: 57-62. PMID: 22518350, PMCID: PMC3327509, DOI: 10.1007/s12553-012-0020-9.
- Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head & Neck 2012, 35: 160-164. PMID: 22302641, PMCID: PMC4037756, DOI: 10.1002/hed.22929.
- Astsaturov I, Meyer J, Cheng J, Olszanski A, Dushkin H, Berger A, Davey M, Cohen S, Burtness B, Scott W. A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction. Journal Of Clinical Oncology 2012, 30: 74-74. DOI: 10.1200/jco.2012.30.4_suppl.74.
- Shaikh T, Ruth K, Scott W, Burtness B, Cohen S, Konski A, Cooper H, Astsaturov I, Meyer J. Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer. Journal Of Clinical Oncology 2012, 30: 84-84. DOI: 10.1200/jco.2012.30.4_suppl.84.
- Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study. Journal Of Gastrointestinal Cancer 2012, 43: 562-569. PMID: 22294255, PMCID: PMC3400721, DOI: 10.1007/s12029-012-9368-3.
- Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY. Psychological functioning of caregivers for head and neck cancer patients. Oral Oncology 2011, 48: 18-25. PMID: 22154127, PMCID: PMC3357183, DOI: 10.1016/j.oraloncology.2011.11.012.
- Sopka D, Chun Y, Cohen S, Zhu F, Milestone B, Cooper H, Freedman G, Burtness B, Hoffman J, Meyer J. Maximizing the Effect of Neoadjuvant Chemoradiation in Patients with Borderline Resectable Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s335. DOI: 10.1016/j.ijrobp.2011.06.1804.
- Galloway T, Turaka A, Ruth K, Mehra R, Lango M, Burtness B, Ridge J, Horwitz E. Low Rates of Gastrostomy Tube Dependence in Patients with T1-T2 Oropharynx Cancer Treated without Pharyngeal Constrictor Sparing. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s504. DOI: 10.1016/j.ijrobp.2011.06.1029.
- Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3601-3607. PMID: 21947697, DOI: 10.1245/s10434-011-2086-4.
- Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 2011, 14: 260-279. PMID: 21920801, PMCID: PMC3195944, DOI: 10.1016/j.drup.2011.08.002.
- Burtness B. Commentary. The Cancer Journal 2011, 17: 273-275. PMID: 21952274, DOI: 10.1097/ppo.0b013e3182326944.
- Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network 2011, 9: 596-650. PMID: 21636536, DOI: 10.6004/jnccn.2011.0053.
- Tejani M, Cai K, Zhu F, Dubyk C, Chun Y, Cohen S, Hoffman J, Burtness B. ERCC1 and RRM1 expression in resected pancreatic adenocarcinoma. Journal Of Clinical Oncology 2011, 29: e14606-e14606. DOI: 10.1200/jco.2011.29.15_suppl.e14606.
- Psyrri A, Ghebremichael M, Pectasides E, Dimou A, Burtness B, Rimm D, Wanebo H, Forastiere A. p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2011, 29: e16032-e16032. DOI: 10.1200/jco.2011.29.15_suppl.e16032.
- Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2011, 17: 2947-2954. PMID: 21355076, DOI: 10.1158/1078-0432.ccr-10-2040.
- Husain H, Psyrri A, Slebos R, Ross D, Burtness B, Chung C. Abstract 2254: Nuclear and cytoplasmic epidermal growth factor receptor and p16 expression as prognostic biomarkers in head and neck squamous cell carcinoma. Cancer Research 2011, 71: 2254-2254. DOI: 10.1158/1538-7445.am2011-2254.
- Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal Of Clinical Oncology 2011, 34: 70-75. PMID: 20458210, PMCID: PMC3030655, DOI: 10.1097/coc.0b013e3181d2734a.
- Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. Cancer 2011, 117: 3374-3382. PMID: 21246525, PMCID: PMC3135694, DOI: 10.1002/cncr.25852.
- Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal Of Clinical Oncology 2010, 33: 599-603. PMID: 21063195, DOI: 10.1097/coc.0b013e3181c4c3cc.
- Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. Head & Neck 2010, 33: 1433-1440. PMID: 21928415, DOI: 10.1002/hed.21615.
- Shanbhag S, Burtness B. Antibody-Based Therapies for Solid Tumors. Cancer Growth And Progression 2010, 245-256. DOI: 10.1007/978-90-481-9704-0_13.
- Richard C, Turaka A, Li T, Nicolaou N, Horwitz E, Lango M, Burtness B, Ridge J, Feigenberg S. Intensity Modulated Radiation Therapy (IMRT) for the Para-nasal Sinus (PNS) Malignancies. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s478-s479. DOI: 10.1016/j.ijrobp.2010.07.1122.
- Psyrri A, Burtness B. Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 2010, 7: 621-622. PMID: 20981127, DOI: 10.1038/nrclinonc.2010.156.
- Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals Of Surgical Oncology 2010, 17: 2832-2838. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.
- Turaka A, Weinberg B, Li T, Nicos N, Burtness B, Lango M, Ridge J, Feigenberg S. SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia. Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468568.
- Turaka A, Cattaneo R, Nicos N, Lango M, Burtness B, Ridge J, Feigenberg S. SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC). Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468570.
- Enzinger P, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson A, Mayer R, Goldberg R. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. Journal Of Clinical Oncology 2010, 28: 4006-4006. DOI: 10.1200/jco.2010.28.15_suppl.4006.
- Wanebo H, Ghebremichael M, Burtness B, Ridge J, Spencer S, Rosen F, Hancock M, Tolba K, Forastiere A. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal Of Clinical Oncology 2010, 28: 5513-5513. DOI: 10.1200/jco.2010.28.15_suppl.5513.
- Egloff A, Lee J, Vaezi A, Langer C, Forastiere A, Quon H, Burtness B, Grandis J. Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). Journal Of Clinical Oncology 2010, 28: 5537-5537. DOI: 10.1200/jco.2010.28.15_suppl.5537.
- Pectasides E, Fountzilas G, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Rimm D, Burtness B, Psyrri D. Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. Journal Of Clinical Oncology 2010, 28: 5538-5538. DOI: 10.1200/jco.2010.28.15_suppl.5538.
- Mehra R, Cai K, Zhu F, Weaver J, Nicolaou N, Cohen R, Lango M, Ridge J, Godwin A, Burtness B. Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. Journal Of Clinical Oncology 2010, 28: 5539-5539. DOI: 10.1200/jco.2010.28.15_suppl.5539.
- Fountzilas G, Pectasides E, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Pectasides D, Rimm D, Burtness B, Psyrri D. The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. Journal Of Clinical Oncology 2010, 28: 5550-5550. DOI: 10.1200/jco.2010.28.15_suppl.5550.
- Mehra R, Cai K, Zhu F, Weaver J, Nicolaou N, Lango M, Ridge J, Godwin A, Burtness B. Abstract 2804: ERCC1 (excision repair cross complementing group 1) is a predictive biomarker of survival in squamous cell carcinoma of the head and neck (SCCHN). Cancer Research 2010, 70: 2804-2804. DOI: 10.1158/1538-7445.am10-2804.
- Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research 2010, 16: 2427-2434. PMID: 20371693, PMCID: PMC3030188, DOI: 10.1158/1078-0432.ccr-09-2658.
- Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.
- Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: 1020-1025. PMID: 20231078, DOI: 10.1016/j.ijrobp.2009.09.003.
- Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 358-365. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.epi-09-0937.
- Turaka A, Li T, Nicolaou N, Lango M, Burtness B, Horwitz E, Ridge J, Feigenberg S. The use of a Low Neck Field (LNF) and Intensity-Modulated Radiation Therapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF during the Treatment of Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s427-s428. DOI: 10.1016/j.ijrobp.2009.07.978.
- Rusthoven K, Feigenberg S, Raben D, Kane M, Song J, Nicolaou N, Mehra R, Burtness B, Swing R, Chen C. Initial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-irradiation for Recurrent and New Primary Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s408. DOI: 10.1016/j.ijrobp.2009.07.935.
- Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets And Therapy 2009, Volume 3: 419-428. PMID: 19774209, PMCID: PMC2747340, DOI: 10.2147/btt.s3170.
- Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). Journal Of Clinical Oncology 2009, 27: 6011-6011. DOI: 10.1200/jco.2009.27.15_suppl.6011.
- Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A. Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. Journal Of Clinical Oncology 2009, 27: 6020-6020. DOI: 10.1200/jco.2009.27.15_suppl.6020.
- Psyrri D, Pectasides E, Weinberger P, Sasaki C, Burtness B, Fountzilas G. Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. Journal Of Clinical Oncology 2009, 27: 6031-6031. DOI: 10.1200/jco.2009.27.15_suppl.6031.
- Mehra R, Sherman E, Ruth K, Litwin S, Sylvester J, Tuttle H, Burtness B, Cohen R, Langer C. Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN). Journal Of Clinical Oncology 2009, 27: 6052-6052. DOI: 10.1200/jco.2009.27.15_suppl.6052.
- Pectasides E, Founztilas G, Sasaki C, Burtness B, Psyrri A. Assessment of phosphatidylinositol-3 kinase (PI3K) as a prognostic marker in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2009, 27: e17028-e17028. DOI: 10.1200/jco.2009.27.15_suppl.e17028.
- Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Annals Of Oncology 2009, 20: 1242-1248. PMID: 19429872, PMCID: PMC2699385, DOI: 10.1093/annonc/mdn787.
- Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal Of The National Comprehensive Cancer Network 2009, 7 Suppl 1: s5-21; quiz s22-4. PMID: 19470276, DOI: 10.6004/jnccn.2009.0074.
- Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling 2009, 21: 1255-1268. PMID: 19258037, PMCID: PMC2770888, DOI: 10.1016/j.cellsig.2009.02.021.
- Psyrri A, Burtness B, Harari PM, Vermorken JB, Licitra L, Sasaki CT. Head and Neck Cancer. Journal Of Oncology 2009, 2009: 358098. PMID: 20169126, PMCID: PMC2821645, DOI: 10.1155/2009/358098.
- Burtness B, Weiner L, Astsaturov I, Golemis E. 246 INVITED Targeting Her: Can resistance to EGFR inhibitors be overcome? European Journal Of Cancer Supplements 2008, 6: 80. DOI: 10.1016/s1359-6349(08)72178-5.
- Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clinical Advances In Hematology And Oncology 2008, 6: 742-50. PMID: 18997665, PMCID: PMC2745918.
- Psyrri A, Burtness B. Viruses in head and neck cancers: prevention and therapy. Expert Review Of Anticancer Therapy 2008, 8: 1365-1371. PMID: 18759688, DOI: 10.1586/14737140.8.9.1365.
- Forastiere A, Ang K, Brizel D, Brockstein B, Burtness B, Cmelak A, Colevas A, Dunphy F, Eisele D, Goepfert H, Hicks W, Kies M, Lydiatt W, Maghami E, Martins R, McCaffrey T, Mittal B, Pfister D, Pinto H, Posner M, Ridge J, Samant S, Schuller D, Shah J, Spencer S, Trotti A, Weber R, Wolf G, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network 2008, 6: 646-95. PMID: 18691457, DOI: 10.6004/jnccn.2008.0051.
- Psyrri A, Prezas L, Burtness B. Oropharyngeal cancer. Clinical Advances In Hematology And Oncology 2008, 6: 604-12. PMID: 18820604.
- Psyrri A, Egleston B, Pectasides E, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B. Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue Microarray. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 1486-1492. PMID: 18559565, DOI: 10.1158/1055-9965.epi-07-2684.
- Burtness B, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson A. Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19–9 results. Journal Of Clinical Oncology 2008, 26: 4642-4642. DOI: 10.1200/jco.2008.26.15_suppl.4642.
- Psyrri A, Sasaki C, Burtness B, Rampias T. Regulation of cytoplasmic and nuclear PTEN levels by human papillomavirus (HPV) type 16 E6 and E7 oncogenes in HPV16+ oropharyngeal cancer cell line. Journal Of Clinical Oncology 2008, 26: 6034-6034. DOI: 10.1200/jco.2008.26.15_suppl.6034.
- Molecular prognostic markers in squamous cell carcinoma of the head and neck: the role of E-cadherinKountourakis P, Pectasides E, Burtness B, Pectasides D, Psyrri A, Fountzilas G. Molecular prognostic markers in squamous cell carcinoma of the head and neck: the role of E-cadherin. Journal Of Clinical Oncology 2008, 26: 6040-6040. DOI: 10.1200/jco.2008.26.15_suppl.6040.
- Murphy B, Dietrich M, Cmelak A, Burtness B, Forastiere A. E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC). Journal Of Clinical Oncology 2008, 26: 6022-6022. DOI: 10.1200/jco.2008.26.15_suppl.6022.
- Pectasides E, Kountourakis P, Fountzilas G, Burtness B, Psyrri A. Evaluation of the prognostic significance of activated STAT3 expression levels in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2008, 26: 6015-6015. DOI: 10.1200/jco.2008.26.15_suppl.6015.
- Rampias T, Sasaki C, Burtness B, Psyrri A. Gene expression differences associated with silencing of E6 and E7 viral oncogenes in HPV16 + oropharyngeal cancer cell lines. Journal Of Clinical Oncology 2008, 26: 6009-6009. DOI: 10.1200/jco.2008.26.15_suppl.6009.
- Burtness BA. Advanced gastric cancer: new treatments raise new questions. Gastrointestinal Cancer Research : GCR 2008, 2: 158-9. PMID: 19259295, PMCID: PMC2633076.
- Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals Of Oncology 2008, 19: 977-983. PMID: 18296423, DOI: 10.1093/annonc/mdm591.
- Burtness B. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. Oncology 2007, 21: 964-70; discussion 970, 974, 976-7. PMID: 17715697.
- Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal 2007, 13: 257-262. PMID: 17762761, DOI: 10.1097/ppo.0b013e31813c1174.
- Burtness B, Powell M, Berlin J, Liles D, Chapman A, Mitchell E, Benson A. Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology. Journal Of Clinical Oncology 2007, 25: 4519-4519. DOI: 10.1200/jco.2007.25.18_suppl.4519.
- Wanebo H, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A, Ghebremichael M. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). Journal Of Clinical Oncology 2007, 25: 6015-6015. DOI: 10.1200/jco.2007.25.18_suppl.6015.
- Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.
- Psyrri A, Weinberger P, Yu Z, Sasaki C, Haffty B, Kowalski D, Burtness B. Correlates and determinants of nuclear epidermal growth factor receptor (EGFR) content in an oropharyngeal cancer tissue microarray. Journal Of Clinical Oncology 2007, 25: 6022-6022. DOI: 10.1200/jco.2007.25.18_suppl.6022.
- Weinberger P, Psyrri A, Kountourakis P, Rampias T, Sasaki C, Sasaki C, Haffty B, Kowalski D, Fountzilas G, Rimm D, Burtness B. Gene copy number of epidermal growth factor receptor (EGFR) by fluorescent in situ hybridization (FISH) in head and neck squamous cell carcinomas (HNSCC) is closely correlated with EGFR protein levels assessed by automated quantitative protein analysis (AQUA). Journal Of Clinical Oncology 2007, 25: 6023-6023. DOI: 10.1200/jco.2007.25.18_suppl.6023.
- Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal Population or Pathologist Artifact? Journal Of Clinical Oncology 2007, 25: 2487-2488. PMID: 17557963, DOI: 10.1200/jco.2006.07.7537.
- Burtness B. Her signaling in pancreatic cancer. Expert Opinion On Biological Therapy 2007, 7: 823-829. PMID: 17555368, DOI: 10.1517/14712598.7.6.823.
- Forastiere AA, Burtness BA. Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer—More Insights, but More Questions. Journal Of Clinical Oncology 2007, 25: 2152-2155. PMID: 17538157, DOI: 10.1200/jco.2007.10.9017.
- Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell CancerYu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 553-558. PMID: 17372251, DOI: 10.1158/1055-9965.epi-06-0121.
- Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.
- Burtness B, Manola J, Argiris A, Altieri D, Axelrod R, Forastiere A. 632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301. European Journal Of Cancer Supplements 2006, 4: 190-191. DOI: 10.1016/s1359-6349(06)70637-1.
- Landry J, Catalano P, Hoffman J, Staley C, Harris W, Burtness B, Frontiera M, Berlin J, Benson A. 2111 ECOG 1200: A Randomized Phase II Trial of Gemcitabine Plus Radiotherapy vs Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil in Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s272. DOI: 10.1016/j.ijrobp.2006.07.515.
- Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.
- Cohen SJ, Burtness BA. Novel targets in pancreatic cancer: focus on future paths to therapy. Expert Opinion On Therapeutic Targets 2006, 10: 771-775. PMID: 16981833, DOI: 10.1517/14728222.10.5.771.
- Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion On Biological Therapy 2006, 6: 951-962. PMID: 16918262, DOI: 10.1517/14712598.6.9.951.
- Arciero C, Salem R, Lacy J, Sigurdson E, Hoffman J, Watson J, Joseph N, Cooper H, Meropol N, Burtness B. Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases. Journal Of Clinical Oncology 2006, 24: 13523-13523. DOI: 10.1200/jco.2006.24.18_suppl.13523.
- Burtness B, Goldwasser M, Axelrod R, Argiris A, Forastiere A. A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. Journal Of Clinical Oncology 2006, 24: 5532-5532. DOI: 10.1200/jco.2006.24.18_suppl.5532.
- Argiris A, Goldwasser M, Burtness B, Deconti R, Axelrod R, Van Waes C, Forastiere A. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. Journal Of Clinical Oncology 2006, 24: 5573-5573. DOI: 10.1200/jco.2006.24.18_suppl.5573.
- Abu-Khalaf M, Kim R, Cohenuram M, Chung G, Digiovanna M, Haffty B, Carter D, Horvath L, Tavassoli F, Burtness B. Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC). Journal Of Clinical Oncology 2006, 24: 10721-10721. DOI: 10.1200/jco.2006.24.18_suppl.10721.
- Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer. The Cancer Journal 2006, 12: 212-221. PMID: 16803680, DOI: 10.1097/00130404-200605000-00010.
- Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106: 1677-1684. PMID: 16532435, DOI: 10.1002/cncr.21783.
- Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 2006, 24: 135-140. PMID: 16502351, DOI: 10.1007/s10637-006-5934-5.
- Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer. Oncology 2005, 69: 372-383. PMID: 16319508, DOI: 10.1159/000089991.
- Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. Journal Of Clinical Oncology 2005, 23: 8646-8654. PMID: 16314626, DOI: 10.1200/jco.2005.02.4646.
- Moss JE, Burtness B. Cetuximab-Associated Acneiform Eruption. New England Journal Of Medicine 2005, 353: e17. PMID: 16282170, DOI: 10.1056/nejmicm050560.
- Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin Induces a Delayed Immune-Mediated Hemolytic Anemia: A Case Report and Review of the Literature. Clinical Colorectal Cancer 2005, 5: 283-286. PMID: 16356307, DOI: 10.3816/ccc.2005.n.041.
- Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation. International Journal Of Surgical Pathology 2005, 13: 319-327. PMID: 16273187, DOI: 10.1177/106689690501300403.
- Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 2005, 11: 5856-5862. PMID: 16115926, DOI: 10.1158/1078-0432.ccr-05-0420.
- Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opinion On Biological Therapy 2005, 5: 1085-1093. PMID: 16050785, DOI: 10.1517/14712598.5.8.1085.
- Burtness B. Cetuximab and Cisplatin for Chemotherapy-Refractory Squamous Cell Cancer of the Head and Neck. Journal Of Clinical Oncology 2005, 23: 5440-5442. PMID: 16009959, DOI: 10.1200/jco.2005.02.002.
- Burtness B, Gibson M, Lacy J, Rowen E, Thomas L, Sipples R, McGurk M, Murren J, Forastiere A. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal Of Clinical Oncology 2005, 23: 4070-4070. DOI: 10.1200/jco.2005.23.16_suppl.4070.
- Psyrri A, Yu Z, Haffty B, Sasaki C, Weinberger P, Camp R, Rimm D, Burtness B. Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC). Journal Of Clinical Oncology 2005, 23: 5518-5518. DOI: 10.1200/jco.2005.23.16_suppl.5518.
- Yu Z, Weinberger P, Sasaki C, Haffty B, Camp R, Rimm D, Burtness B, Psyrri A. Molecular prognostic markers in oropharyngeal squamous cell carcinoma: The role of phospho-Akt. Journal Of Clinical Oncology 2005, 23: 5517-5517. DOI: 10.1200/jco.2005.23.16_suppl.5517.
- Psyrri A, Burtness B. Pregnancy-Associated Breast Cancer. The Cancer Journal 2005, 11: 83-95. PMID: 15969981, DOI: 10.1097/00130404-200503000-00001.
- Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Of Today 2005, 41: 107-27. PMID: 15821783, DOI: 10.1358/dot.2005.41.2.882662.
- Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates. Journal Of Clinical Oncology 2004, 23: 17-23. PMID: 15545666, DOI: 10.1200/jco.2005.09.048.
- Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL. Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up. Journal Of Clinical Oncology 2004, 22: 3061-3069. PMID: 15284256, DOI: 10.1200/jco.2004.01.108.
- Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere A. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal Of Clinical Oncology 2004, 22: 4032-4032. DOI: 10.1200/jco.2004.22.14_suppl.4032.
- Burtness B, Sipples R, Mirto G, Thomas L, Rahman Z, Kloss R, Murren J, Lacy J. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer. Journal Of Clinical Oncology 2004, 22: 4116-4116. DOI: 10.1200/jco.2004.22.14_suppl.4116.
- Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere A. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal Of Clinical Oncology 2004, 22: 4032-4032. DOI: 10.1200/jco.2004.22.90140.4032.
- Burtness B, Sipples R, Mirto G, Thomas L, Rahman Z, Kloss R, Murren J, Lacy J. Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer. Journal Of Clinical Oncology 2004, 22: 4116-4116. DOI: 10.1200/jco.2004.22.90140.4116.
- Alvero AB, Burtness BA, Ercan AG, Sapi E. Improved method for the detection of cytokeratin 19-positive cells in the peripheral blood of breast cancer patients. Laboratory Investigation 2004, 84: 658-661. PMID: 15105816, DOI: 10.1038/labinvest.3700086.
- Angelopoulou MK, Rinder H, Wang C, Burtness B, Cooper DL, Krause DS. A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftment. Transfusion 2004, 44: 555-566. PMID: 15043572, DOI: 10.1111/j.1537-2995.2004.03285.x.
- Burtness B. Chapter 23 Neoplastic Diseases. 2004, 479-504. DOI: 10.1016/b978-0-7216-0435-0.50027-4.
- Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clinical Cancer Research 2003, 9: 6461-8. PMID: 14695149.
- Bou‐Khalil J, Rose M, Psyrri A, D’Andrea E, Medoff E, Staugaard‐Hahn C, Holtkamp C, Gran S, Pezzimente J, Snyder E, Cooper D, Haffty B, Reiss M, Burtness B. Sequential High‐Dose Alkylating Therapy and Stem Cell Support for High‐Risk Stage III Breast Cancer. The Breast Journal 2003, 9: 472-477. PMID: 14616941, DOI: 10.1046/j.1524-4741.2003.09604.x.
- Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 2003, 56: 328-334. PMID: 12738305, DOI: 10.1016/s0360-3016(02)04598-4.
- Knisely JP, Burtness BA, Salem RR. Surgical treatment of esophageal cancer. New England Journal Of Medicine 2003, 348: 1177-9; author reply 1177-9. PMID: 12647729.
- Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology 2003, 10: 132-139. PMID: 12673177, DOI: 10.1067/mnc.2003.7.
- Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer. Cancer Biology & Therapy 2002, 1: 646-651. PMID: 12642688, DOI: 10.4161/cbt.314.
- Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy 2002, 1: 130-135. PMID: 12170772, DOI: 10.4161/cbt.57.
- Burtness B. Head and Neck Cancer. 2002, 339-346. DOI: 10.1016/b0-12-227555-1/00096-4.
- Kleinberg L, Knisely J, Heitmiller R, Zahurak M, Yang S, Salem R, Heath E, Burtness B, Forastiere A. Mature survival results with preoperative cisplatin, protracted infusion 5-FU, and 45 GY radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 32. DOI: 10.1016/s0360-3016(01)01880-6.
- Gollerkeri A, Harrold L, Rose M, Jain D, Burtness B. Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience. International Journal Of Cancer 2001, 93: 139-141. PMID: 11391633, DOI: 10.1002/ijc.1295.
- Rich R, Argiris A, Peccerillo K, McKeon A, Gallipoli M, Burtness B, Murren J. Weekly chemotherapy with irinotecan plus a taxane in advanced non small cell lung cancer (NSCLC). Lung Cancer 2000, 29: 6. DOI: 10.1016/s0169-5002(00)80014-8.
- Snyder EL, Baril L, Cooper DL, Min K, Mechanic S, Stoddart L, Burtness B, Seagraves P, Debelak J, Gudino M, McCullough J. In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation. Transfusion 2000, 40: 961-967. PMID: 10960524, DOI: 10.1046/j.1537-2995.2000.40080961.x.
- Rose M, Lee F, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness B. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation 2000, 26: 133-139. PMID: 10918422, DOI: 10.1038/sj.bmt.1702449.
- Murren J, Peccerillo K, DiStasio S, Li X, Leffert J, Pizzorno G, Burtness B, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577, DOI: 10.1007/s002800000115.
- Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.
- Zhang Z, Burtness B, Zelterman D. The maximum negative binomial distribution. Journal Of Statistical Planning And Inference 2000, 87: 1-19. DOI: 10.1016/s0378-3758(99)00177-9.
- Heath E, Burtness B, Heitmiller R, Salem R, Kleinberg L, Knisely J, Yang S, Talamini M, Kaufman H, Canto M, Topazian M, Wu T, Olukayode K, Forastiere A. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. Journal Of Clinical Oncology 2000, 18: 868-76. PMID: 10673530, DOI: 10.1200/jco.2000.18.4.868.
- Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal Of Clinical Oncology 2000, 18: 904-14. PMID: 10673534, DOI: 10.1200/jco.2000.18.4.904.
- Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. The Cancer Journal 2000, 6: 309-15. PMID: 11079170.
- Horvath LJ, Burtness BA, McCarthy S, Johnson KM. Total-Body Echo-planar MR Imaging in the Staging of Breast Cancer: Comparison with Conventional Methods—Early Experience. Radiology 1999, 211: 119-128. PMID: 10189461, DOI: 10.1148/radiology.211.1.r99ap33119.
- Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.
- Burtness B, Psyrri A, Rose M, D’Andrea E, Staugaard-Hahn C, Henderson-Bakas M, Clark M, Mechanic S, Krause D, Snyder E, Cooper R, Abrantes J, Corringham R, Deisseroth A, Cooper D. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplantation 1999, 23: 311-315. PMID: 10100573, DOI: 10.1038/sj.bmt.1701589.
- Kleinberg L, Knisley J, Heitmiller R, Yang S, Zahurak M, Salem R, Burtness B, Heath E, Forastiere A. 83 Long term local control and survival with preoperative cisplatin, continuous infusion 5-FU, and 45 Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 189-190. DOI: 10.1016/s0360-3016(99)90101-3.
- Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty BG, Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. The Cancer Journal 1999, 5: 224-9. PMID: 10439168.
- Burtness B. High-dose chemotherapy for the treatment of high-risk and advanced breast cancer. Connecticut Medicine 1999, 63: 41-6. PMID: 10071438.
- Burtness BA. Preoperative chemoradiation for esophageal cancer. The Cancer Journal 1999, 5: 73-4. PMID: 10198727.
- Chabannon C, Cornetta K, Lotz J, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau J, Sledge G, Novakovitch G, Srour E, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-921. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.
- Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation. Blood 1998, 92: 672-682. PMID: 9657770, DOI: 10.1182/blood.v92.2.672.
- Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clinical Cancer Research 1998, 4: 1165-75. PMID: 9607574.
- Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal Of Clinical Oncology 1997, 15: 148-57. PMID: 8996136, DOI: 10.1200/jco.1997.15.1.148.
- Burtness BA. Histologic markers and long-term prognosis in breast cancer. The Cancer Journal 1997, 3: 211-2. PMID: 9263626.
- Haffty B, Burtness B, Papac R, Marsh J, Ward B, Farber L, Reiss M. 2036 The natural history of local regional breast cancer recurrence: Prognosis and implications for systemic therapy. International Journal Of Radiation Oncology • Biology • Physics 1997, 39: 258. DOI: 10.1016/s0360-3016(97)80804-8.
- Hanania E, Giles R, Kavanagh J, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove J, Bird R, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth A. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 15346-15351. PMID: 8986814, PMCID: PMC26407, DOI: 10.1073/pnas.93.26.15346.
- Burtness B. Oncology and hematology. JAMA 1995, 273: 1702-1703. DOI: 10.1001/jama.273.21.1702.
- Burtness BA. Oncology and Hematology. JAMA 1995, 273: 1702-1703. PMID: 7752426, DOI: 10.1001/jama.1995.03520450072037.
- Conner R, Burtness B, Ferguson K. Fatty acid desaturase specificity in tetrahymena. Lipids 1984, 19: 285-288. PMID: 6717257, DOI: 10.1007/bf02534456.
- Burtness B. Rape crisis centers. JAMA 1983, 250: 1391b-1391. DOI: 10.1001/jama.250.11.1391b.
- Burtness B. Rape Crisis Centers. JAMA 1983, 250: 1391-1391. PMID: 6887453, DOI: 10.1001/jama.1983.03340110015010.
Departments and Programs
Locations
Smilow Cancer Hospital Head and Neck Cancers Program
55 Park Street
Ste Phase I Clinical Trial Infusion Center
New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511
Smilow Cancer Hospital Head and Neck Cancers Program
55 Park Street
Ste Phase I Clinical Trial Infusion Center
New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511